

Providing Quality Family Planning Services Recommendations of CDC and the U.S. Office of Population Affairs



Continuing Education Examination available at <http://www.cdc.gov/mmwr/cme/conted.html>.



U.S. Department of Health and Human Services
Centers for Disease Control and Prevention

CONTENTS

Introduction	1
Methods.....	3
Contraceptive Services.....	7
Pregnancy Testing and Counseling	13
Clients Who Want to Become Pregnant	14
Basic Infertility Services.....	15
Preconception Health Services	16
Sexually Transmitted Disease Services	18
Related Preventive Health Services	20
Summary of Recommendations for Providing Family Planning and Related Preventive Health Services	21
Conducting Quality Improvement.....	21
Conclusion	25
Appendix A.....	30
Appendix B	35
Appendix C.....	45
Appendix D.....	47
Appendix E.....	48
Appendix F.....	51

Disclosure of Relationship

CDC, our planners, content experts, and their spouses/partners wish to disclose that they have no financial interests or other relationships with the manufacturers of commercial products, suppliers of commercial services, or commercial supporters. Planners have reviewed content to ensure there is no bias.

The *MMWR* series of publications is published by the Center for Surveillance, Epidemiology, and Laboratory Services, Centers for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services, Atlanta, GA 30329-4027.

Suggested Citation: [Author names; first three, then et al., if more than six.] [Title]. *MMWR* 2014;63(No. RR-#):[inclusive page numbers].

Centers for Disease Control and Prevention

Thomas R. Frieden, MD, MPH, *Director*
 Harold W. Jaffe, MD, MA, *Associate Director for Science*
 Joanne Cono, MD, ScM, *Acting Director, Office of Science Quality*
 Chesley L. Richards, MD, MPH, *Deputy Director for Public Health Scientific Services*
 Michael F. Iademarco, MD, MPH, *Director, Center for Surveillance, Epidemiology, and Laboratory Services*

MMWR Editorial and Production Staff (Serials)

John S. Moran, MD, MPH, <i>Acting Editor-in-Chief</i>	Martha F. Boyd, <i>Lead Visual Information Specialist</i>
Christine G. Casey, MD, <i>Editor</i>	Maureen A. Leahy, Julia C. Martinroe,
Teresa F. Rutledge, <i>Managing Editor</i>	Stephen R. Spriggs, Terraye M. Starr
David C. Johnson, <i>Lead Technical Writer-Editor</i>	<i>Visual Information Specialists</i>
Jeffrey D. Sokolow, MA, <i>Project Editor</i>	Quang M. Doan, MBA, Phyllis H. King
	<i>Information Technology Specialists</i>

MMWR Editorial Board

William L. Roper, MD, MPH, Chapel Hill, NC, <i>Chairman</i>	Timothy F. Jones, MD, Nashville, TN
Matthew L. Boulton, MD, MPH, Ann Arbor, MI	Rima F. Khabbaz, MD, Atlanta, GA
Virginia A. Caine, MD, Indianapolis, IN	Dennis G. Maki, MD, Madison, WI
Barbara A. Ellis, PhD, MS, Atlanta, GA	Patricia Quinlisk, MD, MPH, Des Moines, IA
Jonathan E. Fielding, MD, MPH, MBA, Los Angeles, CA	Patrick L. Remington, MD, MPH, Madison, WI
David W. Fleming, MD, Seattle, WA	William Schaffner, MD, Nashville, TN
William E. Halperin, MD, DrPH, MPH, Newark, NJ	
King K. Holmes, MD, PhD, Seattle, WA	

Providing Quality Family Planning Services

Recommendations of CDC and the U.S. Office of Population Affairs

Prepared by

Loretta Gavin, PhD,¹ Susan Moskosky, MS,² Marion Carter, PhD,¹ Kathryn Curtis, PhD,¹ Evelyn Glass, MSPH,² Emily Godfrey, MD,¹ Arik Marcell, MD,³ Nancy Mautone-Smith, MSW,² Karen Pazol, PhD,¹ Naomi Tepper, MD,¹ Lauren Zapata, PhD¹

¹Division of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion, CDC

²Office of Population Affairs, US Department of Health and Human Services, Rockville, Maryland

³The Johns Hopkins University and the Male Training Center for Family Planning and Reproductive Health, Baltimore, Maryland

Summary

This report provides recommendations developed collaboratively by CDC and the Office of Population Affairs (OPA) of the U.S. Department of Health and Human Services (HHS). The recommendations outline how to provide quality family planning services, which include contraceptive services, pregnancy testing and counseling, helping clients achieve pregnancy, basic infertility services, preconception health services, and sexually transmitted disease services. The primary audience for this report is all current or potential providers of family planning services, including those working in service sites that are dedicated to family planning service delivery as well as private and public providers of more comprehensive primary care.

The United States continues to face substantial challenges to improving the reproductive health of the U.S. population. Nearly one half of all pregnancies are unintended, with more than 700,000 adolescents aged 15–19 years becoming pregnant each year and more than 300,000 giving birth. One of eight pregnancies in the United States results in preterm birth, and infant mortality rates remain high compared with those of other developed countries.

This report can assist primary care providers in offering family planning services that will help women, men, and couples achieve their desired number and spacing of children and increase the likelihood that those children are born healthy. The report provides recommendations for how to help prevent and achieve pregnancy, emphasizes offering a full range of contraceptive methods for persons seeking to prevent pregnancy, highlights the special needs of adolescent clients, and encourages the use of the family planning visit to provide selected preventive health services for women, in accordance with the recommendations for women issued by the Institute of Medicine and adopted by HHS.

Introduction

The United States continues to face challenges to improving the reproductive health of the U.S. population. Nearly half (49%) of all pregnancies are unintended (1). Although adolescent birth rates declined by more than 61% during 1991–2012, the United States has one of the highest adolescent pregnancy rates in the developed world, with >700,000 adolescents aged 15–19 years becoming pregnant each year and >300,000 giving birth (2,3). Approximately one of eight pregnancies in the United States results in a preterm birth, and infant mortality rates remain high compared with other developed countries (3,4). Moreover, all of these outcomes affect racial and ethnic minority populations disproportionately (1–4).

Family planning services can help address these and other public health challenges by providing education, counseling, and medical services (5). Family planning services include the following:

- providing contraception to help women and men plan and space births, prevent unintended pregnancies, and reduce the number of abortions;
- offering pregnancy testing and counseling;
- helping clients who want to conceive;
- providing basic infertility services;
- providing preconception health services to improve infant and maternal outcomes and improve women's and men's health; and
- providing sexually transmitted disease (STD) screening and treatment services to prevent tubal infertility and improve the health of women, men, and infants.

This report provides recommendations developed collaboratively by CDC and the Office of Population Affairs (OPA) of the U.S. Department of Health and Human Services (HHS). The recommendations outline how to provide family planning services by:

Corresponding preparers: Loretta Gavin, PhD, Division of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion, CDC. Telephone: 770-488-6284; E-mail: lcg6@cdc.gov; Susan Moskosky, MS, Office of Population Affairs, US Department of Health and Human Services. Telephone: 240-453-2818; E-mail: susan.moskosky@hhs.gov.

- defining a core set of family planning services for women and men,
- describing how to provide contraceptive and other clinical services, serve adolescents, and perform quality improvements, and
- encouraging the use of the family planning visit to provide selected preventive health services for women, in accordance with the recommendations for women issued by the Institute of Medicine (IOM) and adopted by HHS (6).

The collaboration between CDC and OPA drew on the strengths of both agencies. CDC has a long-standing history of developing evidence-based recommendations for clinical care, and OPA's Title X Family Planning Program (7) has served as the national leader in direct family planning service delivery since the Title X program was established in 1970.

This report provides recommendations for providing care to clients of reproductive age who are in need of family planning services. These recommendations are intended for all current or potential providers of family planning services, including those funded by the Title X program.

Current Context of Family Planning Services

Women of reproductive age often report that their family planning provider is also their usual source of health care (8). As the U.S. health-care system evolves in response to increased efforts to expand health insurance coverage, contain costs, and emphasize preventive care (9), providers of family planning services will face new challenges and opportunities in care delivery. For example, they will have increased opportunities to serve new clients and to serve as gateways for their clients to other essential health-care services. In addition, primary care and other providers who provide a range of health-care services will be expected to integrate family planning services for all persons of reproductive age, including those whose primary reason for their health-care visit might not be family planning. Strengthened, multidirectional care coordination also will be needed to improve health outcomes. For example, this type of care coordination will be needed with clients referred to specialist care after initial screening at a family planning visit, as well as with specialists referring clients with family planning needs to family planning providers.

Defining Quality in Family Planning Service Delivery

The central premise underpinning these recommendations is that improving the quality of family planning services will lead to improved reproductive health outcomes (10–12). IOM

defines health-care quality as the extent to which health-care services improve health outcomes in a manner that is consistent with current professional knowledge (10,13). According to IOM, quality health care has the following attributes:

- **Safety.** These recommendations integrate other CDC recommendations about which contraceptive methods can be provided safely to women with various medical conditions, and integrate CDC and U.S. Preventive Services Task Force (USPSTF) recommendations on STD, preconception, and related preventive health services.
- **Effectiveness.** These recommendations support offering a full range of Food and Drug Administration (FDA)–approved contraceptive methods as well as counseling that highlights the effectiveness of contraceptive methods overall and, in specific patient situations, draws attention to the effectiveness of specific clinical preventive health services and identifies clinical preventive health services for which the potential harms outweigh the benefits (i.e., USPSTF “D” recommendations).
- **Client-centered approach.** These recommendations encourage taking a client-centered approach by 1) highlighting that the client's primary purpose for visiting the service site must be respected, 2) noting the importance of confidential services and suggesting ways to provide them, 3) encouraging the availability of a broad range of contraceptive methods so that clients can make a selection based on their individual needs and preferences, and 4) reinforcing the need to deliver services in a culturally competent manner so as to meet the needs of all clients, including adolescents, those with limited English proficiency, those with disabilities, and those who are lesbian, gay, bisexual, transgender, or questioning their sexual identity (LGBTQ). Organizational policies, governance structures, and individual attitudes and practices all contribute to the cultural competence of a health-care entity and its staff. Cultural competency within a health-care setting refers to attitudes, practices, and policies that enable professionals to work effectively in cross-cultural situations (14–16).
- **Timeliness.** These recommendations highlight the importance of ensuring that services are provided to clients in a timely manner.
- **Efficiency.** These recommendations identify a core set of services that providers can focus on delivering, as well as ways to maximize the use of resources.
- **Accessibility.** These recommendations address how to remove barriers to contraceptive use, use the family planning visit to provide access to a broader range of primary care and behavioral health services, use the primary care visit to

provide access to contraceptive and other family planning services, and strengthen links to other sources of care.

- **Equity.** These recommendations highlight the need for providers of family planning services to deliver high-quality care to all clients, including adolescents, LGBTQ persons, racial and ethnic minorities, clients with limited English proficiency, and persons living with disabilities.
- **Value.** These recommendations highlight services (i.e., contraception and other clinical preventive services) that have been shown to be very cost-effective (17–19).

Methods

Recommendations Development Process

The recommendations were developed jointly under the auspices of CDC's Division of Reproductive Health and OPA, in consultation with a wide range of experts and key stakeholders. More information about the processes used to conduct systematic reviews, the role of technical experts in reviewing the evidence, and the process of using the evidence to develop recommendations is provided (Appendix A). A multistage process was used to develop the recommendations that drew on established procedures for developing clinical guidelines (20,21). First, an Expert Work Group* was formed comprising family planning clinical providers, program administrators, and representatives from relevant federal agencies and professional medical associations to help define the scope of the recommendations. Next, literature about three priority topics (i.e., counseling and education, serving adolescents, and quality improvement) was reviewed by using the USPSTF methodology for conducting systematic reviews (22). The results were presented to three technical panels† comprising subject matter experts (one panel for each priority topic) who considered the quality of the evidence and made suggestions for what recommendations might be supported on the basis of the evidence. In a separate process, existing clinical recommendations on women's and men's preventive services were compiled from more than 35 federal and professional medical associations, and these results were presented to two technical panels of subject matter experts, one that addressed women's clinical services and one that addressed men's clinical services. The panels provided individual feedback about which clinical preventive services should be offered in a family planning setting and which clinical recommendations should receive the highest consideration.

* A list of the members of the Expert Work Group appears on page 52.

† A list of the members of the technical panels appears on pages 52 and 53.

CDC and OPA used the input from the subject matter experts to develop a set of core recommendations and asked the Expert Work Group to review them. The members of the Expert Work Group were more familiar with the family planning service delivery context than the members of the Technical Panel and thus could better comment on the feasibility and appropriateness of the recommendations, as well as the supporting evidence. The Expert Work Group considered the core recommendations by using the following criteria: 1) the quality of the evidence; 2) the positive and negative consequences of implementing the recommendations on health outcomes, costs or cost-savings, and implementation challenges; and 3) the relative importance of these consequences, (e.g., the likelihood that implementation of the recommendation will have a substantial effect on health outcomes might be considered more than the logistical challenges of implementing it) (20). In certain cases, when the evidence from the literature reviews was inconclusive or incomplete, recommendations were made on the basis of expert opinion. Finally, CDC and OPA staff considered the individual feedback from Expert Work Group members when finalizing the core recommendations and writing the recommendations document. A description of how the recommendations link to the evidence is provided together with the rationale for the inclusion of each recommendation in this report (Appendix B).

The evidence used to prepare these recommendations will appear in background papers that will be published separately. Resources that will help providers implement the recommendations will be provided through a web-based tool kit that will be available at <http://www.hhs.gov/opa>.

Audience for the Recommendations

The primary audience for this report is all providers or potential providers of family planning services to clients of reproductive age, including providers working in clinics that are dedicated to family planning service delivery, as well as private and public providers of more comprehensive primary care. Providers of dedicated family planning services might be less familiar with the specific recommendations for the delivery of preconception services. Providers of more comprehensive primary care might be less familiar with the delivery of contraceptive services, pregnancy testing and counseling, and services to help clients achieve pregnancy.

This report can be used by medical directors to write clinical protocols that describe how care should be provided. Job aids and other resources for use in service sites are being developed and will be made available when ready through OPA's website (<http://www.hhs.gov/opa>).

In this report, the term “provider” refers to any staff member who is involved in providing family planning services to a client. This includes physicians, physician assistants, nurse practitioners, nurse-midwives, nursing staff, and health educators. The term “service site” represents the numerous settings in which family planning services are delivered, which include freestanding service sites, community health centers, private medical facilities, and hospitals. A list of special terms used in this report is provided (Box 1).

The recommendations are designed to guide general clinical practice; however, health-care providers always should consider the individual clinical circumstances of each person seeking family planning services. Similarly, these recommendations might need to be adapted to meet the needs of particular populations, such as clients who are HIV-positive or who are substance users.

Organization of the Recommendations

This report is divided into nine sections. An initial section provides an overview of steps to assess the needs of a client and decide what family planning services to offer. Subsequent sections describe how to provide each of the following services: contraceptive services, pregnancy testing and counseling, helping clients achieve pregnancy, basic infertility services, preconception health services, STD services and related preventive health services. A final section on quality improvement describes actions that all providers of family planning services should consider to ensure that services are of high quality. More detailed information about selected topics addressed in the recommendations is provided (Appendices A–F).

These recommendations focus on the direct delivery of care to individual clients. However, parallel steps might need to be taken to maintain the systems required to support the provision of quality services for all clients (e.g., record-keeping procedures that preserve client confidentiality, procedures that improve efficiency and reduce clients’ wait time, staff training to ensure that all clients are treated with respect, and the establishment and maintenance of a strong system of care coordination and referrals).

Client Care

Family planning services are embedded within a broader framework of preventive health services (Figure 1). In this report, health services are divided into three main categories:

- **Family planning services.** These include contraceptive services for clients who want to prevent pregnancy and space births, pregnancy testing and counseling, assistance to achieve pregnancy, basic infertility services, STD services (including HIV/AIDS), and other preconception health services (e.g., screening for obesity, smoking, and mental health). STD/HIV

BOX 1. Definitions of quality terms used in this report

Accessible. The timely use of personal health services to achieve the best possible health outcomes.*

Client-centered. Care is respectful of, and responsive to, individual client preferences, needs, and values; client values guide all clinical decisions.†

Effective. Services are based on scientific knowledge and provided to all who could benefit and are not provided to those not likely to benefit.†

Efficient. Waste is avoided, including waste of equipment, supplies, ideas, and energy.†

Equitable. Care does not vary in quality because of the personal characteristics of clients (e.g., sex, race/ethnicity, geographic location, insurance status, or socioeconomic status).†

Evidence-based. The process of integrating science-based interventions with community preferences to improve the health of populations.§

Health-care quality. The degree to which health-care services for individuals and populations increase the likelihood of desired health outcomes and are consistent with current professional knowledge.†

Process. Whether services are provided correctly and completely and how clients perceive the care they receive.¶

Safe. Avoids injuries to clients from the care that is intended to help them.†

Structure. The characteristics of the settings in which providers deliver health care, including material resources, human resources, and organizational structure.¶

Timely. Waits and sometimes harmful delays for both those who receive and those who provide care are reduced.†

Value. The care provides good return relative to the costs involved, such as a return on investment or a reduction in the per capita cost of health care.*

* Source: Institute of Medicine. Future directions for the national healthcare quality and disparities reports. Ulmer C, Bruno M, Burke S, eds. Washington, DC: The National Academies Press; 2010.

† Source: Institute of Medicine. Crossing the quality chasm: a new health system for the 21st century. Committee on Quality of Health Care in America, ed. Washington, DC: National Academies of Science; 2001.


§ Source: Kohatsu ND, Robinson JG, Torner JC. Evidence-based public health: an evolving concept. *Am J Prev Med* 2004;27:417–21.

¶ Source: Donabedian A. The quality of care. *JAMA* 1988;260:1743–8.

and other preconception health services are considered family planning services because they improve women’s and men’s health and can influence a person’s ability to conceive or to have a healthy birth outcome.

- **Related preventive health services.** These include services that are considered to be beneficial to reproductive health,

FIGURE 1. Family planning and related and other preventive health services



are closely linked to family planning services, and are appropriate to deliver in the context of a family planning visit but that do not contribute directly to achieving or preventing pregnancy (e.g., breast and cervical cancer screening).

- **Other preventive health services.** These include preventive health services for women that were not included above (6), as well as preventive services for men. Screening for lipid disorders, skin cancer, colorectal cancer, or osteoporosis are examples of this type of service. Although important in the context of primary care, these have no direct link to family planning services.

Providers of family planning services should be trained and equipped to offer all family planning and related preventive health services so that they can provide optimal care to clients, with referral for specialist care, as needed. Other preventive health services should be available either on-site or by referral, but these recommendations do not address this category of services. Information about preventive services that are beyond the scope of this report is available at <http://www.uspreventiveservicestaskforce.org>.

Determining the Client's Need for Services


These recommendations apply to two types of encounters with women and men of reproductive age. In the first type of encounter, the primary reason for a client's visit to a health-care provider is related to preventing or achieving pregnancy,

(i.e., contraceptive services, pregnancy testing and counseling, or becoming pregnant). Other aspects of managing pregnancy (e.g., prenatal and delivery care) are not addressed in these recommendations. For clients seeking to prevent or achieve pregnancy, providers should assess whether the client needs other related services and offer them to the client. In the second type of encounter, the primary reason for a client's visit to a health-care provider is not related to preventing or achieving pregnancy. For example, the client might come in for acute care (e.g., a male client coming in for STD symptoms or as a contact of a person with an STD), for chronic care, or for another preventive service. In this situation, providers not only should address the client's primary reason for the visit but also assess the client's need for services related to preventing or achieving pregnancy.

A clinical pathway of family planning services for women and men of reproductive age is provided (Figure 2). The following questions can help providers determine what family planning services are most appropriate for a given visit.

- **What is the client's reason for the visit?** It is essential to understand the client's goals for the visit and address those needs to the extent possible.
- **Does the client have another source of primary health care?** Understanding whether a provider is the main source of primary care for a client will help identify what preventive services a provider should offer. If a provider is the client's main source of primary care, it will be important to assess the client's needs for the other services listed in this report. If the client receives ongoing primary care from another provider, the provider should confirm that the client's preventive health needs are met while avoiding the delivery of duplicative services.
- **What is the client's reproductive life plan?** An assessment should be made of the client's reproductive life plan, which outlines personal goals about becoming pregnant (23–25) (Box 2). The provider should avoid making assumptions about the client's needs based on his or her characteristics, such as sexual orientation or disabilities. For clients whose initial reason for coming to the service site was not related to preventing or achieving pregnancy, asking questions about his or her reproductive life plan might help identify unmet reproductive health-care needs. Identifying a need for contraceptive services might be particularly important given the high rate of unintended pregnancy in the United States.
 - If the client does not want a child at this time and is sexually active, then offer contraceptive services.
 - If the client desires pregnancy testing, then provide pregnancy testing and counseling.
 - If the client wants to have a child now, then provide services to help the client achieve pregnancy.

FIGURE 2. Clinical pathway of family planning services for women and men of reproductive age



– If the client wants to have a child and is experiencing difficulty conceiving, then provide basic infertility services.

- **Does the client need preconception health services?** Preconception health services (such as screening for obesity, smoking, and mental health) are a subset of all preventive services for women and men. Preconception health care is intended to promote the health of women and men of reproductive age before conception, with the goal of improving pregnancy-related outcomes (24). Preconception health services are also important because they improve the health of women and men, even if they choose not to become pregnant. The federal and professional medical recommendations cited in this report should be followed when determining which preconception health services a client might need.
- **Does the client need STD services?** The need for STD services, including HIV/AIDS testing, should be considered

at every visit. Many clients requesting contraceptive services also might meet the criteria for being at risk of one or more STDs. Screening for chlamydia and gonorrhea is especially important in a family planning context because these STDs contribute to tubal infertility if left untreated. STD services are also necessary to maximize preconception health. The federal recommendations cited in this report should be followed when determining which STD services a client might need. Aspects of managing symptomatic STDs are not addressed in these recommendations.

- **What other related preventive health services does the client need?** Whether the client needs related preventive health services, such as breast and cervical cancer screening for female clients, should be assessed. The federal and professional medical recommendations cited in this report should be followed when determining which related preventive health services a client might need.

BOX 2. Recommended questions to ask when assessing a client's reproductive life plan

Providers should discuss a reproductive life plan with clients receiving contraceptive, pregnancy testing and counseling, basic infertility, sexually transmitted disease, and preconception health services in accordance with CDC's recommendation that all persons capable of having a child should have a reproductive life plan.*

Providers should assess the client's reproductive life plan by asking the client questions such as:

- Do you have any children now?
- Do you want to have (more) children?
- How many (more) children would you like to have and when?

* Source: CDC. Recommendations to improve preconception health and health care—United States: a report of the CDC/ATSDR Preconception Care Work Group and the Select Panel on Preconception Care. MMWR 2006;55(No. RR-6).

The individual client's needs should be considered when determining what services to offer at a given visit. It might not be feasible to deliver all the needed services in a single visit, and they might need to be delivered over the course of several visits. Providers should tailor services to meet the specific needs of the population they serve. For example, clients who are trying to achieve pregnancy and those at high risk of unintended pregnancy should be given higher priority for preconception health services. In some cases, the provider will deliver the initial screening service but then refer to another provider for further diagnosis or follow-up care.

The delivery of preconception, STD, and related preventive health services should not become a barrier to a client's ability to receive services related to preventing or achieving pregnancy. For these clients, receiving services related to preventing or achieving pregnancy is the priority; if other family planning services cannot be delivered at the initial visit, then follow-up visits should be scheduled.

In addition, professional recommendations for how to address the needs of diverse clients, such as LGBTQ persons (26–32) or persons with disabilities (33), should be consulted and integrated into procedures, as appropriate. For example, as noted before, providers should avoid making assumptions about a client's gender identity, sexual orientation, race, or ethnicity; all requests for services should be treated without regard to these characteristics. Similarly, services for adolescents should be provided in a “youth-friendly” manner, which means that they are accessible, equitable, acceptable, appropriate, comprehensive, effective, and efficient for youth, as recommended by the World Health Organization (34).

Contraceptive Services

Providers should offer contraceptive services to clients who wish to delay or prevent pregnancy. Contraceptive services should include consideration of a full range of FDA-approved contraceptive methods, a brief assessment to identify the contraceptive methods that are safe for the client, contraceptive counseling to help a client choose a method of contraception and use it correctly and consistently, and provision of one or more selected contraceptive method(s), preferably on site, but by referral if necessary. Contraceptive counseling is defined as a process that enables clients to make and follow through on decisions about their contraceptive use. Education is an integral component of the contraceptive counseling process that helps clients to make informed decisions and obtain the information they need to use contraceptive methods correctly.

Key steps in providing contraceptive services, including contraceptive counseling and education, have been outlined (Box 3). These key steps are in accordance with the five principles of quality counseling (Appendix C). To help a client who is initiating or switching to a new method of contraception, providers should follow these steps. These steps most likely will be implemented iteratively when working with a client and should help clients adopt, change, or maintain contraceptive use.

Step 1. Establish and maintain rapport with the client.

Providers should strive to establish and maintain rapport. Strategies to achieve these goals include the following:

- using open-ended questions;
- demonstrating expertise, trustworthiness, and accessibility;
- ensuring privacy and confidentiality;
- explaining how personal information will be used;
- encouraging the client to ask questions and share information;
- listening to and observing the client; and
- being encouraging and demonstrating empathy and acceptance.

Step 2. Obtain clinical and social information from the client. Providers should ask clients about their medical history to identify methods that are safe. In addition, to learn more about factors that might influence a client's choice of a contraceptive method, providers should confirm the client's pregnancy intentions or reproductive life plan, ask about the client's contraceptive experiences and preferences, and conduct a sexual health assessment. When available, standardized tools should be used.

- **Medical history.** A medical history should be taken to ensure that methods of contraception being considered by a client are safe for that particular client. For a female client, the medical history should include menstrual history (including last menstrual period, menstrual frequency, length and amount of bleeding, and other

BOX 3. Steps in providing contraceptive services, including contraceptive counseling* and education

- Establish and maintain rapport with the client.
- Obtain clinical and social information from the client.
- Work with the client interactively to select the most effective and appropriate contraceptive method.
- Conduct a physical assessment related to contraceptive use, only when warranted.
- Provide the contraceptive method along with instructions about correct and consistent use, help the client develop a plan for using the selected method and for follow up, and confirm client understanding.

*Key principles of providing quality counseling including education have been outlined (Appendix C).

patterns of uterine/vaginal bleeding), gynecologic and obstetrical history, contraceptive use, allergies, recent intercourse, recent delivery, miscarriage, or termination, and any relevant infectious or chronic health condition and other characteristics and exposures (e.g., age, postpartum, and breastfeeding) that might affect the client's medical eligibility criteria for contraceptive methods (35). Clients considering combined hormonal contraception should be asked about smoking tobacco, in accordance with CDC guidelines on contraceptive use (35). Additional details about the methods of contraception that are safe to use for female clients with specific medical conditions and characteristics (e.g., hypertension) are addressed in previously published guidelines (35). For a male client, a medical history should include use of condoms, known allergies to condoms, partner use of contraception, recent intercourse, whether his partner is currently pregnant or has had a child, miscarriage, or termination, and the presence of any infectious or chronic health condition. However, the taking of a medical history should not be a barrier to making condoms available in the clinical setting (i.e., a formal visit should not be a prerequisite for a client to obtain condoms).

- **Pregnancy intention or reproductive life plan.** Each client should be encouraged to clarify decisions about her or his reproductive life plan (i.e., whether the client wants to have any or more children and, if so, the desired timing and spacing of those children) (24).
- **Contraceptive experiences and preferences.** Method-specific experiences and preferences should be assessed by asking questions such as, "What method(s) are you currently using, if any?"; "What methods have you used in the past?"; "Have you previously used emergency

contraception?"; "Did you use contraception at last sex?"; "What difficulties did you experience with prior methods if any (e.g., side effects or noncompliance)?"; "Do you have a specific method in mind?"; and "Have you discussed method options with your partner, and does your partner have any preferences for which method you use?" Male clients should be asked if they are interested in vasectomy.

- **Sexual health assessment.** A sexual history and risk assessment that considers the client's sexual practices, partners, past STD history, and steps taken to prevent STDs (36) is recommended to help the client select the most appropriate method(s) of contraception. Correct and consistent condom use is recommended for those at risk for STDs. CDC recommendations for how to conduct a sexual health assessment have been summarized (Box 4).

Step 3. Work with the client interactively to select the most effective and appropriate contraceptive method. Providers should work with the client interactively to select an effective and appropriate contraceptive method. Specifically, providers should educate the client about contraceptive methods that the client can safely use, and help the client consider potential barriers to using the method(s) under consideration. Use of decision aids (e.g., computerized programs that help a client to identify a range of methods that might be appropriate for the client based on her physical characteristics such as health conditions or preferences about side effects) before or while waiting for the appointment can facilitate and maximize the utility of the time spent on this step.

Providers should inform clients about all contraceptive methods that can be used safely. Before the health-care visit, clients might have only limited information about all or specific methods of contraception (37). A broad range of methods, including long-acting reversible contraception (i.e., intrauterine devices [IUDs] and implants), should be discussed with all women and adolescents, if medically appropriate.

Providers are encouraged to present information on potential reversible methods of contraception by using a tiered approach (i.e., presenting information on the most effective methods first, before presenting information on less effective methods) (38,39). This information should include an explanation that long-acting reversible contraceptive methods are safe and effective for most women, including those who have never given birth and adolescents (35). Information should be tailored and presented to ensure a client-centered approach. It is not appropriate to omit presenting information on a method solely because the method is not available at the service site. If not all methods are available at the service site, it is important to have strong referral links in place to other providers to maximize opportunities for clients to obtain their preferred method that is medically appropriate.

BOX 4. Steps in conducting a sexual health assessment*

- **Practices:** Explore the types of sexual activity in which the patient engages (e.g., vaginal, anal, or oral sex).
- **Pregnancy prevention:** Discuss current and future contraceptive options. Ask about current and previous use of methods, use of contraception at last sex, difficulties with contraception, and whether the client has a particular method in mind.
- **Partners:** Ask questions to determine the number, gender (men, women, or both), and concurrency of the patient's sex partners (if partner had sex with another partner while still in a sexual relationship with the patient). It might be necessary to define the term "partner" to the patient or use other, relevant terminology.
- **Protection from sexually transmitted diseases (STDs):** Ask about condom use, with whom they do or do not use condoms, and situations that make it harder or easier to use condoms. Topics such as monogamy and abstinence also can be discussed.
- **Past STD history:** Ask about any history of STDs, including whether their partners have ever had an STD. Explain that the likelihood of an STD is higher with a past history of an STD.

* Source: CDC. Sexually transmitted diseases treatment guidelines, 2010. MMWR 2010;59(No. RR-12).

For clients who have completed childbearing or do not plan to have children, permanent sterilization (female or male) is an option that may be discussed. Both female and male sterilization are safe, are highly effective, and can be performed in an office or outpatient surgery setting (40,41). Women and men should be counseled that these procedures are not intended to be reversible and that other highly effective, reversible methods of contraception (e.g., implants or IUDs) might be an alternative if they are unsure about future childbearing. Clients interested in sterilization should be referred to an appropriate source of care if the provider does not perform the procedure.

When educating clients about contraceptive methods that the clients can use safely, providers should ensure that clients understand the following:

- **Method effectiveness.** A contraceptive method's rate of typical effectiveness, or the percentage of women experiencing an unintended pregnancy during the first year of typical use, is an important consideration (Figure 3; Appendix D) (38,42).
- **Correct use of the method.** The mode of administration and understanding how to use the method correctly might be important considerations for the client when choosing


a method. For example, receiving a contraceptive injection every 3 months might not be acceptable to a woman who fears injections. Similarly, oral contraceptives might not be acceptable to a woman who is concerned that she might not be able to remember to take a pill every day.

- **Noncontraceptive benefits.** Many contraceptives have noncontraceptive benefits, in addition to preventing pregnancy, such as reducing heavy menstrual bleeding. Although the noncontraceptive benefits are not generally the major determinant for selecting a method, awareness of these benefits can help clients decide between two or more suitable methods and might enhance the client's motivation to use the method correctly and consistently.
- **Side effects.** Providers should inform the client about risks and side effects of the method(s) under consideration, help the client understand that certain side effects of contraceptive methods might disappear over time, and encourage the client to weigh the experience of coping with side effects against the experience and consequences of an unintended pregnancy. The provider should be prepared to discuss and correct misperceptions about side effects. Clients also should be informed about warning signs for rare, but serious, adverse events with specific contraceptive methods, such as stroke and venous thromboembolism with use of combined hormonal methods.
- **Protection from STDs, including HIV.** Clients should be informed that contraceptive methods other than condoms offer no protection against STDs, including HIV. Condoms, when used correctly and consistently, help reduce the risk of STDs, including HIV, and provide protection against pregnancy. Dual protection (i.e., protection from both pregnancy and STDs) is important for clients at risk of contracting an STD, such as those with multiple or potentially infected partner(s). Dual protection can be achieved through correct and consistent use of condoms with every act of sexual intercourse, or correct and consistent use of a condom to prevent infection plus another form of contraception to prevent pregnancy. (For more information about preventing and treating STDs, see STD Services.)

When educating clients about the range of contraceptive methods, providers should ensure that clients have information that is medically accurate, balanced, and provided in a nonjudgmental manner. To assist clients in making informed decisions, providers should educate clients in a manner that can be readily understood and retained. The content, format, method, and medium for delivering education should be evidence-based (see Appendix E).

When working with male clients, when appropriate, providers should discuss information about female-controlled methods

FIGURE 3. The typical effectiveness of Food and Drug Administration–approved contraceptive methods



(including emergency contraception) encourage discussion of contraception with partners, and provide information about how partners can access contraceptive services. Male clients should also be reminded that condoms should be used correctly and consistently to reduce risk of STDs, including HIV.

When working with any client, encourage partner communication about contraception, as well as understanding partner barriers (e.g., misperceptions about side effects) and facilitators (e.g., general support) of contraceptive use (43–46).

The provider should help the client consider potential barriers to using the method(s) under consideration. This includes consideration of the following factors:

- **Social-behavioral factors.** Social-behavioral factors might influence the likelihood of correct and consistent use of

contraception (47). Providers should help the client consider the advantages and disadvantages of the method(s) being considered, the client's feelings about using the method(s), how her or his partner is likely to respond, the client's peers' perceptions of the method(s), and the client's confidence in being able to use the method correctly and consistently (e.g., using a condom during every act of intercourse or remembering to take a pill every day) (37).

- **Intimate partner violence and sexual violence.** Current and past intimate partner sexual or domestic violence might impede the correct and consistent use of contraception, and might be a consideration when choosing a method (47–49). For example, an IUD might

be preferred because it does not require the partner's participation. The medical history might provide information on signs of current or past violence and, if not, providers should ask clients about relationship issues that might be potential barriers to contraceptive use. In addition, clients experiencing intimate partner violence or sexual violence should be referred for appropriate care.

- **Mental health and substance use behaviors.** Mental health (e.g., depression, anxiety disorders, and other mental disorders) and substance use behaviors (e.g., alcohol use, prescription abuse, and illicit drug use) might affect a client's ability to correctly and consistently use contraception (47,50). The medical history might provide information about the signs of such conditions or behaviors, and if not, providers should ask clients about substance use behaviors or mental health disorders, such as depression or anxiety, that might interfere with the motivation or ability to follow through with contraceptive use. If needed, clients with mental health disorders or risky substance use behaviors should be referred for appropriate care.

Step 4. Conduct a physical assessment related to contraceptive use, when warranted. Most women will need no or few examinations or laboratory tests before starting a method of contraception. Guidance on necessary examinations and tests related to initiation of contraception is available (42). A list of assessments that need to be conducted when providing reversible contraceptive services to a female client seeking to initiate or switch to a new method of reversible contraception is provided (Table 1) (42). Clinical evaluation of a client electing permanent sterilization should be guided by the clinician who performs the procedure. Recommendations for contraceptive use are available (42). Key points include the following:

- Blood pressure should be taken before initiating the use of combined hormonal contraception.
- Providers should assess the current pregnancy status of clients receiving contraception (42), which provides guidance on how to be reasonably certain that a woman is not pregnant at the time of contraception initiation. In most cases, a detailed history provides the most accurate assessment of pregnancy risk in a woman about to start using a contraceptive method. Routine pregnancy testing for every woman is not necessary.
- Weight measurement is not needed to determine medical eligibility for any method of contraception because all methods generally can be used among obese women. However, measuring weight and calculating BMI at baseline might be helpful for monitoring any changes and counseling women who might be concerned about weight change perceived to be associated with their contraceptive method.

- Unnecessary medical procedures and tests might create logistical, emotional, or economic barriers to contraceptive access for some women, particularly adolescents and low-income women, who have high rates of unintended pregnancies (1,51,52). For both adolescent and adult female clients, the following examinations and tests are not needed routinely to provide contraception safely to a healthy client (although they might be needed to address other non-contraceptive health needs) (42):

- pelvic examinations, unless inserting an intrauterine device (IUD) or fitting a diaphragm;
- cervical cytology or other cancer screening, including clinical breast exam;
- human immunodeficiency virus (HIV) screening; and
- laboratory tests for lipid, glucose, liver enzyme, and hemoglobin levels or thrombogenic mutations.

For male clients, no physical examination needs to be performed before distributing condoms.

Step 5. Provide the contraceptive method along with instructions about correct and consistent use, help the client develop a plan for using the selected method and for follow-up, and confirm client understanding.

- A broad range of FDA-approved contraceptive methods should be available onsite. Referrals for methods not available onsite should be provided for clients who indicate they prefer those methods. When providing contraception, providers should instruct the client about correct and consistent use and employ the following strategies to facilitate a client's use of contraception:
 - Provide onsite dispensing;
 - Begin contraception at the time of the visit rather than waiting for next menses (also known as “quick start”) if the provider can reasonably be certain that the client is not pregnant (42). A provider can be reasonably certain that a woman is not pregnant if she has no symptoms or signs of pregnancy and meets any one of the following criteria (42,53):
 - is ≤ 7 days after the start of normal menses,
 - has not had sexual intercourse since the start of last normal menses,
 - has been using a reliable method of contraception correctly and consistently,
 - is ≤ 7 days after spontaneous or induced abortion,
 - is within 4 weeks postpartum,
 - is fully or nearly fully breastfeeding (exclusively breastfeeding or the vast majority [$\geq 85\%$] of feeds are breastfeeds), amenorrheic, and < 6 months postpartum;
 - Provide or prescribe multiple cycles (ideally a full year's supply) of oral contraceptive pills, the patch, or the ring

TABLE 1. Assessments to conduct when a female client is initiating a new method of reversible contraception

	Cu-IUD and LNG-IUD	Implant	Injectable	Combined hormonal contraception	Progestin-only pills	Condom	Diaphragm or cervical cap	Spermicide
Examination								
Blood pressure	C	C	C	A*	C	C	C	C
Weight (BMI) (weight [kg]/height [m] ²)	—†	—†	—†	—†	—†	C	C	C
Clinical breast examination	C	C	C	C	C	C	C	C
Bimanual examination and cervical inspection	A	C	C	C	C	C	A [§]	C
Laboratory test								
Glucose	C	C	C	C	C	C	C	C
Lipids	C	C	C	C	C	C	C	C
Liver enzymes	C	C	C	C	C	C	C	C
Hemoglobin	C	C	C	C	C	C	C	C
Thrombogenic mutations	C	C	C	C	C	C	C	C
Cervical cytology (Papanicolaou smear)	C	C	C	C	C	C	C	C
STD screening with laboratory tests	—¶	C	C	C	C	C	C	C
HIV screening with laboratory tests	C	C	C	C	C	C	C	C

Source: CDC. U.S. selected practice recommendations for contraceptive use 2013. MMWR 2013;62(No. RR-5).

Abbreviations: A = Class A: essential and mandatory in all circumstances for safe and effective use of the contraceptive method; B = Class B: contributes substantially to safe and effective use, but implementation might be considered within the public health and/or service context (the risk of not performing an examination or test should be balanced against the benefits of making the contraceptive method available); C = Class C: does not contribute substantially to safe and effective use of the contraceptive method; Cu-IUD = copper-containing intrauterine device; LNG-IUD = levonorgestrel releasing intrauterine device.

* In cases in which access to health care might be limited, the blood pressure measurement can be obtained by the woman in a nonclinical setting (e.g., pharmacy or fire station) and self-reported to the provider.

† Weight (BMI) measurement is not needed to determine medical eligibility for any methods of contraception because all methods can be used (U.S. Medical Eligibility Criteria 1) or generally can be used (U.S. Medical Eligibility Criteria 2) among obese women (Source: CDC. U.S. medical eligibility criteria for contraceptive use 2010. MMWR 2010;59[No. RR-4]). However, measuring weight and calculating BMI at baseline might be helpful for monitoring any changes and counseling women who might be concerned about weight change perceived to be associated with their contraceptive method.

§ A bimanual examination (not cervical inspection) is needed for diaphragm fitting.

¶ Most women do not require additional STD screening at the time of IUD insertion, if they have already been screened according to CDC's STD treatment guidelines (Sources: CDC. STD treatment guidelines. Atlanta, GA: US Department of Health and Human Services, CDC; 2013. Available at <http://www.cdc.gov/std/treatment>. CDC. Sexually transmitted diseases treatment guidelines, 2010. MMWR. 2010;59[No. RR-12]). If a woman has not been screened according to guidelines, screening can be performed at the time of IUD insertion and insertion should not be delayed. Women with purulent cervicitis or current chlamydial infection or gonorrhea should not undergo IUD insertion (U.S. Medical Eligibility Criteria 4). Women who have a very high individual likelihood of STD exposure (e.g., those with a currently infected partner) generally should not undergo IUD insertion (U.S. Medical Eligibility Criteria 3) (Source: CDC. U.S. medical eligibility criteria for contraceptive use 2010. MMWR 2010;59[No. RR-4]). For these women, IUD insertion should be delayed until appropriate testing and treatment occurs.

to minimize the number of times a client has to return to the service site;

- Make condoms easily and inexpensively available; and
- If a client chooses a method that is not available on-site or the same day, provide the client another method to use until she or he can start the chosen method.
- Help the client develop a plan for using the selected method. Using a method incorrectly or inconsistently and having gaps in contraceptive protection because of method switching both increase the likelihood of an unintended pregnancy (37). After the method has been provided, or a plan put into place to obtain the chosen method, providers should help the client develop an action plan for using the selected method.

Providers should encourage clients to anticipate reasons why they might not use their chosen method(s) correctly or consistently, and help them develop strategies to deal with these possibilities. For example, for a client selecting oral contraceptive pills who might forget to take a pill, the provider can work with the client to identify ways to routinize daily pill taking (e.g., use of reminder systems such as daily text

messages or cell phone alarms). Providers also may inform clients about the availability of emergency contraceptive pills and may provide clients an advance supply of emergency contraceptive pills on-site or by prescription, if requested.

Side effects (e.g., irregular vaginal bleeding) are a primary reason for method discontinuation (54), so providers should discuss ways the client might deal with potential side effects to increase satisfaction with the method and improve continuation (42).

- Develop a plan for follow-up. Providers should discuss an appropriate follow-up plan with the client to meet their individual needs, considering the client's risk for discontinuation. Follow-up provides an opportunity to inquire about any initial difficulties the client might be experiencing, and might reinforce the perceived accessibility of the provider and increase rapport. Alternative modes of follow-up other than visits to the service site, such as telephone, e-mail, or text messaging, should be considered (assuming confidentiality can be assured), as needed.

As noted previously, if a client chooses a method that is not available on-site or during the visit, the provider

should schedule a follow-up visit with the client or provide a referral for her or him to receive the method. The client should be provided another method to use until she or he can start the chosen method.

- Confirm the client's understanding. Providers should assess whether the client understands the information that was presented. The client's understanding of the most important information about her or his chosen contraceptive method should be documented in the medical record (e.g., by a checkbox or written statement).

The teach-back method may be used to confirm the client's understanding by asking the client to repeat back messages about risks and benefits and appropriate method use and follow-up. If providers assess the client's understanding, then the check box or written statement can be used in place of a written method-specific informed consent form. Topics that providers may consider having the client repeat back include the following: typical method effectiveness; how to use the method correctly; protection from STDs; warning signs for rare, but serious, adverse events and what to do if they experience a warning sign; and when to return for follow-up.

Provide Counseling for Returning Clients

When serving contraceptive clients who return for ongoing care related to contraception, providers should ask if the client has any concerns with the method and assess its use. The provider should assess any changes in the client's medical history, including changes in risk factors and medications that might affect safe use of the contraceptive method. If the client is using the method correctly and consistently and there are no concerns about continued use, an appropriate follow-up plan should be discussed and more contraceptive supplies given (42). If the client or provider has concerns about the client's correct or consistent use of the method, the provider should ask if the client would be interested in considering a different method of contraception. If the client is interested, the steps described above should be followed.

Counseling Adolescent Clients

Providers should give comprehensive information to adolescent clients about how to prevent pregnancy (55–57). This information should clarify that avoiding sex (i.e., abstinence) is an effective way to prevent pregnancy and STDs. If the adolescent indicates that she or he will be sexually active, providers should give information about contraception and help her or him to choose a method that best meets her or his individual needs, including the use of condoms to reduce the risk of STDs. Long-acting reversible contraception is a safe and effective option for many adolescents, including those who have not been pregnant or given birth (35).

Providers of family planning services should offer confidential services to adolescents and observe all relevant state laws and any legal obligations, such as notification or reporting of child abuse, child molestation, sexual abuse, rape, or incest, as well as human trafficking (58,59). Confidentiality is critical for adolescents and can greatly influence their willingness to access and use services (60–67). As a result, multiple professional medical associations have emphasized the importance of providing confidential services to adolescents (68–70).

Providers should encourage and promote communication between the adolescent and his or her parent(s) or guardian(s) about sexual and reproductive health (71–86). Adolescents who come to the service site alone should be encouraged to talk to their parents or guardians. Educational materials and programs can be provided to parents or guardians that help them talk about sex and share their values with their child (72,87). When both parent or guardian and child have agreed, joint discussions can address family values and expectations about dating, relationships, and sexual behavior.

In a given year, approximately 20% of adolescent births represent repeat births (88), so in addition to providing postpartum contraception, providers should refer pregnant and parenting adolescents to home visiting and other programs that have been demonstrated to provide needed support and reduce rates of repeat teen pregnancy (89–94).

Services for adolescents should be provided in a “youth-friendly” manner, which means that they are accessible, equitable, acceptable, appropriate, comprehensive, effective, and efficient for youth as recommended by the World Health Organization (34).

Pregnancy Testing and Counseling

Providers of family planning services should offer pregnancy testing and counseling services as part of core family planning services, in accordance with recommendations of major professional medical organizations, such as the American College of Obstetricians and Gynecologists (ACOG) and the American Academy of Pediatrics (AAP) (95–97).

Pregnancy testing is a common reason for a client to visit a provider of family planning services. Approximately 65% of pregnancies result in live births, 18% in induced abortion, and 17% spontaneous fetal loss (98). Among live births, only 1% of infants are placed for adoption within their first month of life (99).

The visit should include a discussion about her reproductive life plan and a medical history that includes asking about any coexisting conditions (e.g., chronic medical illnesses, physical disability, psychiatric illness) (95,96). In most cases,

a qualitative urine pregnancy test will be sufficient; however, in certain cases, the provider may consider performing a quantitative serum pregnancy test, if exact hCG levels would be helpful for diagnosis and management. The test results should be presented to the client, followed by a discussion of options and appropriate referrals.

Options counseling should be provided in accordance with recommendations from professional medical associations, such as ACOG and AAP (95–97). A female client might wish to include her partner in the discussion; however, if a client chooses not to involve her partner, confidentiality must be assured.

Positive Pregnancy Test

If the pregnancy test is positive, the clinical visit should include an estimation of gestational age so that appropriate counseling can be provided. If a woman is uncertain about the date of her last normal menstrual period, a pelvic examination might be needed to help assess gestational age. In addition, clients should receive information about the normal signs and symptoms of early pregnancy, and should be instructed to report any concerns to a provider for further evaluation. If ectopic pregnancy or other pregnancy abnormalities or problems are suspected, the provider should either manage the condition or refer the client for immediate diagnosis and management.

Referral to appropriate providers of follow-up care should be made at the request of the client, as needed. Every effort should be made to expedite and follow through on all referrals. For example, providers might provide a resource listing or directory of providers to help the client identify options for care. Depending upon a client's needs, the provider may make an appointment for the client, or call the referral site to let them know the client was referred. Providers also should assess the client's social support and refer her to appropriate counseling or other supportive services, as needed.

For clients who are considering or choose to continue the pregnancy, initial prenatal counseling should be provided in accordance with the recommendations of professional medical associations, such as ACOG (97). The client should be informed that some medications might be contraindicated in pregnancy, and any current medications taken during pregnancy need to be reviewed by a prenatal care provider (e.g., an obstetrician or midwife). In addition, the client should be encouraged to take a daily prenatal vitamin that includes folic acid; to avoid smoking, alcohol, and other drugs; and not to eat fish that might have high levels of mercury (97). If there might be delays in obtaining prenatal care, the client should be provided or referred for any needed STD screening (including HIV) and vaccinations (36).

Negative Pregnancy Test

Women who are not pregnant and who do not want to become pregnant at this time should be offered contraceptive services, as described previously. The contraceptive counseling session should explore why the client thought that she was pregnant and sought pregnancy testing services, and whether she has difficulties using her current method of contraception. A negative pregnancy test also provides an opportunity to discuss the value of making a reproductive life plan. Ideally, these services will be offered in the same visit as the pregnancy test because clients might not return at a later time for contraceptive services.

Women who are not pregnant and who are trying to become pregnant should be offered services to help achieve pregnancy or basic infertility services, as appropriate (see “Clients Who Want to Become Pregnant” and “Basic Infertility Services”). They also should be offered preconception health and STD services (see “Preconception Health Services” and “STD services”).

Clients Who Want to Become Pregnant

Providers should advise clients who wish to become pregnant in accordance with the recommendations of professional medical organizations, such as the American Society for Reproductive Medicine (ASRM) (100).

Providers should ask the client (or couple) how long she or they have been trying to get pregnant and when she or they hope to become pregnant. If the client's situation does not meet one of the standard definitions of infertility (see “Basic Infertility Services”), then she or he may be counseled about how to maximize fertility. Key points are as follows:

- The client should be educated about peak days and signs of fertility, including the 6-day interval ending on the day of ovulation that is characterized by slippery, stretchy cervical mucus and other possible signs of ovulation.
- Women with regular menstrual cycles should be advised that vaginal intercourse every 1–2 days beginning soon after the menstrual period ends can increase the likelihood of becoming pregnant.
- Methods or devices designed to determine or predict the time of ovulation (e.g., over-the-counter ovulation kits, digital telephone applications, or cycle beads) should be discussed.
- It should be noted that fertility rates are lower among women who are very thin or obese, and those who consume high levels of caffeine (e.g., more than five cups per day).
- Smoking, consuming alcohol, using recreational drugs, and using most commercially available vaginal lubricants should be discouraged as these might reduce fertility.

Basic Infertility Services

Providers should offer basic infertility care as part of core family planning services in accordance with the recommendations of professional medical organizations, such as ACOG, ASRM, and the American Urological Association (AUA) (96,101,102).

Infertility commonly is defined as the failure of a couple to achieve pregnancy after 12 months or longer of regular unprotected intercourse (101). Earlier assessment (such as 6 months of regular unprotected intercourse) is justified for women aged >35 years, those with a history of oligo-amenorrhea (infrequent menstruation), those with known or suspected uterine or tubal disease or endometriosis, or those with a partner known to be subfertile (the condition of being less than normally fertile though still capable of effecting fertilization) (101). An early evaluation also might be warranted if risk factors of male infertility are known to be present or if there are questions regarding the male partner's fertility potential (102). Infertility visits to a family planning provider are focused on determining potential causes of the inability to achieve pregnancy and making any needed referrals to specialist care (101,102). ASRM recommends that evaluation of both partners should begin at the same time (101).

Basic Infertility Care for Women

The clinical visit should focus on understanding the client's reproductive life plan (24) and her difficulty in achieving pregnancy through a medical history, sexual health assessment and physical exam, in accordance with recommendations developed by professional medical associations such as ASRM (101) and ACOG (96). The medical history should include past surgery, including indications and outcome(s), previous hospitalizations, serious illnesses or injuries, medical conditions associated with reproductive failure (e.g., thyroid disorders, hirsutism, or other endocrine disorders), and childhood disorders; results of cervical cancer screening and any follow-up treatment; current medication use and allergies; and family history of reproductive failure. In addition, a reproductive history should include how long the client has been trying to achieve pregnancy; coital frequency and timing, level of fertility awareness, and results of any previous evaluation and treatment; gravidity, parity, pregnancy outcome(s), and associated complications; age at menarche, cycle length and characteristics, and onset/severity of dysmenorrhea; and sexual history, including pelvic inflammatory disease, history of STDs, or exposure to STDs. A review of systems should emphasize symptoms of thyroid disease, pelvic or abdominal pain, dyspareunia, galactorrhea, and hirsutism (101).

The physical examination should include: height, weight, and body mass index (BMI) calculation; thyroid examination to identify any enlargement, nodule, or tenderness; clinical breast examination; and assessment for any signs of androgen excess. A pelvic examination should assess for: pelvic or abdominal tenderness, organ enlargement or mass; vaginal or cervical abnormality, secretions, or discharge; uterine size, shape, position, and mobility; adnexal mass or tenderness; and cul-de-sac mass, tenderness, or nodularity. If needed, clients should be referred for further diagnosis and treatment (e.g., serum progesterone levels, follicle-stimulating hormone/luteinizing hormone levels, thyroid function tests, prolactin levels, endometrial biopsy, transvaginal ultrasound, hysterosalpingography, laparoscopy, and clomiphene citrate).

Basic Infertility Care for Men

Infertility services should be provided for the male partner of an infertile couple in accordance with recommendations developed by professional medical associations such as AUA (102). Providers should discuss the client's reproductive life plan, take a medical history, and conduct a sexual health assessment. AUA recommends that the medical history include a reproductive history (102). The medical history should include systemic medical illnesses (e.g., diabetes mellitus), prior surgeries and past infections; medications (prescription and nonprescription) and allergies; and lifestyle exposures. The reproductive history should include methods of contraception, coital frequency and timing; duration of infertility and prior fertility; sexual history; and gonadal toxin exposure, including heat. Patients also should be asked about their female partners' history of pelvic inflammatory disease, their partners' histories of STDs, and problems with sexual dysfunction.

In addition, a physical examination should be conducted with particular focus given to 1) examination of the penis, including the location of the urethral meatus; 2) palpation of the testes and measurement of their size; 3) presence and consistency of both the vas deferens and epididymis; 4) presence of a varicocele; 5) secondary sex characteristics; and 6) a digital rectal exam (102). Male clients concerned about their fertility should have a semen analysis. If this test is abnormal, they should be referred for further diagnosis (i.e., second semen analysis, endocrine evaluation, post-ejaculate urinalysis, or others deemed necessary) and treatment. The semen analysis is the first and most simple screen for male fertility.

Infertility Counseling

Counseling provided during the clinical visit should be guided by information elicited from the client during the medical and reproductive history and the findings of the

physical exam. If there is no apparent cause of infertility and the client does not meet the definition above, providers should educate the client about how to maximize fertility (see “Clients Who Want to Become Pregnant”). ACOG notes the importance of addressing the emotional and educational needs of clients with infertility and recommends that providers consider referring clients for psychological support, infertility support groups, or family counseling (96).

Preconception Health Services

Providers of family planning services should offer preconception health services to female and male clients in accordance with CDC’s recommendations to improve preconception health and health care (24).

Preconception health services are beneficial because of their effect on pregnancy and birth outcomes and their role in improving the health of women and men. The term preconception describes any time that a woman of reproductive potential is not pregnant but at risk of becoming pregnant, or when a man is at risk for impregnating his female partner.

Preconception health-care services for women aim to identify and modify biomedical, behavioral, and social risks to a woman’s health or pregnancy outcomes through prevention and management. It promotes the health of women of reproductive age before conception, and thereby helps to reduce pregnancy-related adverse outcomes, such as low birthweight, premature birth, and infant mortality (24). Moreover, the preconception health services recommended here are equally important because they contribute to the improvement of women’s health and well-being, regardless of her childbearing intentions. CDC recommends that preconception health services be integrated into primary care visits made by women of reproductive age, such as family planning visits (24).

In the family planning setting, providers may prioritize screening and counseling about preconception health for couples that are trying to achieve pregnancy and couples seeking basic infertility services. Women who are using contraception to prevent or delay pregnancy might also benefit from preconception health services, especially those at high risk of unintended pregnancy. A woman is at high risk of unintended pregnancy if she is using no method or a less effective method of contraception (e.g., barrier methods, rhythm, or withdrawal), or has a history of contraceptive discontinuation or incorrect use (38,39). A woman is at lower risk of unintended pregnancy if she is using a highly effective method, such as an IUD or implant, or has an established history of using methods of contraception, such as injections, pills, patch, or ring correctly and consistently (38,39). Clients

who do not want to become pregnant should also be provided preconception health services, since they are recommended by USPSTF for the purpose of improving the health of adults.

Recommendations for improving the preconception health of men also have been identified, although the evidence base for many of the recommendations for men is less than that for women (103). This report includes preconception health services that address men as partners in family planning (i.e., both preventing and achieving pregnancy), their direct contributions to infant health (e.g., genetics), and their role in improving the health of women (e.g., through reduced STD/HIV transmission). Moreover, these services are important for improving the health of men regardless of their pregnancy intention.

In a family planning setting, all women planning or capable of pregnancy should be counseled about the need to take a daily supplement containing 0.4 to 0.8 mg of folic acid, in accordance with the USPSTF recommendation (Grade A) (104).

Other preconception health services for women and men should include discussion of a reproductive life plan and sexual health assessment (Boxes 2 and 4), as well as the screening services described below (24,103,105). Services should be provided in accordance with the cited clinical recommendations, and any needed follow up (further diagnosis, treatment) should be provided either on-site or through referral.

Medical History

For female clients, the medical history should include the reproductive history, history of poor birth outcomes (i.e., preterm, cesarean delivery, miscarriage, and stillbirth), environmental exposures, hazards and toxins (e.g., smoking, alcohol, other drugs), medications that are known teratogens, genetic conditions, and family history (24,105).

For male clients, the medical history should include asking about the client’s past medical and surgical history that might impair his reproductive health (e.g., genetic conditions, history of reproductive failures, or conditions that can reduce sperm quality, such as obesity, diabetes mellitus, and varicocele) and environmental exposures, hazards and toxins (e.g., smoking) (103).

Intimate Partner Violence

Providers should screen women of childbearing age for intimate partner violence and provide or refer women who screen positive to intervention services, in accordance with USPSTF (Grade B) recommendations (106).

Alcohol and Other Drug Use

For female and male adult clients, providers should screen for alcohol use in accordance with the USPSTF recommendation (Grade B) for how to do so, and provide behavioral counseling

interventions, as indicated (107). Screening adults for other drug use and screening adolescents for alcohol and other drug use has the potential to reduce misuse of alcohol and other drugs, and can be recommended (105,108,109). However, the USPSTF recommendation for screening for other drugs in adults, and for alcohol and other drugs in adolescents, is an “I,” and patients should be informed that there is insufficient evidence to assess the balance of benefits and harms of this screening (107,110).

Tobacco Use

For female and male clients, providers should screen for tobacco use in accordance with the USPSTF recommendation (111,112) for how to do so. Adults (Grade A) who use tobacco products should be provided or referred for tobacco cessation interventions, including brief behavioral counseling sessions (<10 minutes) and pharmacotherapy delivered in primary care settings (111). Adolescents (Grade B) should be provided intervention to prevent initiation of tobacco use (112).

Immunizations

For female and male clients, providers should screen for immunization status in accordance with recommendations of CDC’s Advisory Committee on Immunization Practices (113) and offer vaccination, as indicated, or provide referrals to community providers for immunization. Female and male clients should be screened for age-appropriate vaccinations, such as influenza and tetanus–diphtheria–pertussis (Tdap), measles, mumps, and rubella (MMR), varicella, pneumococcal, and meningococcal. In addition, ACOG recommends that rubella titer be performed in women who are uncertain about MMR immunization (108). (For vaccines for reproductive health-related conditions, i.e., human papillomavirus and hepatitis B, see “Sexually Transmitted Disease Services.”)

Depression

For all clients, providers should screen for depression when staff-assisted depression care supports are in place to ensure accurate diagnosis, effective treatment, and follow-up (114,115). Staff-assisted care supports are defined as clinical staff members who assist the primary care clinician by providing some direct depression care, such as care support or coordination, case management, or mental health treatment. The lowest effective staff supports consist of a screening nurse who advises primary care clinicians of a positive screen and provides a protocol facilitating referral to behavioral therapy.

Providers also may follow American Psychiatric Association (116) and American Academy of Child and Adolescent Psychiatry (117) recommendations to assess risk for suicide among persons experiencing depression and other risk factors.

Height, Weight, and Body Mass Index

For all clients, providers should screen adult (Grade B) and adolescent (Grade B) clients for obesity in accordance with the USPSTF recommendation, and obese adults should be referred for intensive counseling and behavioral interventions to promote sustained weight loss (118,119). Clients likely will need to be referred for this service. These interventions typically comprise 12 to 26 sessions in a year and include multiple behavioral management activities, such as group sessions, individual sessions, setting weight-loss goals, improving diet or nutrition, physical activity sessions, addressing barriers to change, active use of self-monitoring, and strategizing how to maintain lifestyle changes.

Blood Pressure

For female and male clients, providers should screen for hypertension in accordance with the USPSTF’s recommendation (Grade A) that blood pressure be measured routinely among adults (120) and the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure’s recommendation that persons with blood pressure less than 120/80 be screened every 2 years, and every year if prehypertensive (i.e., blood pressure 120–139/80–89) (121). Providers also may follow AAP’s recommendation that adolescents receive annual blood pressure screening (109).

Diabetes

For female and male clients, providers should follow the USPSTF recommendation (Grade B) to screen for type 2 diabetes in asymptomatic adults with sustained blood pressure (either treated or untreated) >135/80 mmHg (122).

Sexually Transmitted Disease Services

Providers should offer STD services in accordance with CDC’s STD treatment and HIV testing guidelines (36,123,124). It is important to test for chlamydia annually among young sexually active females and for gonorrhea routinely among all sexually active females at risk for infection because they can cause tubal infertility in women if left untreated. Testing for syphilis, HIV/AIDS, and hepatitis C should be conducted as recommended (36,123,124). Vaccination for human papillomavirus (HPV) and hepatitis B are also important parts of STD services and preconception care (113).

STD services should be provided for persons with no signs or symptoms suggestive of an STD. STD diagnostic management recommendations are not included in these guidelines, so providers should refer to CDC’s STD treatment guidelines

(36) when caring for clients with STD symptoms. STD services include the following steps, which should be provided at the initial visit and at least annually thereafter:

Step 1. Assess: The provider should discuss the client's reproductive life plan, conduct a standard medical history and sexual health assessment (see text box above), and check immunization status. A pelvic exam is not indicated in patients with no symptoms suggestive of an STD.

Step 2. Screen: A client who is at risk of an STD (i.e., sexually active and not involved in a mutually monogamous relationship with an uninfected partner) should be screened for HIV and the other STDs listed below, in accordance with CDC's STD treatment guidelines (36) and recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings (123). Clients also should follow CDC's recommendations for testing for hepatitis C (124), and the Advisory Committee on Immunization Practices's recommendations on reproductive health-related immunizations (113). It is important to follow these guidelines both to ensure that clients receive needed services and to avoid unnecessary screening.

Chlamydia

For female clients, providers should screen all sexually active women aged ≤ 25 years for chlamydia annually, in addition to sexually active women aged >25 years with risk factors for chlamydia infection (36). Women aged >25 years at higher risk include sexually active women who have a new or more than one sex partner or who have a partner who has other concurrent partners. Females with chlamydia infection should be rescreened for re-infection at 3 months after treatment. Pregnant women should be screened for chlamydia at the time of their pregnancy test if there might be delays in obtaining prenatal care (36).

For male clients, chlamydia screening can be considered for males seen at sites with a high prevalence of chlamydia, such as adolescent clinics, correctional facilities, and STD clinics (36,125,126). Providers should screen men who have sex with men (MSM) for chlamydia at anatomic sites of exposure, in accordance with CDC's STD treatment guidelines (36). Males with symptoms suggestive of chlamydia (urethral discharge or dysuria or whose partner has chlamydia) should be tested and empirically treated at the initial visit. Males with chlamydia infection should be re-screened for reinfection at 3 months (36).

Gonorrhea

For female clients, providers should screen clients for gonorrhea, in accordance with CDC's STD treatment guidelines (36). Routine screening for *N. gonorrhoeae* in all sexually active women at risk for infection is recommended annually (36). Women aged

<25 years are at highest risk for gonorrhea infection. Other risk factors that place women at increased risk include a previous gonorrhea infection, the presence of other STDs, new or multiple sex partners, inconsistent condom use, commercial sex work, and drug use. Females with gonorrhea infection should be re-screened for re-infection at 3 months after treatment. Pregnant women should be screened for gonorrhea at the time of their pregnancy test if there might be delays in obtaining prenatal care (36).

For male clients, providers should screen MSM for gonorrhea at anatomic sites of exposure, in accordance with CDC's STD treatment guidelines (36). Males with symptoms suggestive of gonorrhea (urethral discharge or dysuria or whose partner has gonorrhea) should be tested and empirically treated at the initial visit. Males with gonorrhea infection should be re-screened for reinfection at 3 months after treatment (36,126–128).

Syphilis

For female and male clients, providers should screen clients for syphilis, in accordance with CDC's STD treatment guidelines (36). CDC recommends that persons at risk for syphilis infection should be screened. Populations at risk include MSM, commercial sex workers, persons who exchange sex for drugs, those in adult correctional facilities and those living in communities with high prevalence of syphilis (36). Pregnant women should be screened for syphilis at the time of their pregnancy test if there might be delays in obtaining prenatal care (36).

HIV/AIDS

For female and male clients, providers should screen clients for HIV/AIDS, in accordance with CDC HIV testing guidelines (123). Providers should follow CDC recommendations that all clients aged 13–64 years be screened routinely for HIV infection and that all persons likely to be at high risk for HIV be rescreened at least annually (123). Persons likely to be at high risk include injection-drug users and their sex partners, persons who exchange sex for money or drugs, sex partners of HIV-infected persons, and MSM or heterosexual persons who themselves or whose sex partners have had more than one sex partner since their most recent HIV test. CDC further recommends that screening be provided after the patient is notified that testing will be performed as part of general medical consent unless the patient declines (opt-out screening) or otherwise prohibited by state law. The USPSTF also recommends screening for HIV (Grade A) (129).

Hepatitis C

For female and male clients, CDC recommends one-time testing for hepatitis C (HCV) without prior ascertainment of HCV risk for persons born during 1945–1965, a population with a disproportionately high prevalence of HCV infection

and related disease. Persons identified as having HCV infection should receive a brief screening for alcohol use and intervention as clinically indicated, followed by referral to appropriate care for HCV infection and related conditions. These recommendations do not replace previous guidelines for HCV testing that are based on known risk factors and clinical indications. Rather, they define an additional target population for testing: persons born during 1945–1965 (124). USPSTF also recommends screening persons at high risk for infection for hepatitis C and one-time screening for HCV infection for persons in the 1945–1965 birth cohort (Grade B) (130).

Immunizations Related to Reproductive Health

Female clients aged 11–26 years should be offered either human papillomavirus (HPV) 2 or HPV4 vaccine for the prevention of HPV and cervical cancer if not previously vaccinated, although the series can be started in persons as young as age 9 years (113); recommendations include starting at age 11–12 years and catch up vaccine among females aged 13–26 who have not been vaccinated previously or have not completed the 3-dose series through age 26. Routine hepatitis B vaccination should be offered to all unvaccinated children and adolescents aged <19 years and all adults who are unvaccinated and do not have any documented history of hepatitis B infection (113).

Male clients aged 11–21 years (minimum age: 9 years) should be offered HPV4 vaccine, if not vaccinated previously; recommendations include starting at age 11–12 years and catch up vaccine among males aged 13–21 years who have not been vaccinated previously or have not completed the 3-dose series through age 21 years; vaccination is recommended among at-risk males, including MSM and immune-compromised males through age 26 years if not vaccinated previously or males who have not completed the 3-dose series through age 26 years. Heterosexual males aged 22–26 years may be vaccinated (131). Routine hepatitis B vaccination should be offered to all unvaccinated children and adolescents aged <19 years, and all unvaccinated adults who do not have a documented history of hepatitis B infection (113).

Step 3. Treat: A client with an STD and her or his partner(s) should be treated in a timely fashion to prevent complications, re-infection and further spread of the infection in the community in accordance with CDC's STD treatment guidelines; clients with HIV infection should be linked to HIV care and treatment (36,123). Clients should be counseled about the need for partner evaluation and treatment to avoid reinfection at the time the client receives the positive test results. For partners of clients with chlamydia or gonorrhea, one option is to schedule them to come in with the client; another option for partners who cannot come in with the client

is expedited partner therapy (EPT), as permissible by state laws, in which medication or a prescription is provided to the patient to give to the partner to ensure treatment. EPT is a partner treatment strategy for partners who are unable to access care and treatment in a timely fashion. Because of concerns related to resistant gonorrhea, efforts to bring in for treatment partners of patients with gonorrhea infection are recommended; EPT for gonorrhea should be reserved for situations in which efforts to treat partners in a clinical setting are unsuccessful and EPT is a gonorrhea treatment of last resort.

All clients treated for chlamydia or gonorrhea should be rescreened 3 months after treatment; HIV-infected females with *Trichomonas vaginalis* should be linked to HIV care and rescreened for *T. vaginalis* at 3 months. If needed, the client also should be vaccinated for hepatitis B and HPV (113). Ideally, STD treatment should be directly observed in the facility rather than a prescription given or called in to a pharmacy. If a referral is made to a service site that has the necessary medication available on-site, such as the recommended injectable antimicrobials for gonorrhea and syphilis, then the referring provider must document that treatment was given.

Step 4. Provide risk counseling: If the client is at risk for or has an STD, high-intensity behavioral counseling for sexual behavioral risk reduction should be provided in accordance with the USPSTF recommendation (Grade B) (132). One high-intensity behavioral counseling model that is similar to the contraceptive counseling model is Project Respect (133), which could be implemented in family planning settings. All sexually active adolescents are at risk, and adults are at increased risk if they have current STDs, had an STD in the past year, have multiple sexual partners, are in nonmonogamous relationships, or are sexually active and live in a community with a high rate of STDs.

Other key messages to give infected clients before they leave the service site include the following: a) refrain from unprotected sexual intercourse during the period of STD treatment, 2) encourage partner(s) to be screened or to get treatment as quickly as possible in accordance with CDC's STD treatment guidelines (partners in the past 60 days for chlamydia and gonorrhea, 3 to 6 months plus the duration of lesions or signs for primary and secondary syphilis, respectively) if the partner did not accompany the client to the service site for treatment, and 3) return for retesting in 3 months. If the partner is unlikely to access treatment quickly, then EPT for chlamydia or gonorrhea should be considered, if permissible by state law.

A client using or considering contraceptive methods other than condoms should be advised that these methods do not protect against STDs. Providers should encourage a client who is not in a mutually monogamous relationship with an

uninfected partner to use condoms. Patients who do not know their partners' infection status should be encouraged to get tested and use condoms or avoid sexual intercourse until their infection status is known.

Related Preventive Health Services

For many women and men of reproductive age, a family planning service site is their only source of health care; therefore, visits should include provision of or referral to other preventive health services. Providers of family planning services that do not have the capacity to offer comprehensive primary care services should have strong links to other community providers to ensure that clients have access to primary care. If a client does not have another source of primary care, priority should be given to providing related reproductive health services or providing referrals, as needed.

For clients without a primary care provider, the following screening services should be provided, with appropriate follow-up, if needed, while linking the client to a primary care provider. These services should be provided in accordance with federal and professional medical recommendations cited below regarding the frequency of screening, the characteristics of the clients that should be screened, and the screening procedures to be used.

Medical History

USPSTF recommends that women be asked about family history that would be suggestive of an increased risk for deleterious mutations in BRCA1 or BRCA2 genes (e.g., receiving a breast cancer diagnosis at an early age, bilateral breast cancer, history of both breast and ovarian cancer, presence of breast cancer in one or more female family members, multiple cases of breast cancer in the family, both breast and ovarian cancer in the family, one or more family members with two primary cases of cancer, and Ashkenazi background). Women with identified risk(s) should be referred for genetic counseling and evaluation for BRCA testing (Grade B) (134). The USPSTF also recommends that women at increased risk for breast cancer should be counseled about risk-reducing medications (Grade B) (135).

Cervical Cytology

Providers should provide cervical cancer screening to clients receiving related preventive health services. Providers should follow USPSTF recommendations to screen women aged 21–65 years with cervical cytology (Pap smear) every 3 years, or for women aged 30–65 years, screening with a combination of cytology and HPV testing every 5 years (Grade A) (136).

Cervical cytology no longer is recommended on an annual basis. Further, it is not recommended (Grade D) for women aged <21 years (136). Women with abnormal test results should be treated in accordance with professional standards of care, which may include colposcopy (96,137). The need for cervical cytology should not delay initiation or hinder continuation of a contraceptive method (42).

Providers should also follow ACOG and AAP recommendations that a genital exam should accompany a cervical cancer screening to inspect for any suspicious lesions or other signs that might indicate an undiagnosed STD (96,97,138).

Clinical Breast Examination

Despite a lack of definitive data for or against, clinical breast examination has the potential to detect palpable breast cancer and can be recommended. ACOG recommends annual examination for all women aged >19 years (108). ACS recommends screening every 3 years for women aged 20–39 years, and annually for women aged ≥40 years (139). However, the USPSTF recommendation for clinical breast exam is an I, and patients should be informed that there is insufficient evidence to assess the balance of benefits and harms of the service (140).

Mammography

Providers should follow USPSTF recommendations (Grade B) to screen women aged 50–74 years on a biennial basis; they should screen women aged <50 years if other conditions support providing the service to an individual patient (140).

Genital Examination

For adolescent males, examination of the genitals should be conducted. This includes documentation of normal growth and development and other common genital findings, including hydrocele, varicocele, and signs of STDs (141). Components of this examination include inspecting skin and hair, palpating inguinal nodes, scrotal contents and penis, and inspecting the perianal region (as indicated).

Summary of Recommendations for Providing Family Planning and Related Preventive Health Services

The screening components for each family planning and related preventive health service are provided in summary checklists for women (Table 2) and men (Table 3). When considering how to provide the services listed in these recommendations (e.g., the screening components for each

service, risk groups that should be screened, the periodicity of screening, what follow-up steps should be taken if screening reveals the presence of a health condition), providers should follow CDC and USPSTF recommendations cited above, or, in the absence of CDC and USPSTF recommendations, the recommendations of professional medical associations. Following these recommendations is important both to ensure clients receive needed care and to avoid unnecessary screening of clients who do not need the services.

The summary tables describe multiple screening steps, which refer to the following: 1) the process of asking questions about a client's history, including a determination of whether risk factors for a disease or health condition exist; 2) performing a physical exam; and 3) performing laboratory tests in at-risk asymptomatic persons to help detect the presence of a specific disease, infection, or condition. Many screening recommendations apply only to certain subpopulations (e.g., specific age groups, persons who engage in specific risk behaviors or who have specific health conditions), or some screening recommendations apply to a particular frequency (e.g., a cervical cancer screening is generally recommended every 3 years rather than annually). Providers should be aware that the USPSTF also has recommended that certain screening services not be provided because the harm outweighs the benefit (see Appendix F).

When screening results indicate the potential or actual presence of a health condition, the provider should either provide or refer the client for the appropriate further diagnostic testing or treatment in a manner that is consistent with the relevant federal or professional medical associations' clinical recommendations.

Conducting Quality Improvement

Service sites that offer family planning services should have a system for conducting quality improvement, which is designed to review and strengthen the quality of services on an ongoing basis. Quality improvement is the use of a deliberate and continuous effort to achieve measurable improvements in the identified indicators of quality of care, which improve the health of the community (142). By improving the quality of care, family planning outcomes, such as reduced rates of unintended pregnancy, improved patient experiences, and reduced costs, are more likely to be achieved (10,12,143,144).

Several frameworks for conducting quality improvement have been developed (144–146). This section presents a general overview of three key steps that providers should take when conducting quality improvement of family planning services: 1) determine which measures are needed to monitor quality; 2) collect the information needed; and 3) use the findings to

make changes to improve quality (147). Ideally, these steps will be conducted on a frequent (optimally, quarterly) and ongoing basis. However, since quality cuts across all aspects of a program, not all domains of quality can necessarily be considered at all times. Within a sustainable system of quality improvement, programs can opt to focus on a subset of quality dimensions and their respective measures.

Determining Which Measures Are Needed

Performance measures provide information about how well the service site is meeting pre-established goals (148). The following questions should be considered when selecting performance measures (143):

- Is the topic important to measure and report? For example, does it address a priority aspect of health care, and is there opportunity for improvement?
- What is the level of evidence for the measure (e.g., that a change in the measure is likely to represent a true change in health outcomes)? Does the measure produce consistent (reliable) and credible (valid) results about the quality of care?
- Are the results meaningful and understandable and useful for informing quality improvement?
- Is the measure feasible? Can it be implemented without undue burden (e.g., captured with electronic data or electronic health records)?

Performance measures should consider the quality of the structure of services (e.g., the characteristics of the settings in which providers deliver health care, including material resources, human resources, and organizational structure), the process by which care is provided (whether services are provided correctly and completely, and how clients perceive the care they receive), and the outcomes of that care (e.g., client behaviors or health conditions that result) (149). They also may assess each dimension of quality services (10,13). Examples of measures that can be used for monitoring the quality of family planning services (150) and suggested measures that might help providers monitor quality of care have been listed (Table 6). However, other measures have been developed that also might be useful (151–153). Service sites that offer family planning services should select, measure, and assess at least one intermediate or outcome measure on an ongoing basis, for which the service site can be accountable. Structure- and process-based measures that assess the eight dimensions of quality services may be used to better determine how to improve quality (154).

Collecting Information

Once providers have determined what information is needed, the next steps are to collect and use that information to improve the quality of care. Commonly used methods of data collection include the following:

TABLE 2. Checklist of family planning and related preventive health services for women

Screening components	Family planning services (provide services in accordance with the appropriate clinical recommendation)					Related preventive health services
	Contraceptive services*	Pregnancy testing and counseling	Basic infertility services	Preconception health services	STD services [†]	
History						
Reproductive life plan [§]	Screen	Screen	Screen	Screen	Screen	
Medical history ^{§,**}	Screen	Screen	Screen	Screen	Screen	Screen
Current pregnancy status [§]	Screen					
Sexual health assessment ^{§,**}	Screen		Screen	Screen	Screen	
Intimate partner violence ^{§,¶,**}				Screen		
Alcohol and other drug use ^{§,¶,**}				Screen		
Tobacco use ^{§,¶}	Screen (combined hormonal methods for clients aged ≥35 years)			Screen		
Immunizations [§]				Screen	Screen for HPV & HBV ^{§§}	
Depression ^{§,¶}				Screen		
Folic acid ^{§,¶}				Screen		
Physical examination						
Height, weight and BMI ^{§,¶}	Screen (hormonal methods) ^{††}		Screen	Screen		
Blood pressure ^{§,¶}	Screen (combined hormonal methods)			Screen ^{§§}		
Clinical breast exam ^{**}			Screen			Screen ^{§§}
Pelvic exam ^{§,**}	Screen (initiating diaphragm or IUD)	Screen (if clinically indicated)	Screen			
Signs of androgen excess ^{**}			Screen			
Thyroid exam ^{**}			Screen			
Laboratory testing						
Pregnancy test ^{**}	Screen (if clinically indicated)	Screen				
Chlamydia ^{§, ¶}	Screen ^{¶¶}				Screen ^{§§}	
Gonorrhea ^{§, ¶}	Screen ^{¶¶}				Screen ^{§§}	
Syphilis ^{§,¶}					Screen ^{§§}	
HIV/AIDS ^{§,¶}					Screen ^{§§}	
Hepatitis C ^{§,¶}					Screen ^{§§}	
Diabetes ^{§,¶}				Screen ^{§§}		
Cervical cytology [¶]						Screen ^{§§}
Mammography [¶]						Screen ^{§§}

Abbreviations: BMI = body mass index; HBV = hepatitis B virus; HIV/AIDS = human immunodeficiency virus/acquired immunodeficiency syndrome; HPV = human papillomavirus; IUD = intrauterine device; STD = sexually transmitted disease.

* This table presents highlights from CDC's recommendations on contraceptive use. However, providers should consult appropriate guidelines when treating individual patients to obtain more detailed information about specific medical conditions and characteristics (Source: CDC. U.S. medical eligibility criteria for contraceptive use 2010. MMWR 2010;59[No. RR-4].

† STD services also promote preconception health but are listed separately here to highlight their importance in the context of all types of family planning visits. The services listed in this column are for women without symptoms suggestive of an STD.

§ CDC recommendation.

¶ U.S. Preventive Services Task Force recommendation.

** Professional medical association recommendation.

†† Weight (BMI) measurement is not needed to determine medical eligibility for any methods of contraception because all methods can be used (U.S. Medical Eligibility Criteria 1) or generally can be used (U.S. Medical Eligibility Criteria 2) among obese women (Source: CDC. U.S. medical eligibility criteria for contraceptive use 2010. MMWR 2010;59[No. RR-4]). However, measuring weight and calculating BMI at baseline might be helpful for monitoring any changes and counseling women who might be concerned about weight change perceived to be associated with their contraceptive method.

§§ Indicates that screening is suggested only for those persons at highest risk or for a specific subpopulation with high prevalence of an infection or condition.

¶¶ Most women do not require additional STD screening at the time of IUD insertion if they have already been screened according to CDC's STD treatment guidelines (Sources: CDC. STD treatment guidelines. Atlanta, GA: US Department of Health and Human Services, CDC; 2013. Available at <http://www.cdc.gov/std/treatment>. CDC. Sexually transmitted diseases treatment guidelines, 2010. MMWR 2010;59[No. RR-12]). If a woman has not been screened according to guidelines, screening can be performed at the time of IUD insertion and insertion should not be delayed. Women with purulent cervicitis or current chlamydial infection or gonorrhea should not undergo IUD insertion (U.S. Medical Eligibility Criteria 4) women who have a very high individual likelihood of STD exposure (e.g. those with a currently infected partner) generally should not undergo IUD insertion (U.S. Medical Eligibility Criteria 3) (Source: CDC. US medical eligibility criteria for contraceptive use 2010. MMWR 2010;59[No. RR-4]). For these women, IUD insertion should be delayed until appropriate testing and treatment occurs.

- **Review of medical records.** All records that detail service delivery activities can be reviewed, including encounters and claims data, client medical records, facility logbooks, and others. It is important that records be carefully designed, sufficiently detailed, provide accurate information, and have access restricted to protect confidentiality. The use of electronic health records can facilitate some types of medical record review.

- **Exit interview with the client.** A patient is asked (through either a written or in-person survey) to describe what happened during the encounter or their assessment of their satisfaction with the visit. Both quantitative (close-ended questions) and qualitative (open-ended questions) methods can be used. Limitations include a bias toward clients reporting higher degrees of satisfaction, and the

TABLE 3. Checklist of family planning and related preventive health services for men

Screening components and source of recommendation	Family planning services (provide services in accordance with the appropriate clinical recommendation)				Related preventive health services
	Contraceptive services*	Basic infertility services	Preconception health services†	STD services§	
History					
Reproductive life plan¶	Screen	Screen	Screen	Screen	
Medical history¶,††	Screen	Screen	Screen	Screen	
Sexual health assessment¶,††	Screen	Screen	Screen	Screen	
Alcohol & other drug use ¶,**,††			Screen		
Tobacco use¶,**			Screen		
Immunizations¶			Screen		
Depression¶,**			Screen		Screen for HPV & HBV§§
Physical examination					
Height, weight, and BMI¶,**			Screen		
Blood pressure**,††			Screen§§		
Genital exam††		Screen (if clinically indicated)		Screen (if clinically indicated)	Screen§§
Laboratory testing					
Chlamydia¶				Screen§§	
Gonorrhea¶				Screen§§	
Syphilis¶,**				Screen§§	
HIV/AIDS¶,**				Screen§§	
Hepatitis C¶,**				Screen§§	
Diabetes¶,**			Screen§§		

Abbreviations: HBV = hepatitis B virus; HIV/AIDS = human immunodeficiency virus/acquired immunodeficiency syndrome; HPV = human papillomavirus virus; STD = sexually transmitted disease.

* No special evaluation needs to be done prior to making condoms available to males. However, when a male client requests advice on pregnancy prevention, he should be provided contraceptive services as described in the section “Provide Contraceptive Services.”

† The services listed here represent a sub-set of recommended preconception health services for men that were recommended and for which there was a direct link to fertility or infant health outcomes (Source: Frey K, Navarro S, Kotelchuck M, Lu M. The clinical content of preconception care: preconception care for men. *Am J Obstet Gynecol* 2008;199[6 Suppl 2]:S389–95).

§ STD services also promote preconception health, but are listed separately here to highlight their importance in the context of all types of family planning visit. The services listed in this column are for men without symptoms suggestive of an STD.

¶ CDC recommendation.

** U.S. Preventive Services Task Force recommendation.

†† Professional medical association recommendation.

§§ Indicates that screening is suggested only for those persons at highest risk or for a specific subpopulation with high prevalence of infection or other condition.

provider’s behavior might be influenced if she or he knows clients are being interviewed.

- **Facility audit.** Questions about a service site’s structure (e.g., on-site availability of a broad range of FDA-approved methods) and processes (e.g., skills and technical competence of staff, referral mechanisms) can be used to determine the readiness of the facility to serve clients.
- **Direct observation.** A provider’s behavior is observed during an actual encounter with a client. Evaluation of a full range of competencies, including communication skills, can be carried out. A main limitation is that the observer’s presence might influence the provider’s performance.
- **Interview with the health-care provider.** Providers are interviewed about how specific conditions are managed. Both closed- and open-ended questions can be used, although it is important to frame the question so that the ‘correct’ answer is not suggested. A limitation is that providers tend to over-report their performance.

Consideration and Use of the Findings

After data are collected, they should be tabulated, analyzed, and used to improve care. Staff whose performance was assessed should be involved in the development of the data collection tools and analysis of results. Analysis should address the following questions (155):

- What is the performance level of the facility?
- Is there a consistent pattern of performance among providers?
- What is the trend in performance?
- What are the causes of poor performance?
- How can performance gaps be minimized?

Given the findings, service site staff should use a systematic approach to identifying ways to improve the quality of care. One example of a systematic approach to improving the quality of care is the “Plan, Do, Study, and Act” (PDSA) model (147,156), in which staff first develop a plan for improving quality, then execute the plan on a small scale, evaluate feedback to confirm or adjust the plan, and finally, make the plan

TABLE 4. Suggested measures of the quality of family planning services

Type of measure and dimension of quality	Measure	Source
Health outcome	<ul style="list-style-type: none"> • Unintended pregnancy • Teen pregnancy • Birth spacing • Proportion of female users at risk for unintended pregnancy who adopt or continue use of an FDA-approved contraceptive method (measured for any method; highly effective methods; or long-acting reversible methods) [Intermediate outcome] 	PIMS*
Safe (Structure)	<ul style="list-style-type: none"> • Proportion of providers that follow the most current CDC recommendations on contraceptive safety 	
Effective (Structure, or the characteristics of the settings in which providers deliver health care, including material resources, human resources, and organizational structure)	<ul style="list-style-type: none"> • Site dispenses or provides on-site a full range of FDA-approved contraceptive methods to meet the diverse reproductive needs and goals of clients; short-term hormonal, long-acting reversible contraception (LARC), emergency contraception (EC). • Proportion of female users aged ≥24 years who are screened annually for chlamydial infection. • Proportion of female users aged ≥24 years who are screened annually for gonorrhea. • Proportion of users who were tested for HIV during the past 12 months. • Proportion of female users aged ≥21 years who have received a Pap smear within the past 3 years. 	PIMS*
Client-centered (Process, or whether services are provided correctly and completely, and how clients perceive the care they receive)	<ul style="list-style-type: none"> • Proportion of clients who report the provider communicates well, shows respect, spends enough time with the client, and is informed about the client's medical history. • Proportion of clients who report that <ul style="list-style-type: none"> – Staff are helpful and treat clients with courtesy and respect. – His or her privacy is respected. – She or he receives contraceptive method that is acceptable to her or him. 	CAHPS [†] RQIP [§]
Efficient (Structure)	<ul style="list-style-type: none"> • Site uses electronic health information technology or electronic health records to improve client reproductive health. 	PIMS*
Timely (Structure and process)	<ul style="list-style-type: none"> • Average number of days to the next appointment. • Site offers routine contraceptive resupply on a walk-in basis. • Site offers on-site HIV testing (using rapid technology). • Site offers on-site HPV and hepatitis B vaccination. 	PIMS*
Accessible (Structure and process)	<ul style="list-style-type: none"> • Site offers family planning services during expanded hours of operation. • Proportion of total family planning encounters that are encounters with ongoing or continuing users. • Proportion of clients who report that his or her care provider follows up to give test results, has up-to-date information about care from specialists, and discusses other prescriptions. • Site has written agreements (e.g., MOUs) with the key partner agencies for health care (especially prenatal care, primary care, HIV/AIDS) and social service (domestic violence, food stamps) referrals. 	PIMS* CAHPS-PCMH item set on care coordination [†]
Equitable (Structure)	<ul style="list-style-type: none"> • Site offers language assistance at all points of contact for the most frequently encountered language(s). 	PIMS*
Value	<ul style="list-style-type: none"> • Average cost per client. 	CDC [¶]

Abbreviations: CAHPS = Agency for Healthcare Research and Quality's Consumer Assessment of Health Care Providers and Systems; FDA = Food and Drug Administration; HPV = human papillomavirus; MOU = memorandum of understanding; PIMS = Performance Information and Monitoring System; RQIP = Regional Quality Indicators Program.

* **Source:** Fowler C. Title X Family Planning Program Performance Information and Monitoring System (PIMS): Description of Proposed Performance Measures [DRAFT]. Washington, DC: Research Triangle Institute; 2012.

[†] **Source:** Agency for Healthcare Research and Quality. Consumer Assessment of Healthcare Providers and Systems (CAHPS). Available at <https://www.cahps.ahrq.gov/default.asp>.

[§] **Source:** John Snow International. The Regional Quality Indicators Project (RQIP). Boston, MA: John Snow International; 2014. Available at <http://www.jsi.com/JSIInternet/USHealth/project/display.cfm?ctid=na&cid=na&tid=40&id=2621>.

[¶] **Sources:** Haddix A, Corso P, Gorsky R. Costs. In: Haddix A, Teutsch S, Corso P, eds. Prevention effectiveness: a guide to decision analysis and economic evaluation. 2nd ed. Oxford, UK: Oxford University Press; 2003; Stiefel M, Nolan K. A guide to measuring the triple aim: population health, experience of care, and per capita cost. Cambridge, MA: Institute for Healthcare Improvements; 2012.

permanent. Examples of steps that may be taken to improve the quality of care include developing job aids, providing task-specific training for providers, conducting more patient education, or strengthening relationships with referral sites through formal memoranda of understanding (146).

Conclusion

The United States continues to face substantial challenges to improving the reproductive health of the U.S. population. The recommendations in this report can contribute to improved reproductive health by defining a core set of family planning

services for women and men, describing how to provide contraceptive and other family planning services to both adult and adolescent clients, and encouraging the use of the family planning visit to provide selected preventive health services for women and men. This guidance is intended to assist primary care providers to offer the family planning services that will help persons and couples achieve their desired number and spacing of children and increase the likelihood that those children are born healthy.

Recommendations are updated periodically. The most recent versions are available at <http://www.hhs.gov/opa>.

References

- Finer LB, Zolna MR. Unintended pregnancy in the United States: incidence and disparities, 2006. *Contraception* 2011;84:478–85.
- CDC. Adolescent pregnancy and childbirth—United States, 1991–2008. In: CDC. CDC health disparities and inequalities report—United States, 2011. *MMWR* 2011;60(Suppl; January 14, 2011):105–8.
- Martin J, Hamilton B, Osterman J, et al. Births: final data for 2012. *Natl Vital Stat Rep* 2013;62(9).
- Mathews T, Macdorman M. Infant mortality statistics from the 2010 period linked birth/infant data set. *Natl Vital Stat Rep* 2013;62(8).
- US Department of Health and Human Services, Office of Population Affairs. Mission statement for the Office of Family Planning. Washington, DC: US Department of Health and Human Services; 2013. Available at <http://www.hhs.gov/opa/about-opa-and-initiatives/mission>.
- Institute of medicine. Clinical preventive services for women: closing the gaps. Washington, DC: The National Academies Press; 2011. Available at http://www.nap.edu/catalog.php?record_id=13181.
- US Department of Health and Human Services, Office of Population Affairs. Title X family planning. Washington, DC: US Department of Health and Human Services; 2013. Available at <http://www.hhs.gov/opa/title-x-family-planning/index.html>.
- Frost J. U.S. women's use of sexual and reproductive health services: trends, sources of care and factors associated with use, 1995–2010. New York, NY: Guttmacher Institute; 2013.
- US Department of Health and Human Services Coverage of certain preventive services under the Affordable Care Act: final rules. 45 CFR Parts 147 and 156. July 19, 2010. Washington, DC: US Department of Health and Human Services; 2010.
- Institute of Medicine. Committee on Quality of Health Care in America. Crossing the quality chasm: a new health system for the 21st century. Washington, DC: National Academies of Science; 2001.
- Bruce J. Fundamental elements of the quality of care: a simple framework. *Stud Fam Plann* 1990;21:61–91.
- Becker D, Koenig MA, Kim YM, Cardona K, Sonenstein FL. The quality of family planning services in the United States: findings from a literature review. *Perspect Sex Reprod Health* 2007;39:206–15.
- Institute of Medicine. Future directions for the national health care quality and disparities reports. Ullmer CBM, Burke S, eds. Washington, DC: The National Academies Press; 2010.
- Tucker CM. US Department of Health and Human Services, Advisory Committee on Minority Health. Reducing health disparities by promoting patient-centered culturally and linguistically sensitive/competent health care. Rockville, MD: US Department of Health and Human Services, Public Health Service; 2009.
- US Department of Health and Human Services, Office of Minority Health. The national standards for culturally and linguistically appropriate services in health and health care. Washington, DC: US Department of Health and Human Services; 2012. Available at https://www.thinkculturalhealth.hhs.gov/Content/clas.asp#clas_standards.
- Olavarria M, Beaulac J, Belanger A, Young M, Aubry T. Organizational cultural competence in community health and social service organizations: how to conduct a self-assessment. *J Cult Divers* 2009;16:140–50.
- Frost J, Finer L, Tapales A. The impact of publicly funded family planning clinic services on unintended pregnancies and government cost savings. *J Health Care Poor Underserved* 2008;19:778–96.
- Trussell J, Henry N, Hassan F, Prezioso A, Law A, Filonenko A. Burden of unintended pregnancy in the United States: potential savings with increased use of long-acting reversible contraception. *Contraception* 2013;87:154–61.
- Foster DG, Rostovtseva DP, Brindis CD, Biggs MA, Hulett D, Darney PD. Cost savings from the provision of specific methods of contraception in a publicly funded program. *Am J Public Health* 2009;99:446–51.
- GRADE Working Group. GRADE: going from evidence to recommendations. *BMJ* 2008;336:1049–51.
- Institute of Medicine. Clinical practice guidelines we can trust. Washington, DC: The National Academies Press; 2011. Available at http://www.nap.edu/catalog.php?record_id=13058.
- US Preventive Services Task Force. USPSTF: methods and processes. Rockville, MD: US Department of Health and Human Services, Agency for Healthcare Research and Quality; 2013. Available at <http://www.uspreventiveservicestaskforce.org/methods.htm>.
- Lu M. Recommendations for preconception care. *Am Fam Physician* 2007;76:397–400.
- CDC. Recommendations to improve preconception health and health care—United States. *MMWR* 2006;55(No. RR-6).
- Moos M. Preconceptional health promotion: progress in changing a prevention paradigm. *J Perinat Neonatal Nurs* 2004;18:2–13.
- American College of Obstetricians and Gynecologists. Committee Opinion #512: health care for transgender individuals. *Obstet Gynecol* 2011;118:1454–8.
- American College of Obstetricians and Gynecologists, Committee on Health Care for Underserved Women. ACOG Committee Opinion No. 525: health care for lesbians and bisexual women. *Obstet Gynecol* 2012;119:1077–80.
- McNair R, Hegarty K. Guidelines for the primary care of lesbian, gay and bisexual people: a systematic review. *Ann Fam Med* 2010;8:533–41.
- World Professional Association for Transgender Health. Standards of care for the health of transsexual, transgender, and gender-nonconforming people. Minneapolis, MN: World Professional Association for Transgender Health; 2011.
- The Center of Excellence for Transgender Health. Primary care protocol for transgender patient care. San Francisco, CA: University of California–San Francisco; 2011.
- American Academy of Pediatrics. Office-based care for lesbian, gay, bisexual, transgender, and questioning youth: Policy statement and Technical report. *Pediatrics* 2013;132:198–203.
- Adelson SL, American Academy of Child and Adolescent Psychiatry Committee on Quality Issues. Practice parameter on gay, lesbian or bisexual orientation, gender nonconformity, and gender discordance in children and adolescents. *J Am Acad Child Adolesc Psychiatry* 2012;51:957–74.

33. Office on Women's Health. Illnesses and disabilities: sexual and reproductive health. Available at <http://www.womenshealth.gov/illnesses-disabilities/your-health/sexuality-reproductive-health.cfm>.
34. McIntyre P. Adolescent friendly health services: an agenda for change. Geneva, Switzerland: World Health Organization; 2002.
35. CDC. U.S. medical eligibility criteria for contraceptive use 2010. *MMWR* 2010;59(No. RR-4).
36. CDC. Sexually transmitted diseases treatment guidelines, 2010. *MMWR* 2010;59(No. RR-12).
37. Jaccard J. Careful, current, and consistent: tips to improve contraceptive use. Washington, DC: National Campaign to Prevent Teen Pregnancy; 2010.
38. Trussell J. Contraceptive failure in the United States. *Contraception* 2011;83:397–404.
39. Winner B, Peipert J, Zhao Q, et al. Effectiveness of long-acting reversible contraception. *N Engl J Med* 2012;366:1998–2007.
40. Beerthuizen R. State-of-the-art of non-hormonal methods of contraception: V. Female sterilisation. *Eur J Contracept Reprod Health Care* 2010;15:124–35.
41. Michielsen D, Beerthuizen R. State-of-the art of non-hormonal methods of contraception: VI. Male sterilisation. *Eur J Contracept Reprod Health Care* 2010;15:136–49.
42. CDC. U.S. Selected practice recommendations for contraceptive use 2013. *MMWR* 2013;62(No. RR-5).
43. Kerns J, Westhoff C, Morroni C, Murphy P. Partner influence on early discontinuation of the pill in a predominantly Hispanic population. *Perspect Sex Reprod Health* 2003;35:256–60.
44. Forste R, Morgan J. How relationships of US men affect contraceptive use and efforts to prevent STD. *Fam Plann Perspect* 1998;30:56–62.
45. Severy L, Silver S. Two reasonable people: joint decision-making in contraceptive choice and use. In: LJ S, ed. *Advances in population: psychosocial perspectives*. London, UK: Jessica Kingsley Publishers; 1994:207–27.
46. Grady W, Klepinger D, Billy J, Cubbins L. The role of relationship power in couple decisions about contraception in the US. *J Biosoc Sci* 2010;42:307–25.
47. Jaccard J. *Unlocking the contraceptive conundrum*. Washington, DC: The National Campaign to Prevent Teen and Unplanned Pregnancy; 2009.
48. Pallitto CC, Campbell JC, O'Campo P. Is intimate partner violence associated with unintended pregnancy? A review of the literature. *Trauma Violence Abuse* 2005;6:217–35.
49. Paterno MT, Jordan ET. A review of factors associated with unprotected sex among adult women in the United States. *J Obstet Gynecol Neonatal Nurs* 2012;41:258–74.
50. Rehm J, Shield KD, Joharchi N, Shuper PA. Alcohol consumption and the intention to engage in unprotected sex: systematic review and meta-analysis of experimental studies. *Addiction* 2012;107:51–9.
51. Harper C, Balistreri E, Boggess J, Leon K, Darney P. Provision of hormonal contraceptives without a mandatory pelvic examination: the first stop demonstration project. *Fam Plann Perspect* 2001;33:13–8.
52. Stormo A, Hawkins N, Cooper C, Saraiya M. The pelvic examination as a screening tool: practices of US physicians. *Arch Intern Med* 2011;171:2053–4.
53. Labbok M, Perez A, Valdez V, et al. The Lactational Amenorrhea Method (LAM): a postpartum introductory family planning method with policy and program implications. *Adv Contracept Deliv Syst* 1994;10:93–109.
54. Huber L, Hogue C, Stein A, et al. Contraceptive use and discontinuation: findings from the contraceptive history, initiation and choice study. *Am J Obstet Gynecol* 2006;194:1290–5.
55. CDC. Guide to community preventive services: prevention of HIV/AIDS, other STIs and pregnancy, group-based comprehensive risk reduction interventions for adolescents. Atlanta, GA: US Department of Health and Human Services, CDC; 2011. Available at www.thecommunityguide.org/hiv/riskreduction.html.
56. Kirby DB, Laris BA, Roller LA. Sex and HIV education programs: their impact on sexual behaviors of young people throughout the world. *J Adolesc Health* 2007;40:206–17.
57. Oringanje C, Meremikwu MM, Eko H, Esu E, Meremikwu A, Ehiri JE. Interventions for preventing unintended pregnancies among adolescents. *Cochrane Database Syst Rev* 2009:CD005215.
58. English A. *State minor consent laws: a summary*. 3rd ed. Washington, DC: Center for Adolescent Health and the Law; 2010.
59. US Department of Health and Human Services. *State requirements for reporting child abuse*. Washington, DC: US Department of Health and Human Services; 2013. Available at http://www.childwelfare.gov/systemwide/laws_policies/state.
60. Guldi M. Fertility effects of abortion and birth control pill access for minors. *Demography* 2008;45:817–27.
61. Klein JD, McNulty M, Flatau CN. Adolescents' access to care: teenagers' self-reported use of services and perceived access to confidential care. *Arch Pediatr Adolesc Med* 1998;152:676–82.
62. Lehrer JA, Pantell R, Tebb K, Shafer MA. Forgone health care among U.S. adolescents: associations between risk characteristics and confidentiality concern. *J Adolesc Health* 2007;40:218–26.
63. Lyren A, Kodish E, Lazebnik R, O'Riordan MA. Understanding confidentiality: perspectives of African American adolescents and their parents. *J Adolesc Health* 2006;39:261–5.
64. Reddy DM, Fleming R, Swain C. Effect of mandatory parental notification on adolescent girls' use of sexual health care services. *JAMA* 2002;288:710–4.
65. Vo DX, Pate OL, Zhao H, Siu P, Ginsburg KR. Voices of Asian American youth: important characteristics of clinicians and clinical sites. *Pediatrics* 2007;120:e1481–93.
66. Zabin LS, Stark HA, Emerson MR. Reasons for delay in contraceptive clinic utilization. Adolescent clinic and nonclinic populations compared. *J Adolesc Health* 1991;12:225–32.
67. Zavodny M. Fertility and parental consent for minors to receive contraceptives. *Am J Public Health* 2004;94:1347–51.
68. Klein J. Achieving quality health services for adolescents: policy statement of the Committee on Adolescence, American Academy of Pediatrics. *Pediatrics* 2008;121:1263.
69. Ford C, English A, Sigman G. Confidential health care for adolescents: position paper for the Society for Adolescent Medicine. *J Adolesc Health* 2004;35:160–7.
70. American College of Obstetricians and Gynecologists. *Confidentiality in adolescent health care. guidelines for adolescent health care*. 2nd ed. Washington, DC: American College of Obstetricians and Gynecologists; 2011.
71. Anderson NLR, Koniak-Griffin D, Keenan CK, Uman G, Duggal BR, Casey C. Evaluating the outcomes of parent-child family life education. *Sch Inq Nurs Pract* 1999;13:211–38.
72. Guilamo-Ramos V, Bouris A, Jaccard J, Gonzalez B, McCoy W, Aranda D. A parent-based intervention to reduce sexual risk behavior in early adolescence: building alliances between physicians, social workers, and parents. *J Adolesc Health* 2011;48:159–63.

73. Blake SM, Simkin L, Ledsky R, Perkins C, Calabrese JM. Effects of a parent-child communications intervention on young adolescents' risk for early onset of sexual intercourse. *Fam Plann Perspect* 2001;33:52–61.
74. Brody GH, Murry VM, Gerrard M, et al. The Strong African American Families Program: translating research into prevention programming. *Child Dev* 2004;75:900–17.
75. Evans WD, Davis KC, Ashley OS, Blitstein J, Koo H, Zhang Y. Efficacy of abstinence promotion media messages: findings from an online randomized trial. *J Adolesc Health* 2009;45:409–16.
76. Forehand R, Armistead L, Long N, et al. Efficacy of a parent-based sexual-risk prevention program for African American preadolescents: a randomized controlled trial. *Arch Pediatr Adolesc Med* 2007;161:1123–9.
77. Haggerty KP, Skinner ML, MacKenzie EP, Catalano RF. A randomized trial of Parents Who Care: effects on key outcomes at 24-month follow-up. *Prev Sci* 2007;8:249–60.
78. Huston RL, Martin LJ, Foulds DM. Effect of a program to facilitate parent-child communication about sex. *Clin Pediatr (Phila)* 1990;29:626–33.
79. Lederman RP, Chan W, Roberts-Gray C. Sexual risk attitudes and intentions of youth aged 12–14 years: survey comparisons of parent-teen prevention and control groups. *Behavioral Medicine (Washington, DC)* 2004;29:155–63.
80. Lederman RP, Chan W, Roberts-Gray C. Parent-adolescent relationship education (PARE): program delivery to reduce risks for adolescent pregnancy and STDs. *Behav Med* 2008;33:137–43.
81. Lefkowitz ES, Sigman M, Au TK. Helping mothers discuss sexuality and AIDS with adolescents. *Child Dev* 2000;71:1383–94.
82. Miller BC, Norton MC, Jenson GO. Pregnancy prevention programs: Impact Evaluation of Facts and Feelings: a home-based video sex education curriculum. *Fam Relat* 1993;42:392–400.
83. Murry VM, Berkel C, Brody GH, Gerrard M, Gibbons FX. The Strong African American Families program: longitudinal pathways to sexual risk reduction. *J Adolesc Health* 2007;41:333–42.
84. Schuster MA, Corona R, Elliott MN, et al. Evaluation of Talking Parents, Healthy Teens, a new worksite based parenting programme to promote parent-adolescent communication about sexual health: randomised controlled trial. *BMJ* 2008;337:a308.
85. Stanton B, Cole M, Galbraith J, et al. Randomized trial of a parent intervention: parents can make a difference in long-term adolescent risk behaviors, perceptions, and knowledge. *Arch Pediatr Adolesc Med* 2004;158:947–55.
86. Stanton BF, Li X, Galbraith J, et al. Parental underestimates of adolescent risk behavior: a randomized, controlled trial of a parental monitoring intervention. *J Adolesc Health* 2000;26:18–26.
87. American Academy of Pediatrics. Parents matter: your children want to learn about the facts of life from you. Elk Grove Village, IL: American Academy of Pediatrics; ND. Available at <http://www2.aap.org/visit/ParentsMatterBrochure.pdf>.
88. Hamilton B. Births: final Data for 2010. *National Vital Statistics Reports* 2012;61(1).
89. Olds DL, Henderson CR Jr, Tatelbaum R, Chamberlin R. Improving the life-course development of socially disadvantaged mothers: a randomized trial of nurse home visitation. *Am J Public Health* 1988;78:1436–45.
90. Olds DL, Kitzman H, Cole R, et al. Effects of nurse home-visiting on maternal life course and child development: age 6 follow-up results of a randomized trial. *Pediatrics* 2004;114:1550–9.
91. Olds DL, Kitzman H, Hanks C, et al. Effects of nurse home visiting on maternal and child functioning: age-9 follow-up of a randomized trial. *Pediatrics* 2007;120:e832–45.
92. Rabin JM, Seltzer V, Pollack S. The long term benefits of a comprehensive teenage pregnancy program. *Clin Pediatr (Phila)* 1991;30:305–9.
93. Avellar S, Paulsell D, Sama-Miller E, Del Grosso P. Home visiting evidence of effectiveness review. Washington, DC: US Department of Health and Human Services, Office of Planning, Research and Evaluation, Administration for Children and Families; 2012.
94. Black M, Bentley M, Papas M, et al. Delaying second births among adolescent mothers: a randomized, controlled trial of a home-based mentoring program. *Pediatrics* 2006;118:1087–99.
95. American Academy of Pediatrics. Counseling the adolescent about pregnancy options. *Pediatrics* 2006;101:938–40.
96. American College of Obstetricians and Gynecologists. Guidelines for women's health care: a resource manual. 3rd ed. Washington, DC: American College of Obstetricians and Gynecologists; 2007.
97. American College of Obstetricians and Gynecologists. Guidelines for perinatal care. 6th ed. Washington, DC: American College of Obstetricians and Gynecologists; 2007.
98. Ventura S, Curtin S, Abma J, Henshaw S. Estimated pregnancy rates and rates of pregnancy outcomes for the US: 1990–2008. *Natl Vital Stat Rep* 2012;60(7).
99. Jones J. Adoption experiences of women and men and demand for children to adopt by women 18–44 years of age in the United States, 2002. *Vital Health Stat* 2008;23(7).
100. American Society for Reproductive Medicine in collaboration with the Society for Reproductive Endocrinology and Infertility. Optimizing natural fertility. *Fertil Steril* 2008;90(Suppl):S1–6.
101. American Society for Reproductive Medicine. Optimal evaluation of the infertile female. *Fertil Steril* 2006;86.
102. American Urological Association. The optimal evaluation of the infertile male: AUA best practice statement. Linthicum, MD: American Urological Association; 2010.
103. Frey K, Navarro S, Kotelchuck M, Lu M. The clinical content of preconception care: preconception care for men. *Am J Obstet Gynecol* 2008;6:S389–95.
104. US Preventive Services Task Force. Folic acid to prevent neural tube defects. Rockville, MD: US Department of Health and Human Services, Agency for Healthcare Research and Quality; 2009. Available at <http://www.uspreventiveservicestaskforce.org/uspstf/uspnsrnfol.htm>.
105. Jack B, Atrash H, Coonrod D, Moos M, O'Donnell J, Johnson K. The clinical content of preconception care: an overview and preparation of this supplement. *Am J Obstet Gynecol* 2008;199(Suppl B):S266–79.
106. US Preventive Services Task Force. Screening for intimate partner violence and abuse of elderly and vulnerable adults. Rockville, MD: US Department of Health and Human Services, Agency for Healthcare Research and Quality; 2013. Available at <http://www.uspreventiveservicestaskforce.org/uspstf/uspripsv.htm>.
107. US Preventive Services Task Force. Screening and Behavioral Counseling Interventions in Primary Care to Reduce Alcohol Misuse. AHRQ, US Department of Health and Human Services; 2013.
108. American College of Obstetricians and Gynecologists. Committee Opinion No. 483: primary and preventive care: periodic assessments. *Obstet Gynecol* 2011;117:1008–15.
109. Committee on Practice and Ambulatory Medicine, Bright Futures Periodicity Schedule Workgroup. 2014 recommendations for pediatric preventive health care. *Pediatrics* 2014;133:568.
110. US Preventive Services Task Force. Screening for illicit drug use. Rockville, MD: US Department of Health and Human Services, Agency for Healthcare Research and Quality; 2008.

111. US Preventive Services Task Force. Counseling and interventions to prevent tobacco use and tobacco-caused disease in adults and pregnant women. Rockville, MD: US Department of Health and Human Services, Agency for Healthcare Research and Quality; 2009. Available at <http://www.uspreventiveservicestaskforce.org/uspstf/uspstbac2.htm>.
112. US Preventive Services Task Force. Primary care interventions to prevent tobacco use in children and adolescents. Rockville, MD: US Department of Health and Human Services, Agency for Healthcare Research and Quality; 2013.
113. CDC. Advisory Committee on Immunization Practices (ACIP) recommended immunization schedules for persons aged 0 through 18 years and adults aged 19 years and older—United States, 2013. *MMWR* 2013;62(Suppl 1):1–19.
114. US Preventive Services Task Force. Screening for depression in adults. Rockville, MD: US Department of Health and Human Services, Agency for Healthcare Research and Quality; 2009. Available at <http://www.uspreventiveservicestaskforce.org/uspstf/uspstdepr.htm>.
115. US Preventive Services Task Force. Major depressive disorder in children and adolescents. Rockville, MD: US Department of Health and Human Services, Agency for Healthcare Research and Quality; 2009. Available at <http://www.uspreventiveservicestaskforce.org/uspstf/uspstschdepr.htm>.
116. American Psychiatric Association. Practice guideline for the assessment and treatment of patients with suicidal behaviors. *Am J Psychiatry* 2003;160(Suppl):1–60.
117. American Academy of Child and Adolescent Psychiatry. Practice parameter for the assessment and treatment of children and adolescents with suicidal behavior. *J Am Acad Child Adolesc Psychiatry* 2001;40(Suppl):24S–51S.
118. US Preventive Services Task Force. Screening for obesity in children and adolescents: US Preventive Services Task Force recommendation statement. Rockville, MD: US Department of Health and Human Services, Agency for Healthcare Research and Quality; 2010. Available at <http://www.uspreventiveservicestaskforce.org/uspstf/uspstschobes.htm>.
119. US Preventive Services Task Force. Screening for and management of obesity in adults. Rockville, MD: US Department of Health and Human Services, Agency for Healthcare Research and Quality; 2012. Available at <http://www.uspreventiveservicestaskforce.org/uspstf11/obeseadult/obesers.htm>.
120. US Preventive Services Task Force. Screening for high blood pressure in adults. Rockville, MD: US Department of Health and Human Services, Agency for Healthcare Research and Quality; 2007. Available at <http://www.uspreventiveservicestaskforce.org/uspstf/uspshype.htm>.
121. US Department of Health and Human Services. The seventh report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Washington, DC: US Department of Health and Human Services; 2004.
122. US Preventive Services Task Force. Screening for type 2 diabetes mellitus in adults. Rockville, MD: US Department of Health and Human Services, Agency for Healthcare Research and Quality; 2008. Available at <http://www.uspreventiveservicestaskforce.org/uspstf/uspstdiab.htm>.
123. CDC. Revised recommendations for HIV testing of adults, adolescents and pregnant women in health care settings. *MMWR* 2006;55(No. RR-14).
124. CDC. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945–1965. *MMWR* 2012;61(No. RR-4).
125. CDC. Male chlamydia screening consultation. Atlanta, GA: US Department of Health and Human Services, DCD; 2006. Available at <http://www.cdc.gov/std/chlamydia>.
126. Burstein GR, Eliscu A, Ford K, et al. Expedited partner therapy for adolescents diagnosed with chlamydia or gonorrhea: a position paper of the Society for Adolescent Medicine. *J Adolesc Health* 2009;45:303–9.
127. American Academy of Pediatrics. Promoting healthy sexual development and sexuality. *Bright Futures: guidelines for health supervision of infants, children, and adolescents*. Elk Grove, IL: American Academy of Pediatrics; 2007.
128. US Preventive Services Task Force. Screening for gonorrhea. Rockville, MD: US Department of Health and Human Services, Agency for Healthcare Research and Quality; 2005. Available at <http://www.uspreventiveservicestaskforce.org/uspstf/uspstsgono.htm>.
129. US Preventive Services Task Force. Screening for HIV. Rockville, MD: US Department of Health and Human Services, Agency for Healthcare Research and Quality; 2013. Available at <http://www.uspreventiveservicestaskforce.org/uspstf/uspstshivi.htm>.
130. US Preventive Services Task Force. Screening for hepatitis C virus infection in adults. Rockville, MD: US Department of Health and Human Services, Agency for Healthcare Research and Quality; 2013. Available at <http://www.uspreventiveservicestaskforce.org/uspstf12/hepc/hepcfinals.htm#recommendations>.
131. CDC. Recommendations on the use of quadrivalent human papillomavirus vaccine in males—Advisory Committee on Immunization Practices (ACIP). *MMWR* 2011;60:1705–8.
132. US Preventive Services Task Force. Behavioral counseling to prevent sexually transmitted infections. Rockville, MD: US Department of Health and Human Services, Agency for Healthcare Research and Quality; 2008. Available at <http://www.uspreventiveservicestaskforce.org/uspstf/uspststds.htm>.
133. Kamb ML, Fishbein M, Douglas JM Jr, et al. Efficacy of risk-reduction counseling to prevent human immunodeficiency virus and sexually transmitted diseases: a randomized controlled trial. Project RESPECT Study Group. *JAMA* 1998;280:1161–7.
134. US Preventive Services Task Force. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women. Rockville, MD: US Department of Health and Human Services, Agency for Healthcare Research and Quality; 2013. Available at <http://www.uspreventiveservicestaskforce.org/uspstf/uspstbrgen.htm>.
135. US Preventive Services Task Force. Medications for risk reduction of primary breast cancer in women. Rockville, MD: US Department of Health and Human Services, Agency for Healthcare Research and Quality; 2013. Available at <http://www.uspreventiveservicestaskforce.org/uspstf/uspstbrpv.htm>.
136. US Preventive Services Task Force. Screening for cervical cancer. Rockville, MD: US Department of Health and Human Services, Agency for Healthcare Research and Quality; 2012. Available at www.uspreventiveservicestaskforce.org/uspstf11/cervcancer/cervcancerr.htm.
137. Massad L, Einstein M, Huh W, et al. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. *Obstet Gynecol* 2013;121:829–46.
138. Braverman P, Breech L. Gynecologic examination for adolescents in the pediatric office setting. *Pediatrics* 2010;126:583–90.
139. Smith RA, Brooks D, Cokkinides V, Saslow D, Brawley OW. Cancer screening in the United States, 2013: a review of current American Cancer Society guidelines, current issues in cancer screening, and new guidance on cervical cancer screening and lung cancer screening. *CA Cancer J Clin* 2013;63:88–105.

140. US Preventive Services Task Force. Screening for breast cancer. Rockville, MD: US Department of Health and Human Services, Agency for Healthcare Research and Quality; 2009. Available at <http://www.uspreventiveservicestaskforce.org/uspstf/uspbrca.htm>.
141. Marcell A, Bell D, Joffe A. The male genital examination: a position paper of the Society for Adolescent Health and Medicine: a position paper of the Society for Adolescent Health and Medicine. *J Adolesc Health* 2012;50:424–5.
142. Riley W, Moran J, Corso L, Beitsch L, Bialek R, Cofsky A. Defining quality improvement in public health. *J Public Health Manag Pract* 2010;16:5–7.
143. National Quality Forum. ABCs of measurement. Washington, DC: National Quality Forum; 2011. Available at http://www.qualityforum.org/Measuring_Performance/ABCs_of_Measurement.aspx.
144. Berwick D, Nolan T, Whittington J. The Trip Aim: care, health and cost. *Health Aff* 2008;27:759–69.
145. CDC. National Public Health Performance Standards Program. Atlanta, GA: US Department of Health and Human Services, CDC; 2012. Available at www.cdc.gov/od/ocphp/nphpsp.
146. Berwick D. A user's manual for the IOM's "Quality Chasm" Report. *Health Affairs* 2002;21:80–90.
147. Langley G, Nolan K, Nolan T, Norman C, Provost L. *The Improvement Guide: A practical approach to enhancing organizational performance*. 2nd ed. San Francisco, CA: Jossey-Bass Publishers; 2009.
148. Government Accountability Office. Performance measurement and evaluation: definitions and relationships. Washington, DC: Government Accountability Office; 2011.
149. Donabedian A. The quality of care. *JAMA* 1988;260:1743–8.
150. Fowler C. Title X Family Planning Program Performance Information and Monitoring System (PIMS): description of proposed performance measures. Washington, DC: Research Triangle Institute; 2012.
151. California Family Health Council. Performance measures: guiding quality improvement for family planning services. Los Angeles, CA: California Family Health Council; 2011. Available at <http://www.cfhc.org/TitleX/PerformanceMeasures/default.htm>.
152. John Snow International. The Regional Quality Indicators Project (RQIP). Boston, MA: John Snow International; 2012. Available at <http://www.jsi.com/JSIInternet/USHealth/project/display.cfm?ctid=na&cid=na&tid=40&id=2621>.
153. Family Planning Councils of America. Performance Measurement System. Los Angeles, CA: Family Planning Councils of America; ND. Available at <http://www.fpcai.org/pms.html>.
154. Palmer R. Process-based measures of quality: the need for detailed clinical data in large health care databases. *Ann Intern Med* 1997;127:733–8.
155. Bouchet B. Health manager's guide: monitoring the quality of primary care. Bethesda, MD: Center for Human Services; ND. Available at http://pdf.usaid.gov/pdf_docs/PNACK584.pdf.
156. Institute for Health Care Improvement. How to improve. Cambridge, MA: Institute for Health Care Improvement; 2014. Available at <http://www.ihc.org/knowledge/Pages/HowtoImprove/default.aspx>.

Appendix A

How the Recommendations Were Developed

The recommendations were developed jointly under the auspices of CDC's Division of Reproductive Health (DRH) and the Office of Population Affairs (OPA), in consultation with a wide range of experts and key stakeholders. A multistage process that drew on established procedures for developing clinical guidelines (1,2) was used to develop the recommendations. In April 2010, an Expert Work Group (EWG) comprising family planning clinical providers, program administrators, representatives from relevant federal agencies, and representatives from professional medical organizations was created to advise OPA and CDC on the structure and content of the revised recommendations and to help make the recommendations more feasible and relevant to the needs of the field. This group made two key initial recommendations: 1) to examine the scientific evidence for three priority areas of focus identified as key components of family planning service delivery, (i.e., counseling and education, serving adolescents, and quality improvement); and 2) to guide providers of family planning services in the use of various recommendations for how to provide clinical care to women and men.

Developing Recommendations on Counseling, Adolescent Services, and Quality Improvement

Systematic reviews of the published literature from January 1985 through December 2010 were conducted for each priority topic to identify evidence-based and evidence-informed approaches to family planning service delivery. Standard methods for conducting the reviews were used, including the development of key questions and analytic frameworks, the identification of the evidence base through a search of the published as well as "gray literature" (i.e., studies published somewhere other than in a peer-reviewed journal), and a synthesis of the evidence in which findings were summarized and the quality of individual studies was considered, using the methodology of the U.S. Preventive Services Task Force (USPSTF) (3). Eight databases were searched (i.e., MEDLINE, PsychInfo, PubMed, CINAHL, Cochrane, EMBASE, POPLINE, and the U.K. National Clearinghouse Service Economic Evaluation Database) and were restricted to literature from the United States and other developed countries. Summaries of the evidence used to prepare these recommendations will appear in background papers that will be published separately.

In May 2011, three technical panels (one for each priority topic) comprising subject matter experts were convened

to consider the quality of the evidence and suggest what recommendations might be justified on the basis of the evidence. CDC and OPA used this feedback to develop core recommendations for counseling, serving adolescents, and quality improvement. EWG members subsequently reviewed these core recommendations; EWG members differed from the subject matter experts in that they were more familiar with the family planning service delivery context and could comment on the feasibility and appropriateness of the recommendations as well as on their scientific justification. EWG members met to consider the core recommendations using 1) the quality of the evidence; 2) the positive and negative consequences of implementing the recommendations on health outcomes, costs or cost-savings, and implementation challenges; and 3) the relative importance of these consequences (e.g., the ability of the recommendations to have a substantial effect on health outcomes may be weighed more than the logistical challenges of implementing them) (1). In certain cases, when the evidence was inconclusive or incomplete, recommendations were made on the basis of expert opinion (see Appendix B). Finally, CDC and OPA staff considered the feedback from EWG members when finalizing the core recommendations and writing this report.

Developing Recommendations on Clinical Services

DRH and OPA staff members synthesized recommendations for clinical care for women and for men that were developed by >35 federal and professional medical organizations. They were assisted in this effort by staff from OPA's Office of Family Planning Male Training Center and from CDC's Division of STD Prevention, Division of Violence Prevention, Division of Immunization Services, and Division of Cancer Prevention and Control. The synthesis was needed because clinical recommendations are sometimes inconsistent with each other and can vary by the extent to which they are evidence-based. The clinical recommendations addressed contraceptive services, achieving pregnancy, basic infertility services, preconception health services, sexually transmitted disease services, and related health-care services.

An attempt was made to apply the Institute of Medicine's criteria for clinical practice guidelines when deciding which professional medical organizations to include in the review (2). However, many organizations did not articulate the process used to develop the recommendations fully, and many did not

conduct comprehensive and systematic reviews of the literature. In the end, to be included in the synthesis, the recommending organization had to be a federal agency or major professional medical organization that represents established medical disciplines. In addition, a recommendation had to be made on the basis of an independent review of the evidence or expert opinion and be considered a primary source that was developed for the United States.

In July 2011, two technical panels comprising subject matter experts on clinical services for women and men were convened to review the synthesis of federal and professional medical recommendations, reconcile inconsistent recommendations, and provide individual feedback to CDC and OPA about the implications for family planning service delivery. CDC and OPA used this individual feedback to develop core recommendations for clinical services. The core recommendations were subsequently reviewed by EWG members, and feedback was used to finalize the core recommendations and write this report.

Members of the technical panels recommended that contraceptive services, pregnancy testing and counseling, services to achieve pregnancy, basic infertility care, STD services, and other preconception health services should be considered family planning services. This feedback considered federal statute and regulation, CDC and USPSTF recommendations for clinical care, and EWG members' opinion.

Because CDC's preconception health recommendations include many services, the panel narrowed the range of preconception services that were included by using the following criteria: 1) the Select Panel on Preconception Care (4) had assigned an A or B recommendation to that service for women, which means that there was either good or fair evidence to support the recommendation that the condition be considered in a preconception care evaluation (Table 1), or 2) the service was included among recommendations made by experts in preconception health for males (5). Services for men that addressed health conditions that affect reproductive capacity or pregnancy outcomes directly were included as preconception health; services that addressed men's health but that were not related directly to pregnancy outcomes were considered to be related preventive health services.

The Expert Work Group noted that more preventive services are recommended than can be offered feasibly in some settings. However, a primary purpose of this report is to set a broad framework within which individual clinics will tailor services to meet the specific needs of the populations that they serve. In addition, EWG members identified specific subgroups that should have the greatest priority for preconception health services (i.e., those trying to achieve pregnancy and those

at high risk of unintended pregnancy). Future operational research should provide more information about how to deliver these services most efficiently during multiple visits to clients with diverse needs.

Determining How Clinical Services Should Be Provided

Various federal agencies and professional medical associations have made recommendations for how to provide family planning services. When considering these recommendations, the Expert Work Group used the following hierarchy:

- Highest priority was given to CDC guidelines because they are developed after a rigorous review of scientific evidence. CDC guidelines tailor recommendations for higher risk individuals, (whereas USPSTF focuses on average risk individuals), who are more representative of the clients seeking family planning services.
- When no CDC guideline existed to guide the recommendations, the relevant USPSTF A or B recommendations (which indicate a high or moderate certainty that the benefit is moderate to substantial) were used. USPSTF recommendations are made on the basis of a thorough review of the available evidence.
- If neither a CDC nor a USPSTF A or B recommendation existed, the recommendations of selected major professional medical associations were considered as resources. The American Academy of Pediatrics' (AAP) Bright Futures guidelines (6) were used as the primary source of recommendations for adolescents when no CDC or USPSTF recommendations existed.
- For a limited number of recommendations, there were no federal or major professional medical recommendations, but the service was recommended by EWG members on the basis of expert opinion for family planning clients.

In some cases, a service was graded as an I recommendation by USPSTF for the general population (an I recommendation means that the current evidence is insufficient to assess the balance of benefits and harms of the service, so if the service is offered, patients should be informed of this fact), but either CDC, EWG members, or another organization recommended the service for women or men seeking family planning services. The situations in which this occurred and the reasons why the service was recommended despite its receiving an I recommendation by USPSTF have been summarized (Table 2). The approach used to consider the evidence and make recommendations that are used by USPSTF have been summarized (Tables 3 and 4) (7).

References

1. GRADE Working Group. GRADE: going from evidence to recommendations. *BMJ* 2008;336:1049–51.
2. Institute of Medicine. Clinical practice guidelines we can trust. Washington, DC: The National Academies Press; 2011. Available at http://www.nap.edu/catalog.php?record_id=13058.
3. US Preventive Services Task Force. USPSTF: methods and processes. Rockville, MD: US Department of Health and Human Services, Agency for Healthcare Research and Quality; 2013. Available at <http://www.uspreventiveservicestaskforce.org/methods.htm>.
4. Jack BW, Atrash H, Coonrod D, Moos M, O'Donnell J, Johnson K. The clinical content of preconception care: an overview and preparation of this supplement. *Am J Obstet Gynecol* 2008;199(Suppl 2):S266–79.
5. Frey KA, Navarro S, Kotelchuck M, Lu M. The clinical content of preconception care: preconception care for men. *Am J Obstet Gynecol* 2008;199(Suppl 2):S389–95.
6. Committee on Practice and Ambulatory Medicine, Bright Futures Periodicity Schedule Workgroup. 2014 recommendations for pediatric preventive health care. *Pediatrics* 2014;133:568.
7. US Preventive Services Task Force. Grade definitions. Rockville, MD: US Department of Health and Human Services, Agency for Healthcare Research and Quality; 2013. Available at <http://www.uspreventiveservicestaskforce.org/uspstf/grades.htm>.

TABLE 1. Select Panel on Preconception Care grading system

Quality of the evidence*	
I-a	Evidence was obtained from at least one properly conducted, randomized, controlled trial that was performed with subjects who were not pregnant.
I-b	Evidence was obtained from at least one properly conducted, randomized, controlled trial that was done not necessarily before pregnancy.
II-1	Evidence was obtained from well-designed, controlled trials without randomization.
II-2	Evidence was obtained from well-designed cohort or case-control analytic studies, preferably conducted by more than one center or research group.
II-3	Evidence was obtained from multiple-time series with or without the intervention, or dramatic results in uncontrolled experiments.
III	Opinions were gathered from respected authorities on the basis of clinical experience, descriptive studies and case reports, or reports of expert committees.
Strength of the recommendation	
A	There is good evidence to support the recommendation that the condition be considered specifically in a preconception care evaluation.
B	There is fair evidence to support the recommendation that the condition be considered specifically in a preconception care evaluation.
C	There is insufficient evidence to recommend for or against the inclusion of the condition in a preconception care evaluation, but recommendation to include or exclude may be made on other grounds.
D	There is fair evidence to support the recommendation that the condition be excluded in a preconception care evaluation.
E	There is good evidence to support the recommendation that the condition be excluded in a preconception care evaluation.

Source: Jack B, Atrash H, Coonrod D, Moos M, O'Donnell J, Johnson K. The clinical content of preconception care: an overview and preparation of this supplement. *Am J Obstet Gynecol* 2008;199(6 Suppl 2):S266–79.

TABLE 2. Services included in these recommendations that received a U.S. Preventive Services Task Force (USPSTF) I recommendation

Service/screen	USPSTF recommendation	Why the service is recommended despite a USPSTF I recommendation
Alcohol	I for adolescents	The recommendations are consistent with CDC's recommendations on preconception health and AAP's Bright Futures* guidelines.
Other drugs	I for adolescents and adults	The recommendations are consistent with CDC's recommendations on preconception health and AAP's Bright Futures guidelines.
Clinical breast exam	I for all women	No CDC recommendation exists, but ACOG and ACS recommend conducting clinical breast exams, and the Expert Work Group endorsed the ACOG recommendation.
Chlamydia	I for all males	The recommendations are consistent with CDC's STD treatment guidelines.
Gonorrhea	I for all males	The recommendations are consistent with CDC's STD treatment guidelines.

Source: US Preventive Services Task Force. USPSTF recommendations. Available at <http://www.uspreventiveservicestaskforce.org/recommendations.htm>.

Abbreviations: AAP = American Academy of Pediatrics; ACS = American Cancer Society; ACOG = American Congress of Obstetricians and Gynecologists; STD = sexually transmitted disease.

* Source: Committee on Practice and Ambulatory Medicine, Bright Futures Periodicity Schedule Workgroup. 2014 recommendations for pediatric preventive health care. *Pediatrics* 2014;133;568.

TABLE 3. U.S. Preventive Services Task Force (USPSTF) grades, definitions, and suggestions for practice

Grade	Definition	Suggestions for practice
A	USPSTF recommends the service. There is high certainty that the net benefit is substantial.	This service should be offered or provided.
B	USPSTF recommends the service. There is high certainty that the net benefit is moderate, or there is moderate certainty that the net benefit is moderate to substantial.	This service should be offered or provided.
C	Clinicians may provide this service to selected patients depending on individual circumstances. However, for a majority of persons without signs or symptoms there is likely to be only a limited benefit from this service.	This service should be offered or provided only if other considerations support the offering or providing the service in an individual patient.
D	USPSTF recommends against the service. There is moderate or high certainty that the service has no net benefit or that the harms outweigh the benefits.	Use of this service should be discouraged.
I Statement	USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of the service. Evidence is lacking, of poor quality, or conflicting, and the balance of benefits and harms cannot be determined.	The clinical considerations section of USPSTF recommendation statement should be consulted. If the service is offered, patients should be educated about the uncertainty of the balance of benefits and harms.

Source: US Preventive Services Task Force. USPSTF: methods and processes. Available at <http://www.uspreventiveservicestaskforce.org/methods.htm>.

TABLE 4. Levels of certainty regarding net benefit

Level of certainty*	Description
High	The available evidence usually includes consistent results from well-designed, well-conducted studies in representative primary care populations. These studies assess the effects of the preventive service on health outcomes. This conclusion is therefore unlikely to be strongly affected by the results of future studies.
Moderate	The available evidence is sufficient to determine the effects of the preventive service on health outcomes, but confidence in the estimate is constrained by such factors as <ul style="list-style-type: none"> • the number, size, or quality of individual studies; • inconsistency of findings across individual studies; • limited generalizability of findings to routine primary care practice; and • lack of coherence in the chain of evidence. As more information becomes available, the magnitude or direction of the observed effect could change, and this change may be large enough to alter the conclusion.
Low	The available evidence is insufficient to assess effects on health outcomes is insufficient because of <ul style="list-style-type: none"> • the limited number or size of studies, • important flaws in study design or methods, • inconsistency of findings across individual studies, • gaps in the chain of evidence, • findings not generalizable to routine primary care practice, • lack of information on important health outcomes, or • more information required to allow estimation of effects on health outcomes.

Source: US Preventive Services Task Force. USPSTF: methods and processes. Available at <http://www.uspreventiveservicestaskforce.org/methods.htm>.

* The US Preventive Services Task Force (USPSTF) defines certainty as the likelihood that the USPSTF assessment of the net benefit of a preventive service is correct. The net benefit is defined as benefit minus harm of the preventive service as implemented in a general, primary care population. USPSTF assigns a certainty level on the basis of the nature of the overall evidence available to assess the net benefit of a preventive service.

Appendix B

The Evidence, Potential Consequences, and Rationales for Core Recommendations

Sixteen core recommendations that were considered by the Expert Work Group (EWG) are presented below. Each recommendation is accompanied by a summary of the relevant evidence (full summaries of which will be published separately), a list of potential consequences of implementing the recommendation, and its rationale. When considering the recommendations, the Expert Work Group was divided into two groups (one comprising seven members and the other five members), and each group considered separate recommendations.

Definition of Family Planning Services

Recommendation: Primary care providers should offer the following family planning services: contraceptive services for women and men who want to prevent pregnancy and space births, pregnancy testing and counseling, help for clients who wish to achieve pregnancy, basic infertility services, sexually transmitted disease (STD) services and preconception health services to improve the health of women, men, and infants.

Quality of evidence: A systematic review was not conducted; the recommendation was made on the basis of federal statute and regulation (1,2), CDC clinical recommendations (3–5), and expert opinion.

Potential consequences: Adding preconception health services means that more women and men will receive preconception health services. The recommended services also will promote the health of women and men even if they do not have children. The human and financial cost of providing preconception health services might mean that fewer contraceptive and other services can be offered in some settings.

Rationale: Services to prevent and achieve pregnancy are core to the federal government's efforts to promote reproductive health. Adding preconception health as a family planning service is consistent with this mission; it emphasizes achieving a healthy pregnancy and also promotes adult health. Adding preconception health is also consistent with CDC recommendations to integrate preconception health services into primary care platforms (3). All seven EWG members agreed to this recommendation.

Preconception Health — Women

Recommendation: Preconception health services for women include the following screening services: reproductive

life plan; medical history; sexual health assessment; intimate partner violence, alcohol, and other drug use; tobacco use; immunizations; depression; body mass index (BMI); blood pressure; chlamydia, gonorrhea, syphilis, and HIV/AIDS; and diabetes. All female clients also should be counseled about the need to take a daily supplement of folic acid. When screening results indicate the presence of a health condition, the provider should take steps either to provide or to refer the client for the appropriate further diagnostic testing and or treatment. Services should be provided in a manner that is consistent with established federal and professional medical associations' recommendations to enable clients who need services to receive them and to avoid over-screening.

Quality of evidence: A systematic review was not conducted; the recommendation was made on the basis of CDC's recommendations to improve preconception health and health care (3) and a review of preconception health services by an expert panel on preconception care for women (6).

Potential consequences: More women will receive specified preconception health services, which will improve the health of infants and women. The evidence base for preconception health is not fully established. There is a potential risk that a client with a positive screen will not be able to afford treatment if the client is uninsured and not eligible for public programs. The human and financial cost of providing preconception health services might mean that fewer contraceptive and other services can be offered.

Rationale: The potential benefits to the health of women and infants were thought by the panel to be greater than the costs, potential harms, and opportunity costs of providing these services. Implementation (e.g., training and monitoring of providers) can address the issues related to providers over-screening and not following the federal and professional medical recommendations. CDC will continue to monitor related research and modify these recommendations, as needed. Health-care reform might make follow-up care more available to low-income clients. All seven EWG members agreed to this recommendation.

Preconception Health — Men

Recommendation: Preconception health services for men include the following screening services: reproductive life plan; medical history; sexual health assessment; alcohol and other drug use; tobacco use; immunizations; depression; BMI; blood pressure; chlamydia, gonorrhea, syphilis, and HIV/AIDS; and diabetes. When screening results indicate the presence of a health condition, the provider should take

steps either to provide or to refer the client for the appropriate further diagnostic testing and or treatment. Services should be provided in a manner that is consistent with established federal and professional medical associations' recommendations to ensure that clients who need services receive them and to avoid over-screening.

Quality of evidence: A systematic review was not conducted; the recommendation was made on the basis of CDC's recommendations to improve preconception health and health care (3) and a review of preconception health services for men (7).

Potential consequences: More men will receive preconception health services, which might improve infant and men's health. The evidence base for preconception health is not well established and is less than that for women's preconception health. There is a risk of over-screening if recommendations are not followed. There is a potential risk that a client with a positive screen might not be able to afford treatment if the client is uninsured and not eligible for public programs. The human and financial cost of providing preconception health services might mean that fewer contraceptive and other services can be offered.

Rationale: The potential benefits to men and infant health were thought by the panel to be greater than the costs, potential harms, and opportunity costs of not providing these services. Implementation (e.g., training and monitoring of providers) can address the issues related to providers over-screening and not following the federal and professional medical recommendations. CDC will continue to monitor related research and modify these recommendations, as needed. Health-care reform might make follow-up care more available to low-income clients. All seven EWG members agreed to this recommendation.

Contraceptive Services — Contraceptive Counseling Steps

Recommendation: To help a client who is initiating or switching to a new method of contraception, providers should follow these steps, which are in accordance with the key principles for providing quality counseling: 1) establish and maintain rapport with the client; 2) obtain clinical and social information from the client; 3) work with the client interactively to select the most effective and appropriate contraceptive method for her or him; 4) provide a physical assessment related to contraceptive use, when warranted; and 5) provide the contraceptive method along with instructions about correct and consistent use, help the client develop a plan for using the selected method and for follow-up, and confirm understanding.

Quality of evidence: Twenty-two studies were identified that examined the impact of contraceptive counseling in clinical settings and met the inclusion criteria. Of the 16 studies that focused on adults or mixed populations (adolescents and adults) (8–23), 11 found a statistically significant positive impact of counseling interventions with low (11,12,14–16,18–21), moderate (8), or unrated (22) intensity on at least one outcome of interest; study designs included two cross-sectional surveys (14,22), one pre-post study (21), one prospective cohort study (8), one controlled trial (15), and six randomized controlled trials (RCTs) (11,12,16,18–20). Six studies examined the impact of contraceptive counseling among adolescents (24–29), with four finding a statistically significant positive impact of low-intensity (27) or moderate-intensity (24,25,29) counseling interventions on at least one outcome of interest; study designs included two pre-post studies (24,30), one controlled trial (29), and one RCT (27). In addition, five studies were identified that examined the impact of reminder system interventions in clinical settings on family planning outcomes and met the inclusion criteria (31–35); of these, two found a statistically significant positive impact of reminder systems on perfect oral contraceptive compliance, a retrospective historical nonrandomized controlled trial that examined daily reminder email messages (31) and a cohort study that examined use of a small reminder device that emitted a daily audible beep (34). In addition, two studies examined the impact of reminder systems among depot medroxyprogesterone acetate users (DMPA) (33,35) with one, a retrospective cohort study, finding a statistically significant positive impact of receiving a wallet-sized reminder card with the date of the next DMPA injection and a reminder postcard shortly before the next injection appointment on timely DMPA injections. Statements about safety and unnecessary medical examinations and tests are made on the basis of CDC guidelines on contraceptive use (36,37).

Potential consequences: Fewer clients will use methods that are not safe for them, there will be increased contraceptive use, increased use of more effective methods, increased continuation of method use, increased use of dual methods, increased knowledge, increased satisfaction with services, and increased use of repeat or follow-up services.

Rationale: Making sure that a contraceptive method is safe for an individual client is a fundamental responsibility of all providers of family planning services. Removing medical barriers to contraceptive use is key to increasing access to contraception and helping clients prevent unintended pregnancy. Consistent use of contraceptives is needed to prevent unintended pregnancies, so appropriate counseling is critical to ensure clients make the best possible choice of methods for their unique circumstances, and are supported in continued

use of the chosen method. The principles of quality counseling, from which the steps listed in the recommendations are based, are supported by a substantial body of evidence and expert opinion. Future research to evaluate the five principles will be monitored and the recommendations modified, as needed. All seven EWG members agreed to this recommendation.

Contraceptive Services — Tiered Approach to Counseling

Recommendation: For clients who might want to get pregnant in the future and prefer reversible methods of contraception, providers should use a tiered approach to presenting a broad range of contraceptive methods (including long-acting reversible contraception such as intrauterine devices and contraceptive implants), in which the most effective methods are presented before less effective methods.

Quality of evidence: National surveys have demonstrated low rates of LARC use overall (38,39). However, Project CHOICE has demonstrated high uptake of long-acting reversible contraception (approximately two thirds of clients when financial barriers are removed) and a very substantial reduction in rates of unintended pregnancy (40). Further, a recent study of postpartum contraceptive use shows that 50% of teen mothers with a recent live birth are using long-acting reversible contraception postpartum in Colorado, which demonstrates high levels of acceptance in the context of a statewide program to remove financial barriers (41).

Potential consequences: Use of long-acting reversible contraception has the potential to help many more persons prevent unintended pregnancy because of its ease of use, safety, and effectiveness. Several questions were raised about ethical issues in using a tiered approach to counseling. First, is it ethical to educate about long-acting reversible contraception when the methods are not all available on-site? Second, conversely, is it ethical not to inform clients about the most effective methods? In other health service areas, the standard of care is to inform the client about the most effective treatment (e.g., blood pressure medications), so the client can make a fully informed decision, and this standard should apply in this instance as well. On the basis of historic experiences, there is a need to ensure that methods always are offered on a completely voluntary and noncoercive basis. Health-care reform might make contraceptive services more available to the majority of clients.

Rationale: Providers have an obligation to inform clients about the most effective methods available, even if they cannot provide them. Further, health-care reform will reduce the

financial barriers to long-acting reversible contraception for many persons. The potential increase in use of long-acting reversible contraception and other more effective methods is likely to help reduce rates of unintended pregnancy. All seven EWG members agreed to this recommendation.

Contraceptive Services — Broad Range of Methods

Recommendation: A broad range of methods should be available on-site or through referral.

Quality of evidence: Three descriptive studies from the review of quality improvement literature identified contraceptive choice as an important aspect of quality care (42–44).

Potential consequences: Clients will be more likely to select a method that they will use consistently and correctly.

Rationale: A central tenet of quality health care is that it be client-centered. Being able to provide a client with a method that best fits her or his unique circumstances is essential for that reason. All seven EWG members agreed to this recommendation.

Contraceptive Services — Education

Recommendation: The content, format, method, and medium for delivering education should be evidence-based.

Quality of evidence: Seventeen studies were identified that met the inclusion criteria for this systematic review. Of these, 15 studies looked at knowledge of correct method use or contraceptive risks and benefits, including side effects and method effectiveness (45–59). All but one study (56) found a statistically significant positive impact of educational interventions on increased knowledge. These studies included six randomized controlled trials with low risk for bias.

Potential consequences: Clients will make more informed decisions when choosing a contraceptive method. More clients will be satisfied with the process of selecting a contraceptive method.

Rationale: Knowledge obtained through educational activities, as integrated into the larger counseling model, is a critically important precondition for the client's ability to make informed decisions. The techniques described in the recommendations have a well-established evidence base for increasing knowledge and satisfaction with services. This knowledge lays the foundation for further counseling steps that will increase the likelihood of correct and consistent use, and increased satisfaction will increase return visits to the service site, as needed. Four of seven EWG members agreed to this recommendation; three members did not express an opinion.

Contraceptive Services — Confirm Understanding

Recommendation: A check box or written statement should be available in the medical record that can be used to document that the client expressed understanding of the most important information about her/his chosen contraceptive method. The teach-back method may be used to get clients to express the most important points by repeating back messages about risks and benefits and appropriate method use and follow-up. Documentation of understanding using the teach-back method and a check box or written statement can be used in place of a written method-specific informed consent.

Quality of evidence: Two studies from outside the family planning literature (one cohort study and one controlled trial with unclear randomization) (60,61) and a strong recommendation by members of the Technical Panel on Counseling and Education were considered.

Potential consequences: More clients will make informed decisions, adherence to contraceptive and treatment plans will improve, and reproductive and other health conditions will be better controlled.

Rationale: Asking providers to document in the record that the client is making an informed decision will increase providers' attention to this task. This recommendation will replace a previous requirement that providers obtain method-specific informed consent from each client (in addition to a general consent form). Six of seven EWG members agreed to this recommendation.

Adolescent Services — Comprehensive Information

Recommendation: Providers should provide comprehensive information to adolescent clients about how to prevent pregnancy and STDs. This should include information about contraception and that avoiding sex (abstinence) is an effective way to prevent pregnancy and STDs.

Quality of evidence: A systematic review was not conducted because other recent reviews were available that have shown a substantial impact of comprehensive sexual health education on reduced adolescent risk behavior (62–66). The evidence for abstinence-only education was more limited: CDC's Community Guide concluded that there was insufficient evidence (67), but the Department of Health and Human Services' Office of Adolescent Health has identified two abstinence-based programs as having evidence of effectiveness (68).

Potential consequences: Teens will make more informed decisions and will delay initiation of sexual intercourse. The

absence of harmful effects from comprehensive sexual health education was noted.

Rationale: The benefits of informing adolescents about all ways to prevent pregnancy are substantial. Ultimately, each adolescent should make an informed decision that meets her or his unique circumstances, based on the counseling provided by the provider. Six of seven EWG members agreed to this recommendation.

Adolescent Services — Use of Long-Acting Reversible Contraception

Recommendation: Education about contraceptive methods should include an explanation that long-acting reversible contraception is safe and effective for nulliparous women (women who have not been pregnant or given birth), including adolescents.

Quality of evidence: CDC guidelines on contraceptive use (37) provide evidence that long-acting reversible contraception is safe and effective for adolescents and nulliparous women.

Potential consequences: More providers will encourage adolescents to consider long-acting reversible contraception; more adolescents will choose long-acting reversible contraception, resulting in reduced rates of teen pregnancy, including rapid repeat pregnancy.

Rationale: Long-acting reversible contraception is safe for adolescents (37). As noted above, providers should inform clients about the most effective methods available. The potential increase in use of long-acting reversible contraception and other more effective methods by adolescents is substantial and is likely to lead to further reductions in teen pregnancy. Three EWG members agreed to this recommendation; two EWG members abstained.

Adolescent Services — Confidential Services

Recommendation: Confidential family planning services should be made available to adolescents, while observing state laws and any legal obligations for reporting.

Quality of evidence: Six descriptive studies documented one or more of the following: that confidentiality is important to adolescents; that many adolescents reported they will not use reproductive health services if confidentiality cannot be assured; and that adolescents might not be honest in discussing reproductive health with providers if confidentiality cannot be assured (69–74). One RCT showed a slight reduction in use of services after receiving conditional confidentiality, compared with complete confidentiality (75). One study showed a

positive association between confidentiality and intention to use services (73).

Potential consequences: Consequences might include an increased intention to use services, increased use of services, and reduced rates of teen pregnancy. However, explaining the need to report under certain circumstances (rape, child abuse) might deter some adolescent clients from using services. Further, some parents/guardians might not agree that adolescents should have access to confidential services.

Rationale: Minors' rights to confidential reproductive health services are consistent with state and federal law. The risks of not providing confidential services to adolescents are great and likely to result in an increased rate of teen pregnancies. Finally, this recommendation is consistent with the recommendations of three professional medical associations that endorse provision of confidential services to adolescents (76–78). All seven EWG members agreed to this recommendation.

Adolescent Services — Family-Child Communication

Recommendation: Providers should encourage and promote family-child communication about sexual and reproductive health.

Quality of evidence: From the family planning literature, 16 parental involvement programs (most using an RCT study design) were found to be positively associated with at least one short-term (13 of 16 studies) or medium-term (four of seven studies) outcome (79–94). However, only one of these studies was linked to clinical services (80); others were implemented in community settings.

Potential consequences: Consequences might include increased parental/guardian involvement and communication, improved knowledge/awareness, increased intentions to use contraceptives, and the adoption of more pro-social norms that support parent-child communication about sexual health.

Rationale: The literature provides strong evidence that increased communication between a child and her/his parent/guardian will lead to safer sexual behavior among teens, and numerous community-based programs have created an evidence base for how to strengthen parents/guardians' ability to hold those conversations. Although less is known about how to do so in a clinical setting, providers can refer their clients to programs in the community, and principles from the community-based approaches can be used to help providers develop appropriate approaches in the clinical setting. Research in this area will be monitored, and the recommendations will be revised, as needed. Four of five EWG members who provided input agreed to this recommendation; one member abstained.

Adolescent Services — Repeat Teen Pregnancy

Recommendation: Providers should refer pregnant and parenting adolescents to home visiting and other programs that have been shown to provide needed support and reduce rates of repeat teen pregnancy.

Quality of evidence: Three of four studies of clinic-based programs (using retrospective case-control cohort, ecological evaluation, and prospective cohort study designs) showed that comprehensive teen pregnancy prevention programs (programs with clinical, school, case management, and community components) were associated with both medium- and long-term outcomes (95–98). In addition, several randomized trials of community-based home visiting programs, and an existing systematic review of the home visiting literature, demonstrated a protective impact of these programs on preventing repeat teen pregnancy and other relevant outcomes (99–103).

Potential consequences: Consequences might include decreased rapid repeat pregnancy and abortion rates, and increased use of contraceptives.

Rationale: There is sufficient evidence to recommend that providers link pregnant and parenting teens to community and social services that might reduce rates of rapid repeat pregnancy. Three of seven EWG members agreed to an earlier version of this recommendation. Other members wanted to remove a clause about prioritizing the contraceptive needs of pregnant/parenting teens because they felt that all clients should be treated as priority clients. This suggestion was adopted, but the EWG did not have a chance to vote again on the modified recommendation.

Contraceptive Method Availability

Recommendation: Family planning programs should stock and offer a broad a range of FDA-approved contraceptive methods so that the needs of individual clients can be met. These methods are optimally available on-site, but strong referrals can serve to make methods not available on-site real options for clients.

Quality of evidence: No research was identified that explicitly addressed the question of whether having a broad range of methods was associated with short-, medium-, or long-term reproductive health outcomes. However, as noted above, three descriptive studies from the review of quality improvement literature identified contraceptive choice as an important aspect of quality care (42–44).

Potential consequences: Consequences might include increased use of contraception and increased use of reproductive

health services. It also was noted that there are sometimes high costs to stocking certain methods (e.g., intrauterine devices and contraceptive implants).

Rationale: Having a broad range of contraceptive methods is central to client-centered care, a core aspect of providing quality services. Individual clients need to have a choice so they can select a method that best fits their particular circumstances. This is likely to result in more correct and consistent use of the chosen methods. The benefits of this recommendation were weighed more heavily than the negative outcomes (e.g., additional cost). All five EWG members agreed to this recommendation.

Youth-Friendly Services

Recommendation: Family planning programs should take steps to make services “youth-friendly.”

Quality of evidence: Of 20 studies that were identified, six looked at short-, medium-, or long-term outcomes with mixed designs (one group time series, one cross-sectional, three prospective cohort, and one nonrandomized trial); protective effects were found on long-term (two of three studies), medium-term (three of three), and short-term (three of three) outcomes (29,30,104–107). One of these six studies (29), plus 13 other descriptive studies (for a total of 14 studies), presented adolescents’ or providers’ views on facilitators for adolescent clients in using youth-friendly family planning services. Key factors described were confidentiality (13 of 14), accessibility (11 of 14), peer involvement (three of 14), parental or familial involvement (four of 14), and quality of provider interaction (11 of 14) (105–121). Four of these studies (111,112,114,121) plus one other descriptive study (108) described barriers to clinics adopting and implementing youth-friendly family planning services.

Potential consequences: Consequences might include increased use of reproductive health services by adolescents, improved contraceptive use, use of more effective methods, more consistent use of contraception, and reduced rates of teen pregnancy. It is also likely to lead to improved satisfaction with services and greater knowledge about pregnancy prevention among adolescents. It is possible that there will be higher costs, and some uncertainty regarding the benefits due to a relatively weak evidence base.

Rationale: Existing evidence has demonstrated the importance of specific characteristics to adolescents’ attitudes and use of clinical services. The potential benefits of providing youth-friendly services outweigh the potential costs and weak evidence base. All five EWG members agreed to this recommendation. Some thought that it should be cast as an

example of comprehensively client-centered care, rather than an end of its own.

Quality Improvement

Recommendation: Family planning programs should have a system for quality improvement, which is designed to review and strengthen the quality of services on an ongoing basis. Family planning programs should select, measure, and assess at least one outcome measure on an ongoing basis, for which the service site can be accountable.

Quality of evidence: A recent systematic review (122) was supplemented with 10 articles that provided information related to client and/or provider perspectives regarding what constitutes quality family planning services (42–44,113,123–128). These studies used a qualitative (k = 4) or cross-sectional (k = 6) study design. Ten descriptive studies identified client and provider perspectives on what constitutes quality family planning services, which include stigma and embarrassment reduction (n = 9), client access and convenience (n = 8); confidentiality (n = 3); efficiency and tailoring of services (n = 6); client autonomy and confidence (n = 5); contraceptive access and choice (n = 4); increased time of patient-provider interaction (n = 3); communication and relationship (n = 3); structure and facilities (n = 2); continuity of care (n = 2). Well-established frameworks for guiding quality improvement efforts were referenced (122,129–132).

Potential consequences: Consequences might include increased use by clients of more effective contraceptive methods, clients might be more likely to return for care, client satisfaction might improve, and there might be reduced rates of teen and unintended pregnancy, and improved spacing of births.

Rationale: Research, albeit limited, has demonstrated that quality services are associated with improved client experience with care and adoption of more protective contraceptive behavior. Further, these recommendations on quality improvement are consistent with those made by national leaders in the quality improvement field. Research is either under way or planned to validate a core set of performance measures, and the recommendations will be updated as new findings emerge. All five EWG members agreed to these recommendations.

References

1. Family Planning Services and Population Research Act of 1970, Title X. Population Research and Voluntary Family Planning Programs Project Grants and Contracts for Family Planning Services Pub. L. No. Public Law 91-572 (1970).
2. Project Grants for Family Planning Services. 42 CFR Part 59, Subpart A, (1971).
3. CDC. Recommendations to improve preconception health and health care—United States. MMWR 2006;55(No. RR-06).

4. CDC. Sexually transmitted diseases treatment guidelines, 2010. *MMWR* 2010;59(No. RR-12).
5. CDC. Revised recommendations for HIV testing of adults, adolescents and pregnant women in health care settings. *MMWR* 2006;55(No. RR-14).
6. Jack B, Atrash H, Coonrod D, Moos M, O'Donnell J, Johnson K. The clinical content of preconception care: an overview and preparation of this supplement. *Am J Obstet Gynecol* 2008;199(Supplement B):S266–79.
7. Frey K, Navarro S, Kotelchuck M, Lu M. The clinical content of preconception care: preconception care for men. *Am J Obstet Gynecol* 2008;199(6 Suppl 2):S389–95.
8. Adams-Skinner J, Exner T, Pili C, Wallace B, Hoffman S, Leu CS. The development and validation of a tool to assess nurse performance in dual protection counseling. *Patient Educ Couns* 2009;76:265–71.
9. Bender SS, Geirsson RT. Effectiveness of preabortion counseling on postabortion contraceptive use. *Contraception* 2004;69:481–7.
10. Boise R, Petersen R, Curtis KM, et al. Reproductive health counseling at pregnancy testing: a pilot study. *Contraception* 2003;68:377–83.
11. Custo G, Saitto C, Cerza S, Sertoli G. The adjusted contraceptive score (ACS) improves the overall performance of behavioural and barrier contraceptive methods. *Adv Contracept Deliv Syst* 1987;3:367–73.
12. Gilliam M, Knight S, McCarthy M Jr. Success with oral contraceptives: a pilot study. *Contraception* 2004;69:413–8.
13. Langston AM, Rosario L, Westhoff CL. Structured contraceptive counseling—a randomized controlled trial. *Patient Educ Couns* 2010;81:362–7.
14. Lee JK, Parisi SM, Akers AY, Borrero S, Schwarz EB. The impact of contraceptive counseling in primary care on contraceptive use. *J Gen Intern Med* 2011;26:731–6.
15. Namerow PB, Weatherby N, Williams-Kaye J. The effectiveness of contingency-planning counseling. *Fam Plann Perspect* 1989;21:115–9.
16. Nobili MP, Piergrossi S, Brusati V, Moja EA. The effect of patient-centered contraceptive counseling in women who undergo a voluntary termination of pregnancy. *Patient Educ Couns* 2007;65:361–8.
17. Petersen R, Albright J, Garrett JM, Curtis KM. Pregnancy and STD prevention counseling using an adaptation of motivational interviewing: a randomized controlled trial. *Perspect Sex Reprod Health* 2007;39:21–8.
18. Proctor A, Jenkins TR, Loeb T, Elliot M, Ryan A. Patient satisfaction with 3 methods of postpartum contraceptive counseling: a randomized, prospective trial. *J Reprod Med* 2006;51:377–82.
19. Schunmann C, Glasier A. Specialist contraceptive counselling and provision after termination of pregnancy improves uptake of long-acting methods but does not prevent repeat abortion: a randomized trial. *Hum Reprod* 2006;21:2296–303.
20. Shlay JC, Mayhugh B, Foster M, Maravi ME, Baron AE, Douglas JM Jr. Initiating contraception in sexually transmitted disease clinic setting: a randomized trial. *Am J Obstet Gynecol* 2003;189:473–81.
21. Todres R. Effectiveness of counseling in the transmission of family planning and sexuality knowledge. *J Sex Educ Ther* 1990;16:279–85.
22. Weisman CS, Maccannon DS, Henderson JT, Shortridge E, Orso CL. Contraceptive counseling in managed care: preventing unintended pregnancy in adults. *Womens Health Issues* 2002;12:79–95.
23. Yassin AS, Cordwell D. Does dedicated pre-abortion contraception counselling help to improve post-abortion contraception uptake? *J Fam Plann Reprod Health Care* 2005;31:115–6.
24. Berger DK, Perez G, Kyman W, et al. Influence of family planning counseling in an adolescent clinic on sexual activity and contraceptive use. *J Adolesc Health Care* 1987;8:436–40.
25. Brindis CD, Geierstanger SP, Wilcox N, McCarter V, Hubbard A. Evaluation of a peer provider reproductive health service model for adolescents. *Perspect Sex Reprod Health* 2005;37:85–91.
26. Cowley CB, Farley T, Beamis K. 'Well, maybe I'll try the pill for just a few months...': Brief motivational and narrative-based interventions to encourage contraceptive use among adolescents at high risk for early childbearing. *Fam Syst Health* 2002;20:183–204.
27. Hanna KM. Effect of nurse-client transaction on female adolescents' oral contraceptive adherence. *Image J Nurs Sch* 1993;25:285–90.
28. Kirby D, Raine T, Thrush G, Yuen C, Sokoloff A, Potter SC. Impact of an intervention to improve contraceptive use through follow-up phone calls to female adolescent clinic patients. *Perspect Sex Reprod Health* 2010;42:251–7.
29. Winter L, Breckenmaker LC. Tailoring family planning services to the special needs of adolescents. *Fam Plann Perspect* 1991;23:24–30.
30. Brindis CD, Geierstanger SP, Wilcox N, McCarter V, Hubbard A. Evaluation of a peer provider reproductive health service model for adolescents. *Perspect Sex Reprod Health* 2005;37:85–91.
31. Fox MC, Creinin MD, Murthy AS, Harwood B, Reid LM. Feasibility study of the use of a daily electronic mail reminder to improve oral contraceptive compliance. *Contraception* 2003;68:365–71.
32. Hou MY, Hurwitz S, Kavanagh E, Fortin J, Goldberg AB. Using daily text-message reminders to improve adherence with oral contraceptives: a randomized controlled trial. *Obstet Gynecol* 2010;116:633–40.
33. Keder LM, Rulin MC, Gruss J. Compliance with depot medroxyprogesterone acetate: a randomized, controlled trial of intensive reminders. *Am J Obstet Gynecol* 1998;179:583–5.
34. Lachowsky M, Levy-Toledano R. Improving compliance in oral contraception: 'the reminder card'. *Eur J Contracept Reprod Health Care* 2002;7:210–5.
35. Madlon-Kay DJ. The effectiveness of a mail reminder system for depot medroxyprogesterone injections. *Arch Fam Med* 1996;5:234–6.
36. CDC. U.S. selected practice recommendations for contraceptive use 2013. *MMWR* 2013;62(No. RR-4).
37. CDC. U.S. medical eligibility criteria for contraceptive use 2010. *MMWR* 2010;59(No. RR-4).
38. Daniels K, Mosher W, Jones J. Contraceptive methods women have ever used: United States, 1982–2010. *National health statistics reports*; 2013;62.
39. Martinez G, Copen C, Abma J. Teenagers in the United States: sexual activity, contraceptive use, and childbearing, 2006–2010 National Survey of Family Growth. *Vital Health Stat* 2011;23(31).
40. Winner B, Peipert J, Zhao Q, et al. Effectiveness of long-acting reversible contraception. *N Engl J Med* 2012;366:1998–2007.
41. CDC. Vital signs: repeat births among teens—United States, 2007–2010. *MMWR* 2013;62:249–55.
42. Becker D, Klassen AC, Koenig MA, LaVeist TA, Sonenstein FL, Tsui AO. Women's perspectives on family planning service quality: an exploration of differences by race, ethnicity and language. *Perspect Sex Reprod Health* 2009;41:158–65.
43. Gilliam ML, Hernandez M. Providing contraceptive care to low-income, African American teens: the experience of urban community health centers. *J Community Health* 2007;32:231–44.
44. Landry DJ, Wei J, Frost JJ. Public and private providers' involvement in improving their patients' contraceptive use. *Contraception* 2008;78:42–51.
45. Deijen JB, Kornaat H. The influence of type of information, somatization, and locus of control on attitude, knowledge, and compliance with respect to the triphasic oral contraceptive Tri-Minulet. *Contraception* 1997;56:31–41.

46. Kirby D, Harvey PD, Claussenius D, Novar M. A direct mailing to teenage males about condom use: its impact on knowledge, attitudes and sexual behavior. *Fam Plann Perspect* 1989;21:12–8.
47. Little P, Griffin S, Kelly J, Dickson N, Sadler C. Effect of educational leaflets and questions on knowledge of contraception in women taking the combined contraceptive pill: randomised controlled trial. *BMJ* 1998;316:1948–52.
48. Smith LF, Whitfield MJ. Women's knowledge of taking oral contraceptive pills correctly and of emergency contraception: effect of providing information leaflets in general practice. *Br J Gen Pract* 1995;45:409–14.
49. Steiner MJ, Dalebout S, Condon S, Dominik R, Trussell J. Understanding risk: a randomized controlled trial of communicating contraceptive effectiveness. *Obstet Gynecol* 2003;102:709–17.
50. DeLamater J, Wagstaff DA, Havens KK. The impact of a culturally appropriate STD/AIDS education intervention on black male adolescents' sexual and condom use behavior. *Health Educ Behav* 2000;27:454–70.
51. Mason V, McEwan A, Walker D, Barrett S, James D. The use of video information in obtaining consent for female sterilisation: a randomised study. *BJOG* 2003;110:1062–71.
52. Schwarz EB, Gerbert B, Gonzales R. Computer-assisted provision of emergency contraception a randomized controlled trial. *J Gen Intern Med* 2008;23:794–9.
53. Paperny DM, Starn JR. Adolescent pregnancy prevention by health education computer games: computer-assisted instruction of knowledge and attitudes. *Pediatrics* 1989;83:742–52.
54. Reis J, Tymchysyn P. A longitudinal evaluation of computer-assisted instruction on contraception for college students. *Adolescence* 1992;27:803–11.
55. Roberto AJ, Zimmerman RS, Carlyle KE, Abner EL, Cupp PK, Hansen GL. The effects of a computer-based pregnancy, STD, and HIV prevention intervention: a nine-school trial. *Health Commun* 2007;21:115–24.
56. Lindenberg CS, Solorzano RM, Bear D, Strickland O, Galvis C, Pittman K. Reducing substance use and risky sexual behavior among young, low-income, Mexican-American women: comparison of two interventions. *Appl Nurs Res* 2002;15:137–48.
57. Chewning B, Mosena P, Wilson D, et al. Evaluation of a computerized contraceptive decision aid for adolescent patients. *Patient Educ Couns* 1999;38:227–39.
58. O'Donnell L, San Doval A, Duran R, O'Donnell CR. The effectiveness of video-based interventions in promoting condom acquisition among STD clinic patients. *Sex Transm Dis* 1995;22:97–103.
59. Pedrazzini AE, McGowan H, Lucking L, Johanson RJ. 'The trouble with sex—it always gets in the way': an evaluation of a peer-produced teenage pregnancy video. *Br J Fam Plann* 2000;26:131–5.
60. McMahon SR, Rimsza ME, Bay RC. Parents can dose liquid medication accurately. *Pediatrics* 1997;100:330–3.
61. Schillinger D, Piette J, Grumbach K, et al. Closing the loop: physician communication with diabetic patients who have low health literacy. *Arch Intern Med* 2003;163:83–90.
62. Kirby D. Comprehensive sex education: strong public support and persuasive evidence of impact, but little funding. *Arch Pediatr Adolesc Med* 2006;160:1182–4.
63. Guide to Community Preventive Services. Preventing HIV/AIDS, other STIs, and teen pregnancy: group-based comprehensive risk reduction interventions for adolescents. Atlanta, GA: US Department of Health and Human Services, CDC; 2009. Available at <http://www.thecommunityguide.org/hiv/riskreduction.html>.
64. Kirby D, Obasi A, Laris BA. The effectiveness of sex education and HIV education interventions in schools in developing countries. *World Health Organ Tech Rep Ser* 2006;938:103–50, discussion 317–41.
65. Kirby DB, Laris BA, Roller LA. Sex and HIV education programs: their impact on sexual behaviors of young people throughout the world. *J Adolesc Health* 2007;40:206–17.
66. Oringanje C, Meremikwu MM, Eko H, Esu E, Meremikwu A, Ehiri JE. Interventions for preventing unintended pregnancies among adolescents. *Cochrane Database Syst Rev* 2009;(4):CD005215.
67. Guide to Community Preventive Services. Preventing HIV/AIDS, other STIs, and teen pregnancy: group-based abstinence education interventions for adolescents. Atlanta, GA: US Department of Health and Human Services, CDC; 2009. Available at http://www.thecommunityguide.org/hiv/abstinence_ed.html.
68. Office of Adolescent Health. Information about effective programs for preventing teen pregnancy. Washington, DC: US Department of Health and Human Services; 2011. Available at www.hhs.gov/ash/oah/oah-initiatives/tpp/programs.html.
69. Ford CA, Thomsen SL, Compton B. Adolescents' interpretations of conditional confidentiality assurances. *J Adolesc Health* 2001;29:156–9.
70. Garside R, Ayres R, Owen M, Pearson VA, Roizen J. Anonymity and confidentiality: rural teenagers' concerns when accessing sexual health services. *J Fam Plann Reprod Health Care* 2002;28:23–6.
71. Rainey DY, Brandon DP, Krowchuk DP. Confidential billing accounts for adolescents in private practice. *J Adolesc Health* 2000;26:389–91.
72. Schuster MA, Bell RM, Petersen LP, Kanouse DE. Communication between adolescents and physicians about sexual behavior and risk prevention. *Arch Pediatr Adolesc Med* 1996;150:906–13.
73. Thomas N, Murray E, Rogstad KE. Confidentiality is essential if young people are to access sexual health services. *Int J STD AIDS* 2006;17:525–9.
74. Thrall JS, McCloskey L, Ettner SL, Rothman E, Tighe JE, Emans SJ. Confidentiality and adolescents' use of providers for health information and for pelvic examinations. *Arch Pediatr Adolesc Med* 2000;154:885–92.
75. Ford CAMS, Halpern-Felsher BL, Irwin CE Jr. Influence of physician confidentiality assurances on adolescents' willingness to disclose information and seek future health care. A randomized controlled trial. *JAMA* 1997;278:1029–34.
76. American College of Obstetricians and Gynecologists. Confidentiality in adolescent health care: guidelines for adolescent health care. 2nd ed. Washington, DC: American College of Obstetricians and Gynecologists; 2011.
77. American Academy of Pediatrics. Achieving quality health services for adolescents: policy statement of the Committee on Adolescence, American Academy of Pediatrics. *Pediatrics* 2008;121:1263.
78. Ford C, English A, Sigman G. Confidential health care for adolescents: position paper for the society for adolescent medicine. *J Adolesc Health* 2004;35:160–7.
79. Anderson NLR, Koniak-Griffin D, Keenan CK, Uman G, Duggal BR, Casey C. Evaluating the outcomes of parent-child family life education [including commentary by Hayman LL]. *Sch Inq Nurs Pract* 1999;13:211–38.
80. Guilamo-Ramos V, Bouris A, Jaccard J, Gonzalez B, McCoy W, Aranda D. A parent-based intervention to reduce sexual risk behavior in early adolescence: building alliances between physicians, social workers, and parents. *J Adolesc Health*;48:159–63.
81. Blake SM, Simkin L, Ledsky R, Perkins C, Calabrese JM. Effects of a parent-child communications intervention on young adolescents' risk for early onset of sexual intercourse. *Fam Plann Perspect* 2001;33:52–61.

82. Brody GH, Murry VM, Gerrard M, et al. The Strong African American Families Program: translating research into prevention programming. *Child Dev* 2004;75:900–17.
83. Evans WD, Davis KC, Ashley OS, Blitstein J, Koo H, Zhang Y. Efficacy of abstinence promotion media messages: findings from an online randomized trial. *J Adolesc Health* 2009;45:409–16.
84. Forehand R, Armistead L, Long N, et al. Efficacy of a parent-based sexual-risk prevention program for African American preadolescents: a randomized controlled trial. *Arch Pediatr Adolesc Med* 2007;161:1123–9.
85. Haggerty KP, Skinner ML, MacKenzie EP, Catalano RF. A randomized trial of Parents Who Care: effects on key outcomes at 24-month follow-up. *Prev Sci* 2007;8:249–60.
86. Huston RL, Martin LJ, Foulds DM. Effect of a program to facilitate parent-child communication about sex. *Clin Pediatr (Phila)* 1990;29:626–33.
87. Lederman RP, Chan W, Roberts-Gray C. Sexual risk attitudes and intentions of youth aged 12–14 years: survey comparisons of parent-teen prevention and control groups. *Behavioral Medicine (Washington, DC)* 2004;29:155–63.
88. Lederman RP, Chan W, Roberts-Gray C. Parent-adolescent relationship education (PARE): program delivery to reduce risks for adolescent pregnancy and STDs. *Behav Med* 2008;33:137–43.
89. Lefkowitz ES, Sigman M, Au TK. Helping mothers discuss sexuality and AIDS with adolescents. *Child Dev* 2000;71:1383–94.
90. Miller BC, Norton MC, Jenson GO. Impact Evaluation of Facts and Feelings: a home-based video sex education curriculum. *Fam Relat* 1993;42:392–400.
91. Murry VM, Berkel C, Brody GH, Gerrard M, Gibbons FX. The Strong African American Families program: longitudinal pathways to sexual risk reduction. *J Adolesc Health* 2007;41:333–42.
92. Schuster MA, Corona R, Elliott MN, et al. Evaluation of Talking Parents, Healthy Teens, a new worksite based parenting programme to promote parent-adolescent communication about sexual health: randomised controlled trial. *BMJ* 2008;337:a308.
93. Stanton B, Cole M, Galbraith J, et al. Randomized trial of a parent intervention: parents can make a difference in long-term adolescent risk behaviors, perceptions, and knowledge. *Arch Pediatr Adolesc Med* 2004;158:947–55.
94. Stanton BF, Li X, Galbraith J, et al. Parental underestimates of adolescent risk behavior: a randomized, controlled trial of a parental monitoring intervention. *J Adolesc Health* 2000;26:18–26.
95. Elster AB, Lamb ME, Tavare J, Ralston CW. The medical and psychosocial impact of comprehensive care on adolescent pregnancy and parenthood. *JAMA* 1987;258:1187–92.
96. Omar HA, Fowler A, McClanahan KK. Significant reduction of repeat teen pregnancy in a comprehensive young parent program. *J Pediatr Adolesc Gynecol* 2008;21:283–7.
97. Rabin JM, Seltzer V, Pollack S. The long term benefits of a comprehensive teenage pregnancy program. *Clin Pediatr (Phila)* 1991;30:305–9.
98. Stevens-Simon C, Kelly L, Kulick R. A village would be nice but...it takes a long-acting contraceptive to prevent repeat adolescent pregnancies. *Am J Prev Med* 2001;21:60–5.
99. Eckenrode J, Campa M, Luckey DW, et al. Long-term effects of prenatal and infancy nurse home visitation on the life course of youths: 19-year follow-up of a randomized trial. *Arch Pediatr Adolesc Med* 2010;164:9–15.
100. Olds D, Henderson CR Jr, Cole R, et al. Long-term effects of nurse home visitation on children's criminal and antisocial behavior: 15-year follow-up of a randomized controlled trial. *JAMA* 1998;280:1238–44.
101. Olds DL, Eckenrode J, Henderson CR Jr, et al. Long-term effects of home visitation on maternal life course and child abuse and neglect. Fifteen-year follow-up of a randomized trial. *JAMA* 1997;278:637–43.
102. Black M, Bentley M, Papas M, et al. Delaying second births among adolescent mothers: a randomized, controlled trial of a home-based mentoring program. *Pediatrics* 2006;118:1087–99.
103. Avellar S, Paulsell D, Sama-Miller E, Del Grosso P. Home visiting evidence of effectiveness review. Washington, DC: US Department of Health and Human Services, Office of Planning, Research and Evaluation, Administration for Children and Families; 2012.
104. Wilson S, Daniel S, Pearson J, Hopton C, Madeley R. An evaluation of a new teenage clinic and its impact on teenage conceptions in Nottingham from 1986 to 1992. *Contraception* 1994;50:77–86.
105. Gupta S, Hogan R, Kirkman RJ. Experience of the first pelvic examination. *Eur J Contracept Reprod Health Care* 2001;6:34–8.
106. Morrison A, Mackie CM, Elliott L, Elliott LM, Gruer L, Bigrigg A. The Sexual Health Help Centre: a service for young people. *J Public Health Med* 1997;19:457–63.
107. Herz EJ, Olson LM, Reis JS. Family planning for teens: strategies for improving outreach and service delivery in public health settings. *Public Health Rep* 1988;103:422–30.
108. Bethea J, Hipsley-Cox J, Coupland C, Pringle M. General practitioners' attitudes towards the provision of services to young people aged under 16: a cross-sectional survey. *Qual Prim Care* 2007;15:11–9.
109. Kapphahn CJ, Wilson KM, Klein JD. Adolescent girls' and boys' preferences for provider gender and confidentiality in their health care. *J Adolesc Health* 1999;25:131–42.
110. Wilson A, Williams R. Sexual health services: what do teenagers want? *Ambul Child Health* 2000;6:253–60.
111. Alberti PM, Steinberg AB, Hadi EK, Abdullah RB, Bedell JF. Barriers at the frontline: assessing and improving the teen friendliness of South Bronx medical practices. *Public Health Rep* 2010;125:611–4.
112. Brindis CD, Loo VS, Adler NE, Bolan GA, Wasserheit JN. Service integration and teen friendliness in practice: a program assessment of sexual and reproductive health services for adolescents. *J Adolesc Health* 2005;37:155–62.
113. Chambers R, Boath E, Chambers S. Young people's and professionals' views about ways to reduce teenage pregnancy rates: to agree or not agree. *J Fam Plann Reprod Health Care* 2002;28:85–90.
114. Cromer BA, McCarthy M. Family planning services in adolescent pregnancy prevention: the views of key informants in four countries. *Fam Plann Perspect* 1999;31:287–93.
115. Donovan C, Mellanby AR, Jacobson LD, Taylor B, Tripp JH; The Adolescent Working Group. Teenagers' views on the general practice consultation and provision of contraception. *Br J Gen Pract* 1997;47:715–8.
116. French RS. The experience of young people with contraceptive consultations and health care workers. *Int J Adolesc Med Health* 2002;14:131–8.
117. Hayter M. Reaching marginalized young people through sexual health nursing outreach clinics: evaluating service use and the views of service users. *Public Health Nurs* 2005;22:339–46.
118. Ingram J, Salmon D. 'No worries!' Young people's experiences of nurse-led drop-in sexual health services in South West England. *J Res Nurs* 2007;12:305–16.

Recommendations and Reports

119. Peremans L, Hermann I, Avonts D, Van Royen P, Denekens J. Contraceptive knowledge and expectations by adolescents: an explanation by focus groups. *Patient Educ Couns* 2000;40:133–41.
120. Perry C, Thurston M. Meeting the sexual health care needs of young people: a model that works? *Child Care Health Dev* 2008;34:98–103.
121. Russell ST, Lee FCH. Practitioners' perspectives on effective practices for Hispanic teenage pregnancy prevention. *Perspect Sex Reprod Health* 2004;36:142–9.
122. Becker D, Koenig MA, Kim YM, Cardona K, Sonenstein FL. The quality of family planning services in the United States: findings from a literature review. *Perspect Sex Reprod Health* 2007;39:206–15.
123. Becker D, Tsui AO. Reproductive health service preferences and perceptions of quality among low-income women: racial, ethnic and language group differences. *Perspect Sex Reprod Health* 2008;40:202–11.
124. Becker H, Stuijbergen A, Tinkle M. Reproductive health care experiences of women with physical disabilities: a qualitative study. *Arch Phys Med Rehabil* 1997;78:S26–33.
125. Bender SS. Attitudes of Icelandic young people toward sexual and reproductive health services. *Fam Plann Perspect* 1999;31:294–301.
126. Dixon-Woods M, Stokes T, Young B, Phelps K, Windridge K, Shukla R. Choosing and using services for sexual health: a qualitative study of women's views. *Sex Transm Infect* 2001;77:335–9.
127. Khan NS, Kirkman R. Intimate examinations: use of chaperones in community-based family planning clinics. *BJOG* 2000;107:130–2.
128. Fiddes P, Scott A, Fletcher J, Glasier A. Attitudes towards pelvic examination and chaperones: a questionnaire survey of patients and providers. *Contraception* 2003;67:313–7.
129. Bruce J. Fundamental elements of the quality of care: a simple framework. *Stud Fam Plann* 1990;21:61–91.
130. Donabedian A. The quality of care. *JAMA* 1988;260:1743–8.
131. Institute of Medicine. *Crossing the quality chasm: a new health system for the 21st century*. Washington, DC: National Academies of Science; 2001.
132. National Quality Forum. *ABCs of measurement*. Washington, DC: National Quality Forum; 2011. Available at http://www.qualityforum.org/Measuring_Performance/ABCs_of_Measurement.aspx.

Appendix C

Principles for Providing Quality Counseling

Counseling is a process that enables clients to make and follow through on decisions. Education is an integral component of the counseling process that helps clients to make informed decisions. Providing quality counseling is an essential component of client-centered care.

Key principles of providing quality counseling are listed below and may be used when providing family planning services. The model was developed in consultation with the Technical Panel on Contraceptive Counseling and Education and reviewed by the Expert Work Group. Although developed specifically for providing contraceptive counseling, the principles are broad and can be applied to health counseling on other topics. Although the principles are listed here in a particular sequence, counseling is an iterative process, and at every point in the client encounter it is necessary to determine whether it is important to readdress and emphasize a given principle.

Principles of Quality Counseling

Principle 1. Establish and Maintain Rapport with the Client

Establishing and maintaining rapport with a client is vital to the encounter and achieving positive outcomes (1). This can begin by creating a welcoming environment and should continue through every stage of the client encounter, including follow-up. The contraceptive counseling literature indicates that counseling models that emphasized the quality of the interaction between client and provider have been associated with decreased teen pregnancy, increased contraceptive use, increased use of more effective methods, increased use of repeat or follow-up services, increased knowledge, and enhanced psychosocial determinants of contraceptive use (2–5).

Principle 2. Assess the Client's Needs and Personalize Discussions Accordingly

Each visit should be tailored to the client's individual circumstances and needs. Clients come to family planning providers for various services and with varying needs. Standardized questions and assessment tools can help providers determine what services are most appropriate for a given visit (6). Contraceptive counseling studies that have incorporated standardized assessment tools during the counseling process have resulted in increased contraceptive use, increased correct

use of contraceptives, and increased use of more effective methods (2,7,8). Contraceptive counseling studies that have personalized discussions to meet the individual needs of clients have been associated with increased contraceptive use, increased correct use of contraceptives, increased use of more effective methods, increased use of dual-method contraceptives to prevent both sexually transmitted diseases (STDs) and pregnancy, increased quality and satisfaction with services, increased knowledge, and enhanced psychosocial determinants of contraceptive use (4,7,9–12).

Principle 3. Work with the Client Interactively to Establish a Plan

Working with a client interactively to establish a plan, including a plan for follow-up, is important. Establishing a plan should include setting goals, discussing possible difficulties with achieving goals, and developing action plans to deal with potential difficulties. The amount of time spent establishing a plan will differ depending on the client's purpose for the visit and health-care needs. A client plan that requires behavioral change should be made on the basis of the client's own goals, interests, and readiness for change (13–15). Use of computerized decision aids before the appointment can facilitate this process by providing a structured yet interactive framework for clients to analyze their available options systematically and to consider the personal importance of perceived advantages and disadvantages (16,17). The contraceptive counseling literature indicates that counseling models that incorporated goal setting and development of action plans have been associated with increased contraceptive use, increased correct use of contraceptives, increased use of more effective methods, and increased knowledge (2,9,18–20). Furthermore, contraceptive counseling models that incorporated follow-up contacts resulted in decreased teen pregnancy, increased contraceptive use, increased correct use of contraceptives, increased use of more effective methods, increased continuation of method use, increased use of dual-method contraceptives to prevent both STDs and pregnancy, increased use of repeat or follow-up services, increased knowledge, and enhanced psychosocial determinants of contraceptive use (2,3,7,11,21,22). From the family planning education literature, computerized decision aids have helped clients formulate questions and have been associated with increased knowledge, selection of more effective methods, and increased continuation and compliance (23–25).

Principle 4. Provide Information That Can Be Understood and Retained by the Client

Clients need information that is medically accurate, balanced, and nonjudgmental to make informed decisions and follow through on developed plans. When speaking with clients or providing educational materials through any medium (e.g., written, audio/visual, or computer/web-based), the provider must present information in a manner that can be readily understood and retained by the client. Strategies for making information accessible to clients are provided (see Appendix D).

Principle 5. Confirm Client Understanding

It is important to ensure that clients have processed the information provided and discussed. One technique for confirming understanding is to have the client restate the most important messages in her or his own words. This teach-back method can increase the likelihood of the client and provider reaching a shared understanding, and has improved compliance with treatment plans and health outcomes (26,27). Using the teach-back method early in the decision-making process will help ensure that a client has the opportunity to understand her or his options and is making informed choices (28).

References

- Lambert M. Implications of outcome research for psychotherapy integration. In: Norcross J, Goldfind M, eds. *Handbook of psychotherapy integration*. New York, NY: Basic Books; 1992:94–129.
- Adams-Skinner J, Exner T, Pili C, Wallace B, Hoffman S, Leu CS. The development and validation of a tool to assess nurse performance in dual protection counseling. *Patient Educ Couns* 2009;76:265–71.
- Brindis CD, Geierstanger SP, Wilcox N, McCarter V, Hubbard A. Evaluation of a peer provider reproductive health service model for adolescents. *Perspect Sex Reprod Health* 2005;37:85–91.
- Nobili MP, Piergrossi S, Brusati V, Moja EA. The effect of patient-centered contraceptive counseling in women who undergo a voluntary termination of pregnancy. *Patient Educ Couns* 2007;65:361–8.
- Proctor A, Jenkins TR, Loeb T, Elliot M, Ryan A. Patient satisfaction with 3 methods of postpartum contraceptive counseling: a randomized, prospective trial. *J Reprod Med* 2006;51:377–82.
- Fiore M, Jaén C, Baker T, Bailey W, Benowitz N, Curry S. Treating tobacco use and dependence: 2008 update. *Clinical practice guideline*. Rockville, MD: US Department of Health and Human Services; 2008. Available at <http://www.ncbi.nlm.nih.gov/books/NBK63952>.
- Boise R, Petersen R, Curtis KM, et al. Reproductive health counseling at pregnancy testing: a pilot study. *Contraception* 2003;68:377–83.
- Custo G, Saitto C, Cerza S, Sertoli G. The adjusted contraceptive score (ACS) improves the overall performance of behavioural and barrier contraceptive methods. *Adv Contracept Deliv Syst* 1987;3:367–73.
- Hanna KM. Effect of nurse-client transaction on female adolescents' oral contraceptive adherence. *Image J Nurs Sch* 1993;25:285–90.
- Schunmann C, Glasier A. Specialist contraceptive counselling and provision after termination of pregnancy improves uptake of long-acting methods but does not prevent repeat abortion: a randomized trial. *Hum Reprod* 2006;21:2296–303.
- Shlay JC, Mayhugh B, Foster M, Maravi ME, Baron AE, Douglas JM Jr. Initiating contraception in sexually transmitted disease clinic setting: a randomized trial. *Am J Obstet Gynecol* 2003;189:473–81.
- Weisman CS, Maccannon DS, Henderson JT, Shorridge E, Orso CL. Contraceptive counseling in managed care: preventing unintended pregnancy in adults. *Womens Health Issues* 2002;12:79–95.
- Kaplan D. *Family Counseling for all counselors*. Greensboro, NC: CAPS Publications; 2003.
- Nupponen R. What is counseling all about—basics in the counseling of health-related physical activity. *Patient Educ Couns* 1998;33(Suppl):S61–7.
- Whitlock EP, Orleans CT, Pender N, Allan J. Evaluating primary care behavioral counseling interventions: an evidence-based approach. *Am J Prev Med* 2002;22:267–84.
- French RS, Wellings K, Cowan F. How can we help people to choose a method of contraception? The case for contraceptive decision aids. *J Fam Plann Reprod Health Care* 2009;35:219–20.
- O'Connor AM, Bennett CL, Stacey D, et al. Decision aids for people facing health treatment or screening decisions. *Cochrane Database Syst Rev* 2009;CD001431.
- Cowley CB, Farley T, Beamis K. "Well, maybe I'll try the pill for just a few months...": brief motivational and narrative-based interventions to encourage contraceptive use among adolescents at high risk for early childbearing. *Fam Syst Health* 2002;20:183–204.
- Gilliam M, Knight S, McCarthy M Jr. Success with oral contraceptives: a pilot study. *Contraception* 2004;69:413–8.
- Namerow PB, Weatherby N, Williams-Kaye J. The effectiveness of contingency-planning counseling. *Fam Plann Perspect* 1989;21:115–9.
- Berger DK, Perez G, Kyman W, et al. Influence of family planning counseling in an adolescent clinic on sexual activity and contraceptive use. *J Adolesc Health Care* 1987;8:436–40.
- Winter L, Breckenmaker LC. Tailoring family planning services to the special needs of adolescents. *Fam Plann Perspect* 1991;23:24–30.
- Chewning B, Mosena P, Wilson D, et al. Evaluation of a computerized contraceptive decision aid for adolescent patients. *Patient Educ Couns* 1999;38:227–39.
- Garbers S, Meserve A, Kottke M, Hatcher R, Chiasson MA. Tailored health messaging improves contraceptive continuation and adherence: results from a randomized controlled trial. *Contraception* 2012;86:536–42.
- Garbers S, Meserve A, Kottke M, Hatcher R, Ventura A, Chiasson MA. Randomized controlled trial of a computer-based module to improve contraceptive method choice. *Contraception* 2012;86:383–90.
- McMahon SR, Rimsza ME, Bay RC. Parents can dose liquid medication accurately. *Pediatrics* 1997;100:330–3.
- Schillinger D, Piette J, Grumbach K, et al. Closing the loop: physician communication with diabetic patients who have low health literacy. *Arch Intern Med* 2003;163:83–90.
- National Quality Forum. Health literacy: a linchpin in achieving national goals for health and healthcare, Issue Brief #13 2009. Available at http://www.qualityforum.org/Publications/2009/03/Health_Literacy_A_Linchpin_in_Achieving_National_Goals_for_Health_and_Healthcare.aspx.

Appendix D

Contraceptive Effectiveness

Providers should counsel clients about the effectiveness of different contraceptive methods. Method effectiveness is measured as the percentage of women experiencing an

unintended pregnancy during the first year of use, and is estimated for both typical and perfect use (Table).

TABLE. Percentage of women experiencing an unintended pregnancy during the first year of typical use* and the first year of perfect use† of contraception and the percentage continuing use at the end of the first year — United States

Method	% of women experiencing an unintended pregnancy within the first year of use		% of women continuing use at 1 year [§]
	Typical use	Perfect use	
No method [¶]	85.0	85.0	
Spermicides**	28.0	18.0	42.0
Fertility awareness-based methods	24.0		47.0
Standard days method ^{††}		5.0	
2-day method ^{††}		4.0	
Ovulation method ^{††}		3.0	
Symptothermal method		0.4	
Withdrawal	22.0	4.0	46.0
Sponge			36.0
Parous women	24.0	20.0	
Nulliparous women	12.0	9.0	
Condom ^{§§}			
Female	21.0	5.0	41.0
Male	18.0	2.0	43.0
Diaphragm ^{¶¶}	12.0	6.0	57.0
Combined pill and progestin-only pill	9.0	0.3	67.0
Evra patch	9.0	0.3	67.0
NuvaRing	9.0	0.3	67.0
Depo-Provera	6.0	0.2	56.0
Intrauterine contraceptives			
ParaGard (copper T)	0.8	0.6	78.0
Mirena (LNG)	0.2	0.2	80.0
Implanon	0.05	0.05	84.0
Female sterilization	0.5	0.5	100.0
Male sterilization	0.15	0.1	100.0

Emergency Contraceptives: Emergency contraceptive pills or insertion of a copper intrauterine contraceptive after unprotected intercourse substantially reduces the risk of pregnancy.^{***}

Lactational Amenorrhea Method: LAM is a highly effective, temporary method of contraception.^{†††}

Source: Adapted from Trussell J. Contraceptive efficacy. In: Hatcher RA, Trussell J, Nelson AL, Cates W, Kowal D, Policar M, eds. Contraceptive technology: 20th revised ed. New York, NY: Ardent Media; 2011.

* Among typical couples who initiate use of a method (not necessarily for the first time), the percentage of couples who experience an accidental pregnancy during the first year if they do not stop use for any other reason. Estimates of the probability of pregnancy during the first year of typical use for spermicides and the diaphragm are taken from the 1995 National Survey of Family Growth corrected for underreporting of abortion; estimates for fertility awareness-based methods, withdrawal, the male condom, the pill, and Depo-Provera are taken from the 1995 and 2002 National Survey of Family Growth corrected for underreporting of abortion. See the text for the derivation of estimates for the other methods.

† Among couples who initiate use of a method (not necessarily for the first time) and who use it perfectly (both consistently and correctly), the percentage of couples who experience an accidental pregnancy during the first year if they do not stop use for any other reason. See the text for the derivation of the estimate for each method.

§ Among couples attempting to avoid pregnancy, the percentage of couples who continue to use a method for 1 year.

¶ The percentages becoming pregnant in columns labeled "typical use" and "perfect use" are based on data from populations in which contraception is not used and from women who cease using contraception to become pregnant. Among such populations, approximately 89% become pregnant within 1 year. This estimate was lowered slightly (to 85%) to represent the percentage of women who would become pregnant within 1 year among women now relying on reversible methods of contraception if they abandoned contraception altogether.

** Foams, creams, gels, vaginal suppositories, and vaginal film.

†† The Ovulation and 2-day methods are based on evaluation of cervical mucus. The Standard Days method avoids intercourse on cycle days 8 through 19. The Symptothermal method is a double-check method based on evaluation of cervical mucus to determine the first fertile day and evaluation of cervical mucus and temperature to determine the last fertile day.

§§ Without spermicides.

¶¶ With spermicidal cream or jelly.

*** Ella, Plan B One-Step, and Next Choice are the only dedicated products specifically marketed for emergency contraception. The label for Plan B One-Step (1 dose is 1 white pill) says to take the pill within 72 hours after unprotected intercourse. Research has indicated that all of the brands listed here are effective when used within 120 hours after unprotected intercourse. The label for Next Choice (1 dose is 1 peach pill) says to take one pill within 72 hours after unprotected intercourse and another pill 12 hours later. Research has indicated that that both pills can be taken at the same time with no decrease in efficacy or increase in side effects and that they are effective when used within 120 hours after unprotected intercourse. The Food and Drug Administration has in addition declared the following 19 brands of oral contraceptives to be safe and effective for emergency contraception: Ogestrel (1 dose is 2 white pills), Nordette (1 dose is 4 light-orange pills), Cryselle, Levora, Low-Ogestrel, Lo/Ovral, or Quasence (1 dose is 4 white pills), Jolessa, Portia, Seasonale or Trivora (1 dose is 4 pink pills), Seasonique (1 dose is 4 light-blue-green pills), Enpresse (1 dose is 4 orange pills), Lessina (1 dose is 5 pink pills), Aviane or LoSeasonique (one dose is 5 orange pills), Lutera or Sronyx (1 dose is 5 white pills), and Lybrel (1 dose is 6 yellow pills).

††† However, for effective protection against pregnancy to be maintained, another method of contraception must be used as soon as menstruation resumes, the frequency or duration of breastfeeds is reduced, bottle feeds are introduced, or the baby reaches age 6 months.

Appendix E

Strategies for Providing Information to Clients

The client should receive and understand the information she or he needs to make informed decisions and follow treatment plans. This requires careful attention to how information is communicated. The following strategies can make information more readily comprehensible to clients:

Strategies for Providing Information to Clients

Educational materials should be provided that are clear and easy to understand. Educational materials delivered through any one of a variety of media (for example, written, audio/visual, computer/web-based) need to be presented in a format that is clear and easy to interpret by clients with a 4th to 6th grade reading level (1–3). Many adults have only a basic ability to obtain, process, and understand health information necessary to make decisions about their health (4). Making easy-to-access materials enhances informed decision-making (1–3). Test all educational materials with the intended audiences for clarity and comprehension before wide-scale use.

The following evidence-based tools provide recommendations for increasing the accessibility of materials through careful consideration of content, organization, formatting, and writing style:

- Health Literacy Universal Precautions Toolkit, provided by the Agency for Healthcare Research and Quality (available at <http://www.ahrq.gov/qual/literacy>),
- Toolkit for Making Written Material Clear and Effective, provided by the Centers for Medicare and Medicaid Services (available at <http://www.cms.gov/WrittenMaterialsToolkit>), and
- Health Literacy Online, provided by the Office of Disease Prevention and Health Promotion (available at <http://www.health.gov/healthliteracyonline>).

Information should be delivered in a manner that is culturally and linguistically appropriate. In presenting information it is important to be sensitive to the client's cultural and linguistic preferences (5,6). Ideally information should be presented in the client's primary language, but translations and interpretation services should be available when necessary. Information presented must also be culturally appropriate, reflecting the client's beliefs, ethnic background, and cultural practices. Tools for addressing cultural and linguistic differences and preferences include

- Health Literacy Universal Precautions Toolkit, provided by the Agency for Healthcare Research and Quality (available at <http://www.ahrq.gov/qual/literacy>), and

- Toolkit for Making Written Material Clear and Effective, Part 11; Understanding and using the “Toolkit Guidelines for Culturally Appropriate Translation,” provided by the Centers for Medicare and Medicaid Services (available at <http://www.cms.gov/outreach-and-education/outreach/writtenmaterialstoolkit/downloads/toolkitpart11.pdf>).

The amount of information presented should be limited and emphasize essential points. Providers should focus on needs and knowledge gaps identified during the assessment. Many clients immediately forget or remember incorrectly much of the information provided. This problem is exacerbated as more information is presented (7–9). Limiting the amount of information presented and highlighting important facts by presenting them first improves comprehension (10–14).

Numeric quantities should be communicated in a way that is easily understood. Whenever possible, providers should use natural frequencies and common denominators (for example, 85 of 100 sexually active women are likely to get pregnant within 1 year using no contraceptive, as compared with 1 in 100 using an IUD or implant), and display quantities in graphs and visuals. Providers also should avoid using verbal descriptors without numeric quantities (for example, sexually active women using an IUD or implant almost never become pregnant). Finally, they should quantify risk in absolute rather than relative terms (for example, “the chance of unintended pregnancy is reduced from 8 in 100 to 1 in 100 by switching from oral contraceptives to an IUD” versus the chance of unintended pregnancy is reduced by 87%). Numeracy is more highly correlated with health outcomes than the ability to read or listen effectively (15). The strategies listed above can help clients interpret numeric quantities correctly (16–28).

Balanced information on risks and benefits should be presented and messages framed positively. In addition to discussing risks, contraindications, and warnings, providers should discuss the advantages and benefits of contraception. In presenting this information, providers should express risks and benefits in a common format (for example, do not present risks in relative terms and benefits in absolute terms), and frame messages in positive terms (for example “99 out of 100 women find this a safe method with no side effects,” versus “1 out of 100 women experience noticeable side effects”). Many clients prefer to receive a balance of information on risks and benefits (29), and using a common format avoids bias in presentation of information (18,22,26,30). Framing messages positively increases acceptance and comprehension (18,22,31,32).

Active client engagement should be encouraged. Providers should use educational materials that encourage active information processing (e.g., questions, quizzes, fill-in-the-blank, web-based games, and activities). In addition, they should be sure the client has an opportunity to discuss the information provided, and when speaking with a client, providers should engage her or him actively. Research has indicated that interactive materials improve knowledge of contraceptive risks, benefits, and correct method use (33–35). Clients also value spoken information (29,36); and educational materials, when delivered by a provider, more effectively increase knowledge (10,37). In particular, presenting information in a question and answer format is more effective than simply presenting the information (10,15,37–41).

References

- Centers for Medicare and Medicaid Services. Toolkit for making written material clear and effective. Baltimore, MD: Centers for Medicare and Medicaid Services; 2011.
- US Department of Health and Human Services, Office of Disease Prevention and Health Promotion. Health literacy online: A guide to writing and designing easy-to-use health Web sites. Washington, DC: US Department of Health and Human Services; 2010.
- DeWalt D, Callahan L, Hawk V, et al. Health literacy universal precautions toolkit. AHRQ Publication No. 10–0046-EF. Rockville, MD: Agency for Healthcare Research and Quality; 2010.
- Kutner M, Greenberg E, Jin Y, Paulsen C. The health literacy of America's adults: results from the 2003 National Assessment of Adult Literacy (NCES 2006–483). Washington, DC: U.S. Department of Education: National Center for Education Statistics; 2006.
- Olavarria M, Beaulac J, Belanger A, Young M, Aubry T. Organizational cultural competence in community health and social service organizations: how to conduct a self-assessment. *J Cult Divers* 2009;16:140–50.
- Tucker C. Reducing health disparities by promoting patient-centered culturally and linguistically sensitive/competent health care. U.S. Department of Health and Human Services Advisory Committee on Minority Health, US Public Health Service; 2009.
- Anderson JL, Dodman S, Kopelman M, Fleming A. Patient information recall in a rheumatology clinic. *Rheumatol Rehabil* 1979;18:18–22.
- Crane JA. Patient comprehension of doctor-patient communication on discharge from the emergency department. *J Emerg Med* 1997;15:1–7.
- McGuire LC. Remembering what the doctor said: organization and adults' memory for medical information. *Exp Aging Res* 1996;22:403–28.
- Little P, Griffin S, Kelly J, Dickson N, Sadler C. Effect of educational leaflets and questions on knowledge of contraception in women taking the combined contraceptive pill: randomised controlled trial. *BMJ* 1998;316:1948–52.
- McGee J. Toolkit for making written material clear and effective: Baltimore, MD: Centers for Medicare and Medicaid Services; 2010. Available at <http://www.cms.gov/WrittenMaterialsToolkit>.
- Peters E, Dieckmann N, Dixon A, Hibbard JH, Mertz CK. Less is more in presenting quality information to consumers. *Med Care Res Rev* 2007;64:169–90.
- Steiner MJ, Dalebout S, Condon S, Dominik R, Trussell J. Understanding risk: a randomized controlled trial of communicating contraceptive effectiveness. *Obstet Gynecol* 2003;102:709–17.
- Berry DC, Michas IC, Rosis F. Evaluating explanations about drug prescriptions: Effects of varying the nature of information about side effects and its relative position in explanations. *Psychol Health* 1998;13:767–84.
- Berkman N, Sheridan S, Donahue K, et al. Health literacy interventions and outcomes: an updated systematic review. Evidence Report/Technology Assessment No. 199. Rockville, MD: Agency for Healthcare Research and Quality; 2011.
- Berry DC. Informing people about the risks and benefits of medicines: implications for the safe and effective use of medicinal products. *Curr Drug Saf* 2006;1:121–6.
- Berry DC, Raynor DK, Knapp P, Bersellini E. Patients' understanding of risk associated with medication use: impact of European Commission guidelines and other risk scales. *Drug Saf* 2003;26:1–11.
- Edwards A, Elwyn G, Mulley A. Explaining risks: turning numerical data into meaningful pictures. *BMJ* 2002;324:827–30.
- Galesic M, Gigerenzer G, Straubinger N. Natural frequencies help older adults and people with low numeracy to evaluate medical screening tests. *Med Decis Making* 2009;29:368–71.
- Garcia-Retamero R, Galesic M. Communicating treatment risk reduction to people with low numeracy skills: a cross-cultural comparison. *Am J Public Health* 2009;99:2196–202.
- Garcia-Retamero R, Galesic M, Gigerenzer G. Do icon arrays help reduce denominator neglect? *Med Decis Making* 2010;30:672–84.
- Gigerenzer G, Edwards A. Simple tools for understanding risks: from innumeracy to insight. *BMJ* 2003;327:741–4.
- Knapp P, Gardner PH, Raynor DK, Woolf E, McMillan B. Perceived risk of tamoxifen side effects: a study of the use of absolute frequencies or frequency bands, with or without verbal descriptors. *Patient Educ Couns* 2010;79:267–71.
- Kurz-Milcke E, Gigerenzer G, Martignon L. Transparency in risk communication: graphical and analog tools. *Ann N Y Acad Sci* 2008;1128:18–28.
- Lipkus IM. Numeric, verbal, and visual formats of conveying health risks: suggested best practices and future recommendations. *Med Decis Making* 2007;27:696–713.
- Paling J. Strategies to help patients understand risks. *BMJ* 2003;327:745–8.
- Skolbekken JA. Communicating the risk reduction achieved by cholesterol reducing drugs. *BMJ* 1998;316:1956–8.
- Visschers VH, Meertens RM, Passchier WW, de Vries NN. Probability information in risk communication: a review of the research literature. *Risk Anal* 2009;29:267–87.
- Raynor DK, Blenkinsopp A, Knapp P, et al. A systematic review of quantitative and qualitative research on the role and effectiveness of written information available to patients about individual medicines. *Health Technol Assess* 2007;11:iii, 1–160.
- Fahey T, Griffiths S, Peters TJ. Evidence based purchasing: understanding results of clinical trials and systematic reviews. *BMJ* 1995;311:1056–9, discussion 9–60.
- Armstrong K, Schwartz JS, Fitzgerald G, Putt M, Ubel PA. Effect of framing as gain versus loss on understanding and hypothetical treatment choices: survival and mortality curves. *Med Decis Making* 2002;22:76–83.
- Gurm HS, Litaker DG. Framing procedural risks to patients: is 99% safe the same as a risk of 1 in 100? *Acad Med* 2000;75:840–2.
- Paperny DM, Starn JR. Adolescent pregnancy prevention by health education computer games: computer-assisted instruction of knowledge and attitudes. *Pediatrics* 1989;83:742–52.
- Reis J, Tymchyshyn P. A longitudinal evaluation of computer-assisted instruction on contraception for college students. *Adolescence* 1992;27:803–11.
- Roberto AJ, Zimmerman RS, Carlyle KE, Abner EL, Cupp PK, Hansen GL. The effects of a computer-based pregnancy, STD, and HIV prevention intervention: a nine-school trial. *Health Commun* 2007;21:115–24.
- Grime J, Blenkinsopp A, Raynor DK, Pollock K, Knapp P. The role and value of written information for patients about individual medicines: a systematic review. *Health Expect* 2007;10:286–98.

Recommendations and Reports

37. DeLamater J, Wagstaff DA, Havens KK. The impact of a culturally appropriate STD/AIDS education intervention on black male adolescents' sexual and condom use behavior. *Health Educ Behav* 2000;27:454–70.
38. McMahon SR, Rimsza ME, Bay RC. Parents can dose liquid medication accurately. *Pediatrics* 1997;100:330–3.
39. Belcher L, Kalichman S, Topping M, et al. A randomized trial of a brief HIV risk reduction counseling intervention for women. *J Consult Clin Psychol* 1998;66:856–61.
40. Eldridge GD, St Lawrence JS, Little CE, et al. Evaluation of the HIV risk reduction intervention for women entering inpatient substance abuse treatment. *AIDS Educ Prev* 1997;9(Suppl):62–76.
41. Jaccard J. *Unlocking the contraceptive conundrum*. Washington, DC: The National Campaign to Prevent Teen and Unplanned Pregnancy; 2009. Available at <http://thenationalcampaign.org/resource/unlocking-contraception-conundrum>.

Appendix F

Screening Services For Which Evidence Does Not Support Screening

The following services have been given a D recommendation from the U.S. Preventive Services Task Force (USPSTF), which indicates that the potential harms of routine screening outweigh the benefits. Providers should not perform these screening services.

The USPSTF has recommended against offering the following services to women and men:

- **Asymptomatic bacteriuria:** USPSTF recommends against screening for asymptomatic bacteriuria in men and nonpregnant women (1).
- **Gonorrhea:** USPSTF recommends against routine screening for gonorrhea infection in men and women who are at low risk of infection (2).
- **Hepatitis B:** USPSTF recommends against routinely screening the general asymptomatic population for chronic hepatitis B virus infection (3).
- **Herpes simplex virus (HSV):** USPSTF recommends against routine serological screening for HSV in asymptomatic adolescents and adults (4).
- **Syphilis:** USPSTF recommends against screening of asymptomatic persons who are not at increased risk of syphilis infection (5).

The USPSTF has recommended against offering the following services to women:

- **BRCA mutation testing for breast and ovarian cancer susceptibility:** USPSTF recommends against routine referral for genetic counseling or routine breast cancer susceptibility gene (BRCA) testing for women whose family history is not associated with an increased risk of deleterious mutations in breast cancer susceptibility gene 1 (BRCA1) or breast cancer susceptibility gene 2 (BRCA2) (6). However, USPSTF continues to recommend that women whose family history is associated with an increased risk of deleterious mutations in BRCA1 or BRCA2 genes be referred for genetic counseling and evaluation for BRCA testing.
- **Breast self-examination:** USPSTF recommends against teaching breast self-examination (7).
- **Cervical cytology:** USPSTF recommends against routine screening for cervical cancer with cytology (Pap smear) in the following groups: women aged <21 years, women aged >65 years who have had adequate prior screening and are not otherwise at high risk for cervical cancer, women who have had a hysterectomy with removal of the cervix and who do not have a history of a high-grade precancerous lesion (i.e., cervical intraepithelial neoplasia grade 2 or 3) or cervical cancer. USPSTF recommends against screening for cervical cancer with HPV testing, alone or in combination with cytology, in women aged <30 years (8).

- **Ovarian cancer:** USPSTF recommends against routine screening for ovarian cancer (9).

The USPSTF has recommended against offering the following services to men:

- **Prostate cancer:** USPSTF recommends against prostate-specific antigen (PSA)-based screening for prostate cancer (10).
- **Testicular cancer:** USPSTF recommends against screening for testicular cancer in adolescent or adult males (11).

References

1. US Preventive Services Task Force. Screening for asymptomatic bacteriuria in adults. Rockville, MD: US Department of Health and Human Services, Agency for Healthcare Research and Quality; 2008. Available at <http://www.uspreventiveservicestaskforce.org/uspstf/uspsbact.htm>.
2. US Preventive Services Task Force. Screening for gonorrhea. Rockville, MD: US Department of Health and Human Services, Agency for Healthcare Research and Quality; 2005. Available at <http://www.uspreventiveservicestaskforce.org/uspstf/uspsgono.htm>.
3. US Preventive Services Task Force. Screening for hepatitis B infection. Rockville, MD: US Department of Health and Human Services, Agency for Healthcare Research and Quality; 2004. Available at <http://www.uspreventiveservicestaskforce.org/uspstf/uspshepb.htm>.
4. US Preventive Services Task Force. Screening for genital herpes: recommendation statement. Rockville, MD: US Department of Health and Human Services, Agency for Healthcare Research and Quality; 2005. Available at <http://www.uspreventiveservicestaskforce.org/uspstf05/herpes/herpesrs.htm>.
5. US Preventive Services Task Force. Screening for syphilis infection. Rockville, MD: US Department of Health and Human Services, Agency for Healthcare Research and Quality; 2004. Available at <http://www.uspreventiveservicestaskforce.org/uspstf/uspsyph.htm>.
6. US Preventive Services Task Force. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women. Rockville, MD: US Department of Health and Human Services, Agency for Healthcare Research and Quality; 2013. Available at <http://www.uspreventiveservicestaskforce.org/uspstf/uspsbrgen.htm>.
7. US Preventive Services Task Force. Screening for breast cancer. Rockville, MD: US Department of Health and Human Services, Agency for Healthcare Research and Quality; 2009. Available at <http://www.uspreventiveservicestaskforce.org/uspstf/uspsbrca.htm>.
8. US Preventive Services Task Force. Screening for cervical cancer. Rockville, MD: US Department of Health and Human Services, Agency for Healthcare Research and Quality; 2012. Available at www.uspreventiveservicestaskforce.org/uspstf11/cervcancer/cervcancerr.htm.
9. US Preventive Services Task Force. Screening for ovarian cancer: U.S. Preventive Services Task Force reaffirmation recommendation statement. Rockville, MD: US Department of Health and Human Services, Agency for Healthcare Research and Quality; 2012. Available at <http://www.uspreventiveservicestaskforce.org/uspstf12/ovarian/ovarcancers.htm>.
10. US Preventive Services Task Force. Screening for prostate cancer. Rockville, MD: US Department of Health and Human Services, Agency for Healthcare Research and Quality; 2012. Available at <http://www.uspreventiveservicestaskforce.org/prostatecancerscreening.htm>.
11. US Preventive Services Task Force. Screening for testicular cancer. Rockville, MD: US Department of Health and Human Services, Agency for Healthcare Research and Quality; 2011. Available at <http://www.uspreventiveservicestaskforce.org/uspstf/uspstest.htm>.

Lead Authors

Loretta Gavin, PhD, Division of Reproductive Health, CDC
Susan Moskosky, MS, Office of Population Affairs, CDC

Systematic Review Authors and Presenters

Anna Brittain, MHS, Division of Reproductive Health, CDC
Marion Carter, PhD, Division of Reproductive Health, CDC
Kathryn Curtis, PhD, Division of Reproductive Health, CDC
Emily Godfrey, MD, Division of Reproductive Health, CDC
Arik V. Marcell, MD, The Johns Hopkins University and the Male Training Center
Cassandra Marshall, MPH, Division of Reproductive Health, CDC
Karen Pazol, PhD, Division of Reproductive Health, CDC
Naomi Tepper, MD, Division of Reproductive Health, CDC
Marie Tiller, PhD, MANILA Consulting Group, Inc.
Stephen Tregear, DPhil, MANILA Consulting Group, Inc.
Michelle Tregear, PhD, MANILA Consulting Group, Inc.
Jessica Williams, MPH, MANILA Consulting Group, Inc.
Lauren Zapata, PhD, Division of Reproductive Health, CDC

Expert Work Group

Courtney Benedict, MSN, Marin Community Clinics
Jan Chapin, MPH, American College of Obstetricians and Gynecologists
Clare Coleman, President and CEO, National Family Planning and Reproductive Health Association
Vanessa Cullins, MD, Planned Parenthood Federation of America
Daryn Eikner, MS, Family Planning Council
Jule Hallerdin, MN, Advisor to the Office of Population Affairs
Mark Hathaway, MD, Unity Health Care and Washington Hospital Center
Seiji Hayashi, MD, Bureau of Primary Health Care, Health Resources and Services Administration
Beth Jordan, MD, Association of Reproductive Health Professionals
Ann Loeffler, MSPH, John Snow Research and Training Institute
Arik V. Marcell, MD, The Johns Hopkins University and the Male Training Center
Tom Miller, MD, Alabama Department of Health
Deborah Nucatola, MD, Planned Parenthood Federation of America
Michael Policar, MD, State of California and UCSF Bixby Center
Adrienne Stith-Butler, PhD, Keck Center of the National Academies
Denise Wheeler, ARNP, Iowa Department of Public Health
Gayla Winston, MPH, Indiana Family Health Council
Jacki Witt, MSN, Clinical Training Center for Family Planning, University of Missouri—Kansas City
Jamal Gwathney, MD, Bureau of Primary Health Care, Health Resources and Services Administration

Technical Panel on Women's Clinical Services

Courtney Benedict, MSN, Marin Community Clinics
Janet Chapin, MPH, American College of Obstetricians and Gynecologists
Elizabeth DeSantis, MSN, South Carolina Department of Health and Environmental Control
Linda Dominguez, CNP, Southwest Women's Health
Eileen Dunne, MD, Division of STD Prevention, CDC
Jamal K. Gwathney, MD, Bureau of Primary Health Care, Health Resources and Services Administration
Jule Hallerdin, Consultant Advisor
Mark Hathaway, MD, Washington Hospital Center
Arik V. Marcell, MD, Johns Hopkins University and the Male Training Center
Cheri Moran, University of Illinois Medical Center at Chicago
Deborah Nucatola, MD, Planned Parenthood Federation of America
Michael Policar, MD, Family PACT Program - California State Office of Family Planning
Pablo Rodriguez, MD, Women's Care Inc., Providence Office
Denise Wheeler, ARNP, Iowa Department of Public Health
Jacki Witt, MSN, Clinical Training Center for Family Planning, University of Missouri—Kansas City

Technical on Men's Clinical Services

Linda Creegan, FNP, California STD/HIV Prevention Training Center
Dennis Fortenberry, MD, Indiana University School of Medicine
Emily Godfrey, MD, University of Illinois at Chicago
Wendy Grube, PhD, University of Pennsylvania School of Nursing
Arik V. Marcell, MD, The Johns Hopkins University and the Male Training Center
Elissa Meites, MD, Division of STD Prevention, CDC
Anne Rompalo, MD, Johns Hopkins University
Thomas Walsh, MD, University of Washington Medical Center
Jacki Witt, MSN, Clinical Training Center for Family Planning, University of Missouri—Kansas City
Sandra Wolf, MD, Women's Care Center, Philadelphia

Technical Panel on Adolescents

Claire Brindis, DrPH, University of California, San Francisco
Gale Burstein, MD, SUNY at Buffalo School of Medicine and Biomedical Sciences, Department of Pediatrics
Laura Davis, MA, Advocates for Youth
Patricia J. Dittus, PhD, Division of STD Prevention, CDC
Paula Duncan, MD, University of Vermont College of Medicine
Carol Ford, MD, The Children's Hospital of Philadelphia
Melissa Gilliam, MD, The University of Chicago
Mark Hathaway, MD, Unity Health Care & Washington Hospital Center
Deborah Kaplan, PhD, New York City Department of Health and Mental Hygiene
Arik V. Marcell, MD, The Johns Hopkins University and the Male Training Center
Brent C. Miller, PhD, Utah State University
Elizabeth M. Ozer, PhD, Division of Adolescent Medicine, University of California, San Francisco
John Santelli, MD, Columbia University, Mailman School of Public Health

Technical Panel on Counseling and Education

Beth Barnett, MD, University of Maryland
Betty Chewning, PhD, University of Wisconsin School of Pharmacy
Christine Dehlendorf, MD, University of California, San Francisco
Linda Dominguez, CNP, Southwest Women's Health
Jillian Henderson, PhD, University of California, San Francisco
James Jaccard, PhD, New York University
Beth Jordan, MD, Association of Reproductive Health Professionals—East
David Kaplan, PhD, American Counseling Association
Alicia Luchowski, American Congress of Obstetricians and Gynecologists
Merry-K Moos, FNP, University of North Carolina at Chapel Hill
Patricia Murphy, DrPH, University of Utah College of Nursing
Elizabeth O'Connor, PhD, Kaiser Permanente Center for Health Research
Jeff Peipert, MD, Washington University in St. Louis

Technical Panel on Quality Improvement

David Becker, PhD, Bixby Center for Global Reproductive Health University of California, San Francisco
Peter Briss, MD, National Center for Chronic Disease Prevention and Health Promotion, CDC
Denise Dougherty, PhD, Agency for Healthcare Research and Quality
Daryn Eikner, MS, Family Planning Council
Christina I. Fowler, PhD, RTI International
Evelyn Glass, MSPH, Consultant Advisor
Yvonne Hamby, MPH, Regional Quality Improvement and Infertility Prevention Programs
A. Seiji Hayashi, MD, Bureau of Primary Health Care, Health Resources and Services Administration
Michael D. Kogan, PhD, Health Resources and Services Administration /Maternal and Child Health Bureau
Tom Miller, MD, Alabama Department of Health
Sam Posner, PhD, National Center for Chronic Disease Prevention and Health Promotion, CDC
Donna Strobino, PhD, Johns Hopkins University
Amy Tsui, PhD, Johns Hopkins Bloomberg School of Public Health
Reva Winkler, MD, National Quality Forum

Advisors on Community Outreach and Participation*

Paula Baraitser, MBBS, Kings College Hospital NHS Foundation Trust/Health Protection Agency
Joy Baynes, MPH, Advocates for Youth
Diane Chamberlain, California Family Health Council
Clare Coleman, National Family Planning & Reproductive Health Association
Emily Godfrey, MD, University of North Carolina and Division of Reproductive Health, CDC
Rachel Gold, MPA, Guttmacher Institute
Rachel Kachur, MPH, Division of STD Prevention, CDC
Michelle Kegler, PhD, Rollins School of Public Health, Emory
Eleanor McLellan-Lemal, PhD, Division of HIV/AIDS Prevention, CDC
Paula Parker-Sawyers, National Campaign to Prevent Teen and Unplanned Pregnancy
Denise Wheeler, MS, Iowa Department of Public Health
Gayla Winston, MPH, Indiana Family Health Council, Inc.

CDC and Office of Population Affairs Reviewers

Wanda Barfield, MD, Division of Reproductive Health, CDC
Gail Bolan, MD, Division of STD Prevention, CDC
Linda Dahlberg, PhD, Division of Violence Prevention, CDC
Patricia Dietz, PhD, Division of Reproductive Health, CDC
Sherry Farr, PhD, Division of Reproductive Health, CDC
Evelyn Glass, MSPH, Office of Population Affairs
Tamara Haegerich, PhD, Division of Violence Prevention, CDC
David Johnson, MPH, Office of Population Affairs
Pamela Kania, MS, Office of Population Affairs
Marilyn Keefe, MPH, Deputy Assistant Secretary for Population Affairs
Dmitry Kissin, MD, Division of Reproductive Health, CDC
Nancy Mautone-Smith, MSW, Office of Population Affairs
Jacqueline Miller, MD, Division of Cancer Prevention and Control, CDC
Sam Posner, PhD, National Center for Chronic Disease and Health Promotion, CDC
Cheryl Robbins, PhD, Division of Reproductive Health, CDC
Lance Rodewald, MD, Division of Immunization Services, CDC
Mona Saraiya, MD, Division of Cancer Prevention and Control, CDC
Van Tong, MPH, Division of Reproductive Health, CDC
Lee Warner, PhD, Division of Reproductive Health, CDC
Kim Workowski, MD, Division of STD Prevention, CDC

External Reviewers

Paula Braverman, MD, Department of Pediatrics at the University of Cincinnati
Claire Brindis, DrPH, University of California–San Francisco
Sarah Brown, MPH, National Campaign to Prevent Teen and Unplanned Pregnancy
Marji Gold, MD, Albert Einstein School of Medicine
Milton Kotelchuck, PhD, Massachusetts General Hospital for Children and Harvard Medical School
David Levine, MD, Morehouse School of Medicine
Pamela Murray, MD, West Virginia University School of Medicine

Competing interests for the development of these guidelines were not assessed.

*These persons made important contributions to a discussion about community outreach and participation. A decision was made to narrow the focus of this report to clinical services, so recommendations informed by the input of these persons will be published separately.

The *Morbidity and Mortality Weekly Report (MMWR)* Series is prepared by the Centers for Disease Control and Prevention (CDC) and is available free of charge in electronic format. To receive an electronic copy each week, visit *MMWR*'s free subscription page at <http://www.cdc.gov/mmwr/mmwrsubscribe.html>. Paper copy subscriptions are available through the Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402; telephone 202-512-1800.

Address all inquiries about the *MMWR* Series, including material to be considered for publication, to Editor, *MMWR* Series, Mailstop E-90, CDC, 1600 Clifton Rd., N.E., Atlanta, GA 30329-4027 or to mmwrq@cdc.gov.

All material in the *MMWR* Series is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated.

Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.

References to non-CDC sites on the Internet are provided as a service to *MMWR* readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of these sites. URL addresses listed in *MMWR* were current as of the date of publication.

ISSN: 1057-5987